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Chapter 1 
Introduction 
 
Hypertension is a complex disease with a high prevalence. It is defined as a systolic 
blood pressure (SBP) ≥ 140 mmHg and a diastolic blood pressure (DBP) ≥ 90 mmHg 
for persons up to 60 years of age and for subjects with diabetes mellitus or familiar 
hypercholesterolemia and as a SBP ≥ 160 mmHg and a DBP ≥ 90 mmHg for persons 
of 60 years and older without diabetes mellitus or familiar hypercholesterolemia.1 
Hypertension is a risk factor for myocardial infarction, stroke, congestive heart failure, 
end-stage renal disease, and peripheral vascular disease.2-5 The World Health 
Organization reported that suboptimal blood pressure (SBP > 115 mmHg) is 
responsible for 62% of all cerebrovascular diseases and 49% of all ischemic heart 
diseases. In addition, suboptimal blood pressure is the number one cause of death 
throughout the Western world.6
 Many physiological, biochemical, and anatomical traits contribute to an individual’s 
blood pressure level, which is homeostatically maintained through complex 
interactions of interrelated systems that exert redundant and counterbalancing 
pressor and depressor effects.7 In normotensive and hypertensive individuals, cardiac 
output (heart rate x stroke volume) and peripheral resistance are controlled by 
overlapping control mechanisms i.e. the baroreflexes mediated by the sympathetic 
nervous system, the parasympatic nervous system, and the renin-angiotensin 
system. Antihypertensive drugs lower blood pressure by acting on specific targets 
within these systems.  
Antihypertensive treatment can be divided into four main classes: diuretics, β-
blockers, calcium channel blockers, and renin-angiotensin system inhibitors 
(angiotensin converting enzyme (ACE)-inhibitors and angiotensin II type 1 receptor 
antagonists). Diuretics are currently recommended as the first-line treatment for 
hypertension.1, 8 Diuretics lower blood pressure, initially by increasing sodium and 
water excretion and with long-term treatment by decreasing peripheral resistance 
(see figure 1). The impairment in sodium excretion may be one of the first changes in 
the development of hypertension.9 Beta-blockers decrease the cardiac output by 
acting on β1-receptors and by inhibiting the release of renin. Calcium channel 
blockers block the inward movement of calcium by binding to L-type calcium channels 
in the heart and in smooth muscle of the coronary and peripheral vasculature. This 
causes a relaxation of smooth muscle cells, although, there are differences between 
calcium channel blockers in their affinity. ACE-inhibitors inhibit the conversion of 
angiotensin I to angiotensin II resulting in a reduction of the peripheral vascular 
resistance. In addition, ACE-inhibitors decrease the secretion of aldosteron, which 
results in a decreased sodium and water retention. It also reduces the breakdown of 
the vasodilator bradykinin. Angiotensin II type 1 receptor antagonists block the action 
of angiotensin II at the angiotensin (AT)1 receptors. In clinical trials, antihypertensive 
therapy has been associated with a 35% to 40% risk reduction in stroke incidence, a 
20% to 25% reduction in myocardial infarction incidence, and a more than 50% 
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reduction in heart failure incidence.10
 
Figure 1. Diagram showing the main mechanisms involved in arterial blood pressure regulation 
and the sites of action of antihypertensive drugs.11
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Finding the most appropriate pharmacological treatment for an individual patient 
is difficult as the response can not be predicted with patient characteristics such as 
age, gender, or body mass index.12, 13 Pharmacogenetics aims to understand how 
genetic variations contribute to variation in response to medication. Polymorphisms in 
genes that code for drug-metabolizing enzymes, drug transporters, drug receptors, 
and ion channels can alter the response of drug treatment in an individual. Targeting 
treatment to the genetic components may enhance treatment efficacy and improve 
overall benefit, resulting in more effective blood pressure control and a lower 
incidence of hypertension-related morbidity. 
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Aim and outline of this thesis 
 
This thesis consists of a number of studies, which are aimed at gaining more insight 
into the variation in response to antihypertensive drugs by investigating the 
interaction between antihypertensive drugs and genetic polymorphisms on short and 
long-term cardiovascular outcomes. 
 In Chapter 2, population-based estimates of the prevalence of 
undertreatment of hypertension were determined. Furthermore, this chapter presents 
determinants associated with non-use and uncontrolled blood pressure levels. 
Chapter 3 gives an overview of studies that investigated the influence of genetic 
variants on the response to antihypertensive drugs. Chapter 4 contains 
pharmacogenetic studies and short-term outcomes. The first study (Chapter 4.1) 
describes the influence of the ACE insertion/deletion (I/D) polymorphism on the 
adherence to ACE-inhibitors in the Rotterdam Study.14 The second (Chapter 4.2) and 
third study (Chapter 4.3) examine the influence of the ACE I/D, α-adducin G460W, 
and angiotensinogen M235T polymorphism on blood pressure response in the 
Rotterdam Study. In Chapter 4.4 the interaction between antihypertensive drugs and 
the ACE I/D, α-adducin G460W, angiotensinogen M235T, the β3-subunit of the G-
protein 825C/T polymorphism, and angiotensin II type 1 receptor 1166A/C 
polymorphism on blood pressure were evaluated in the Doetinchem Cohort Study.15 
The long-term outcomes are described in Chapter 5. In the first study the ACE I/D, 
angiotensinogen M235T, and angiotensin II type 1 receptor 573C/T polymorphism 
modify the risk of atherosclerosis associated with ACE-inhibitors or β-blockers therapy 
(Chapter 5.1). Chapter 5.2 describes pharmacogenetic studies with the long-term 
outcomes myocardial infarction and stroke. For both outcomes the interaction 
between the angiotensinogen M235T polymorphism and the use of ACE-inhibitors on 
the risk of myocardial infarction and stroke was investigated in the Rotterdam Study. 
In chapter 6 the main findings and possible clinical implications are discussed and 
suggestions for further research are given. 
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Abstract 
 
The objective of this study was to determine the prevalence, treatment, and control of 
hypertension and the determinants of undertreatment in the Dutch population. The 
study-design was cross-sectional. A population-based survey on cardiovascular 
disease risk factors in the Netherlands from 1996 to 2002 was the setting of the 
study. A total of 10,820 man and women, aged 30-59 years, were included in the 
study. The mean outcome measures of the study were: prevalence of hypertension, 
treatment, and control of hypertension and determinants of undertreatment of 
hypertension. Hypertension was defined as: systolic blood pressure (SBP) ≥ 140 
mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg, and/or the use of 
antihypertensive medication. Treated and controlled hypertension was defined as SBP 
< 140 mmHg and DBP < 90 mmHg. Multivariate logistic regression was used to 
assess the determinants of undertreatment. The prevalence of hypertension in men 
was 21.4% and in women 14.9%. About 18% of the hypertensive men and 39% of 
the hypertensive women were receiving antihypertensive medication. Of the 
untreated hypertensives, 21.9% of the men and 13.6% of the women were eligible 
for treatment with antihypertensive medication according to Dutch guidelines. Female 
gender and use of cholesterol-lowering medication were associated with an increased 
chance of being treated. Subjects who were physically active, on a low salt diet, and 
current smokers had an increased chance of being untreated. Using cholesterol-
lowering medication and no asthma or allergy were factors associated with better 
control of blood pressure. In conclusion, a considerable proportion of hypertensives 
were untreated and uncontrolled. Therefore, the detection and control of hypertension 
in the Netherlands needs to improve. Several groups of hypertensives were identified 
that need additional care and attention.  
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Introduction 
 
Hypertension is a major public health hazard because of its high prevalence1 and its 
strong positive association with cardiovascular diseases.2-6 The overall beneficial effect 
of treatment of hypertension has been demonstrated.7-9 Therefore, the detection and 
adequate treatment of hypertension is important to reduce the incidence of 
cardiovascular diseases. Knowledge of factors that are associated with 
undertreatment of hypertension may help to identify subgroups that need additional 
care and attention. Previously, it was reported that the prevalence of hypertension 
(systolic blood pressure (SBP) ≥ 140 mmHg and/or diastolic blood pressure (DBP) ≥ 
90 mmHg and/or use of antihypertensive medication) in the Netherlands in the period 
1993 to 1997 was approximately 20.2% of the population in the age-group from 40 to 
59 years.10 Studies from other countries suggest that the proportion of hypertensives 
treated and/or controlled has been stable in recent years or has even decreased.11, 12
Therefore, we performed the present study to assess the prevalence and 
determinants of undertreatment of hypertension in the Netherlands during 1996-
2002.  
 
 
Methods 
 
Data 
Data were obtained from population-based surveys on cardiovascular disease risk 
factors conducted in The Netherlands. The Monitoring Project on Cardiovascular 
Disease Risk Factors (MPCDRF) was carried out from 1987 to 1992 in men and women 
aged 20-59 years.  Each year, a new random sample was collected in basic health 
services in Amsterdam, the capital in the west with about 700,000 inhabitants, 
Doetinchem a small town with circa 40,000 inhabitants in a rural area in the east, and 
Maastricht in the south with roughly 100,000 inhabitants at that time.   
The overall response rate in Amsterdam, Maastricht, and Doetinchem was 45%, 
58%, and 62%, respectively. The average response rate for men was 50% and for 
women 57%. This project was continued from 1993 to 1997 as the “Monitoring risk 
factors and health in The Netherlands” (MORGEN) project. In Amsterdam and 
Maastricht, new random subjects were collected for those aged 20-59 years, whereas 
in Doetinchem the study population consisted of individuals who had participated in 
the previous study. So, patients in Doetinchem were re-examined after 5 years. The 
response rate in Amsterdam was 30% for men and 37% for women, in Maastricht it 
was 42% and 49%, and in Doetinchem it was 57% and 60%, respectively. From 1998 
to 2002, data were only collected from the Doetinchem cohort, which was the second 
re-examination of the participants of the PCDRF (aged 30-69 years). The overall 
response rate was 68% for men and 63% for women. 
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All respondents completed a questionnaire that contained questions on 
demographic variables, cardiovascular risk factors, and current use of medication. 
After this, blood pressure, weight, and height were measured and blood was drawn 
for total and high-density lipoprotein cholesterol determination. The design of this 
study has been described in detail elsewhere.10, 12 A nonresponse survey was 
conducted in order to assess possible selection bias. Of all nonrespondents (n=1,620) 
61% agreed to participate, 23% could not be reached, and 16% refused to 
participate. The results suggested that no selection bias with respect to educational 
level has occurred. Educational level is a main determinant of nonresponse and is 
associated with blood pressure.13, 14 Therefore, no substantial differences are expected 
in blood pressure between respondents and nonrespondents.10
A random zero sphygmomanometer was used to measure blood pressure with the 
subject in a sitting position using a cuff of proper size for arm circumference. After the 
first measurement, the heart rate was measured for 30 s and after 5 min by a second 
blood pressure measurement.  
We selected patients group aged 30-59, because persons aged 20-29 were not 
included in the re-examination of the Doetinchem cohort (1998-2002) and in 
Amsterdam and Maastricht (1996-1997) persons aged 60-69 were not included. 
 
Definitions 
Hypertension was defined according to the WHO-ISH criteria as SBP ≥ 140 mmHg 
and/or DBP ≥ 90 mmHg and/or the use of antihypertensive medication (irrespective 
of the level of blood pressure). Participants with hypertension were further classified 
as: treated and adequately controlled, treated but uncontrolled, and untreated. 
Uncontrolled persons were treated but had their SBP ≥ 140 mmHg and/or DBP ≥ 90 
mmHg. For the analysis of undertreatment, we used Dutch guidelines of 2000 for the 
treatment of hypertension.15 If SBP ≥ 180 mmHg and/or DBP ≥ 100 mmHg treatment 
is always necessary. In addition, when the 10-year cardiovascular risk (estimated 
with the multifactorial Framingham risk equation) exceeds 20%, hypertension should 
also be pharmacologically treated. Persons aged 40-59 years with a cardiovascular 
disease, subjects with diabetes aged 50-59 years, persons with diabetes and smoking 
aged 40-49 years, and smoking males aged 50-59 years with SBP between 140 and 
180 mmHg and/or DBP between 90 and 100 mmHg should be treated because their 
10-year cardiovascular risk exceeds 20%. Among treated hypertensives, blood 
pressure is considered controlled if SBP < 140 mmHg and DBP < 90 mmHg.  
For the analysis of the determinants or treatment and control, besides a cut-off 
value of 140/90 mmHg, also a higher SBP cut-off (≥ 160 mmHg) and/or DBP cut-off 
(≥ 95 mmHg) was chosen, in order to minimize misclassification of subjects as 
untreated or uncontrolled hypertensives on the basis of two blood pressure 
measurements on the same day. 
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Correction for within-person variability 
Repeated measurements of blood pressure and total cholesterol were available from a 
sample of the population screened from 1987 to 1992.9 Among 924 subjects who were 
examined in 1989 and 1990, in each year two blood pressure measurements (in 
duplicate) and a total cholesterol determination were performed. These 
measurements were used to calculate blood pressure, serum total cholesterol, and 
HDL-cholesterol levels adjusted for within-person variability.  
The adjustment for SBP and DBP was performed separately for persons untreated 
for hypertension with no other risk factor present, respondents who were untreated 
for hypertension with one or more risk factors, and drug-treated persons after 
stratification by gender and 10-year age category.16 This adjustment was performed 
within these strata because each stratum can be considered a separate subpopulation 
with a specific distribution of blood pressure values. By this approach, each blood 
pressure value was corrected towards the mean of the stratum to which that 
individual belonged. This will correct for the possibility to classify a person with 
normal blood pressure as hypertensive. For total cholesterol values, this correction 
was performed after stratification for gender and 10-year age category.16  
 
Statistical analysis 
The prevalence of treatment and undertreatment of hypertension was estimated and 
standardized to the age and gender distribution of the general population in 1999. 
Multivariate logistic regression analysis was used to assess the association between 
demographic variables, cardiovascular disease risk factors, medication use as 
independent variables and treatment and control of hypertension as dependent 
variables. The Chi-square statistics for trend was used for the time trends. 
 
 
Results  
 
Prevalence of hypertension, treatment and control of hypertension 
After exclusion of pregnant women (n=125) and subjects with missing blood pressure 
data (n=12), 10,820 subjects remained available for analysis. Using the WHO-ISH 
guidelines,19 20.1% (2,176/10,820) of the study population was classified as 
hypertensive (see table 1). Of the hypertensives, 70% (1,530/2,176) were not 
receive any antihypertensive medication, while among those treated 54% (347/646) 
had blood pressure levels ≥ 140/90 mmHg. Table 2 lists the prevalence of 
hypertension by age and gender. Among men, 21.4% had hypertension, 17.9% was 
treated, and in 67.6% of those treated blood pressure was not controlled. According 
to the current Dutch guidelines, 21.9% of the untreated hypertensive men were 
eligible for treatment. 
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Table 1. Prevalence of hypertension according to the WHO-ISH classification, adjusted for 
within-person variability.  
 
WHO-ISH grade SBP 
(mmHg) 
DBP 
(mmHg) 
Total study 
population  
(n (%)) 
Treated  
(n (%)) 
Untreated  
(n (%)) 
Normotensive      
Optimal < 120 < 80  4,247 (39.3)   32 (0.3) 4,215 (40.0) 
Normal 120-129 80-84  2,713 (25.1)   93 (0.9) 2,620 (24.2) 
High normal 130-139 85-89  1,983 (18.3) 174 (1.6) 1,809 (16.7) 
Hypertensive      
Grade 1 140-159 90-99  1,509 (13.9) 257 (2.4) 1,252 (11.6) 
Grade 2 160-179 100-109     311 (  2.9)   77 (0.7)    234 (  2.2) 
Grade 3 ≥ 180 ≥ 110       57 (  0.5)   13 (0.1)      44 (  0.4) 
All   10,820 (100) 646 (6.0) 1,530 (14.2)1
 
1 Only the sum of the percentages of grade 1,2, and 3 
All percentages refer to the total population 
 
Table 2. Prevalence of hypertension (≥ 140/90 mmHg), treated and undertreated 
hypertension in men and women by 10-year category and adjusted for within-person 
variability. 
 
 Respondents Hypertension  
(n (%))1
Patients 
treated  
(n (%))2
Patients 
treated but 
uncontrolled5 
(n (%))3
Patients 
untreated  
(n (%))2
Patients 
untreated but 
should be 
treated6  
(n (%))4
Men       
30-597 5,004 1,201 (21.4) 285 (17.9) 181 (67.6) 916 (82.1) 271 (21.9) 
30-39 1,237    130 (10.5)   11 (  8.5)     8 (72.7) 119 (91.5)   14 (11.8) 
40-49 1,958    419 (21.4)   75 (17.9)   50 (67.7) 344 (82.1)   65 (16.3) 
50-59 1,809    652 (36.0) 199 (30.5) 123 (61.8) 453 (69.5) 192 (42.4) 
Women       
30-597 5,816    975 (14.9) 361 (38.5) 166 (51.9) 614 (61.5)   94 (13.6) 
30-39 1,593      59 (  3.7)    24 (40.7)   16 (66.7)   35 (59.3)     4 (11.4) 
40-49 2,306    312 (13.5) 119 (38.1)   46 (38.7) 193 (61.9)   26 (13.5) 
50-59 1,917    604 (31.5) 218 (36.1) 104 (47.7) 386 (63.9)   64 (16.6) 
 
1 All percentages refer to the total population 
2 All percentages refer to those hypertensive 
3 All percentages refer to those treated 
4 All percentages refer to those untreated 
5 DBP ≥ 140 mmHg and/or SBP ≥ 90 mmHg 
6 Untreated should be treated refers to the subject not treated for hypertension, who should be 
treated according to the CBO consensus Hypertension because their risk for developing a 
cardiovascular disease is more then 20% based on their age, gender, blood pressure, smoking 
status, and presence of diabetes, or cardiovascular diseases 
7 Weighed by age and gender distribution of the general Dutch population in 1999 
 
Among women, 14.9% had hypertension, 38.5% was treated, of whom 51.9% had 
their blood pressure uncontrolled. About 14% of the untreated hypertensive women 
were eligible for treatment. The prevalence of hypertension increased with age for 
both men and women. In each age category, the treatment with antihypertensive 
medication was more prevalent in women compared to men. Among the 2,176 
subjects with hypertension, a total of 365 untreated subjects were eligible for 
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treatment and of those treated (n=646) 347 persons had their blood pressure 
uncontrolled. 
 
Time trends in the treatment and control of hypertension  
The prevalence of hypertension decreased significantly from 1996 to 2002 in 
Doetinchem (trend test p=0.04). An increasing trend was observed for the percentage 
of treated hypertensives (trend test p=0.02).  
The percentage of controlled persons fluctuated, with the worst situation between 
1998 and 1999 (see table 3). During this period, the percentage of untreated 
hypertensives who were eligible for treatment was highest. The proportion of treated 
hypertensives with uncontrolled blood pressure and the proportion of untreated 
hypertensives who were eligible for treatment was lowest from 2000 to 2002. 
However, none of these differences were statistically significant. 
 
Table 3. Prevalence of hypertension (≥ 140/90 mmHg), treated and undertreated 
hypertension for different time periods, weighted by age and gender distribution of the general 
Dutch population in 1999 and adjusted for within-person variability. 
 
 Respondents Hypertension  
(n (%))1
Patients 
treated  
(n (%))2
Patients 
treated but 
uncontrolled5 
(n (%))3
Patients 
untreated  
(n (%))2
Patients 
untreated but 
should be 
treated6  
(n (%))4
1996-1997       
Amsterdam 2,421 389 (15.8) 133 (32.3) 58 (54.2) 256 (67.6) 62 (14.5) 
Maastricht 2,089 440 (16.7) 157 (38.0) 82 (62.8) 283 (62.0) 68 (25.3) 
Doetinchem 2,518 427 (21.4)   91 (20.7) 63 (65.2) 336 (79.3) 77 (23.0) 
1998-1999       
Doetinchem 1,446 349 (21.3)   94 (27.2) 55 (67.6) 255 (72.8) 78 (23.0) 
2000-2002       
Doetinchem 2,346 571 (20.6) 171 (28.5) 89 (56.3) 400 (71.5) 80 (14.9) 
 
1 All percentages refer to the total population 
2 All percentages refer to those hypertensive 
3 All percentages refer to those treated 
4 All percentages refer to those untreated 
5 DBP ≥ 140 mmHg and/or SBP ≥ 90 mmHg 
6 Untreated should be treated refers to the subject not treated for hypertension, who should be 
treated according to the CBO consensus Hypertension because their risk for developing a 
cardiovascular disease is more then 20% based on their age, gender, BP, smoking status, and 
presence of diabetes, or cardiovascular diseases 
 
Determinants of untreated and treated but uncontrolled hypertension 
Determinants of undertreatment, defined as eligible for treatment but not receiving 
antihypertensive medication, are reported in figure 1a. Subjects who used 
cholesterol-lowering medication and subjects screened during the years 1998 and 
1999 were less likely to be untreated (Odds ratio (OR) < 1). Males, current smokers, 
subjects on a low salt diet, and physically active hypertensives were more likely to be 
untreated (OR > 1).   
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Figure 1. Determinants of untreated and uncontrolled hypertension according to the CBO 
consensus Hypertension. All odds ratio are adjusted for demographic variables, cardiovascular 
risk factors, and medication use. 
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Determinants of treated but uncontrolled hypertension are reported in figure 1b. 
The use of cholesterol-lowering medication was significantly associated with a lower 
probability of uncontrolled hypertension (OR <1) and having asthma or allergy with a 
higher probability of uncontrolled hypertension.  
We also performed an analysis with a higher SBP cut-off (≥ 160 mmHg) and/or 
DBP cut-off (≥ 95 mmHg). The association between determinants and treatment 
status was similar compared to the analysis with lower blood pressure cut-offs. 
Although the following factors showed the same trend, they were no longer 
significant: year of screening (1998-1999 vs. 1996-1997; OR=0.43; 95% CI: 0.16-
1.16) and being physically active (OR=1.96; 95%CI: 0.96-3.99). The place of 
residence became significant (Maastricht vs. Doetinchem; OR=0.28; 95%CI: 0.08-
0.78, Amsterdam vs. Doetinchem; OR=0.25; 95%CI: 0.09-0.84). The association 
between determinants and uncontrolled blood pressure was also similar compared to 
the analysis with a lower blood pressure cut-off level. However, year of screening 
(2000-2002 vs. 1996-1997; OR=0.20; 95%CI: 0.05-0.82) and older age were 
significantly associated (OR=0.93; 95%CI: 0.86-0.99). Asthma or allergy was no 
longer significant (OR=1.69; 95%CI: 0.62-4.57).  
 
 
Discussion   
 
Approximately 21% of the men and 15% of the women aged 30-59 years were 
hypertensive. Approximately 18% of the hypertensive men and 39% of the 
hypertensive women were receiving antihypertensive medication. According to the 
Dutch guidelines, only 21.9% of the untreated hypertensive men and 13.6% of the 
untreated hypertensive women were eligible for pharmacological treatment. Of the 
treated persons, 67.6% of the men and 51.9% of the women had uncontrolled blood 
pressure levels despite pharmacological treatment. A possible explanation for the 
differences found in men and women could be the higher rate of patient-physician 
contact of women and the higher compliance of women in our study population. 
Unfortunately, we did not have information on these variables and were therefore 
unable to investigate these factors. The prevalence of hypertension decreased and the 
prevalence of treatment increased between 1996 and 2002 in Doetinchem. 
The prevalence of hypertension in the Netherlands is similar compared to other 
Western-European studies. In England, the prevalence is approximately 24% for men 
and 22% for women (aged 30-59 years);17 in France, it is 16% for men and 9% for 
women (aged 18-50 years);18 and in Germany 39% for men and 25% for women 
(aged 25-64 years).19 The percentage of treated hypertensives in West-Europe is 
around 60% and the percentage of uncontrolled hypertensives around 20%. Wolf-
Maier et al.20 published that the prevalence of hypertension was 44% in six European 
countries and that only 8% of the hypertensive persons had their blood pressure 
controlled (aged 35-64 years). However, because of differences in study design, such
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as age range, years of screening, and method for blood pressure measurement, it is 
difficult to compare the results. In most studies, treatment and control of 
hypertension is better in women than in men.19 
The results from the multivariate analysis show that females, not being physically 
active, not having been screened at the beginning of the follow-up, low intake of salt, 
and use of cholesterol-lowering medication are positively associated with treatment of 
hypertension. Also, in other European studies, females and non-smoking are 
positively associated with treatment of hypertension, while results for age and 
evidence for cardiovascular diseases are not the same.21-23 This is probably caused by 
the difference in age range. In our study, subjects who are physically active or having 
a low salt diet are less likely to receive treatment. This might have occurred because 
these subjects were borderline hypertensive and were advised by their doctors to be 
more active in order to reduce their blood pressure or eat a low salt diet. The use of 
cholesterol-lowering medication and having asthma or allergy are factors associated 
with a better control of blood pressure. A possible explanation is that patients who 
already use medication besides blood pressure-lowering drugs have a higher 
compliance. In other European studies, female gender and evidence for cardiovascular 
disease are associated with a better control of blood pressure.21-23 The results of our 
study are similar, although, the differences in study designs make it difficult to 
compare the results.  
 
Treatment considerations 
At the moment, two different treatment guidelines are used in the Netherlands.22, 31 
The CBO consensus is the most recent guideline and is the result of a consensus 
between various health-care professionals, whereas the NHG guideline is less recent 
and is an advice from the Dutch General Practitioners Association. The NHG guideline 
still uses blood pressure ≥ 160/95 mmHg as a definition for hypertension, and 
recommends treatment goals < 160/90 mmHg. This may explain the poor control of 
blood pressure since 1996 and improvement during the most recent years. 
Nonetheless, even in the most recent years treatment and control rates of 
hypertension were far from optimal. Recently, the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High Blood pressure even 
recommended starting antihypertensive drug treatment in patients with blood 
pressure ≥ 140/90 mmHg, irrespective of their cardiovascular risk factor profile.25
One possible explanation for lack of control of blood pressure among treated 
hypertensives might be the lack of aggressiveness in treating persons. Another reason 
for not achieving the target blood pressure is poor patient compliance with the 
antihypertensive medication. According to several studies, about 50% to 60% of 
hypertensives adhere well to antihypertensive medication.26, 27 Lack of treatment 
among those eligible for drug treatment may be caused by a lack of detection of 
hypertension, physician noncompliance with treatment guidelines,28-32 or reluctance of 
persons to receive drug treatment.33, 34  
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Unfortunately, despite various intervention strategies of different aspects in the 
management of hypertension, only a few of these interventions have been effective in 
achieving improved control of blood pressure.35 Multiple interventions at the level of 
patients, health-care providers are probably more effective than a single interaction 
by a health-care provider alone.36   
The WHO reported in 1999 that there are worrying signs that the control rates 
had stabilized or even declined in some cases.11 This study demonstrates that the 
prevalence of hypertension has decreased and that the number of hypertensives 
treated has increased between 1996 and 2002 in Doetinchem. It is, however, difficult 
to compare the results from Doetinchem with the general Dutch population. The 
results from the multivariate analysis show that hypertensives living in Doetinchem 
were less likely to be treated and have their blood pressure controlled compared to 
hypertensives living in Amsterdam or Maastricht between 1996 and 1997. So, even in 
a small country as the Netherlands there are regional differences in treatment 
probability, which may be related to differences in lifestyle.   
 
Strengths and limitations 
A potential bias is that patients are classified as hypertensives based on 
measurements, which were obtained on a single occasion, although, averaged over 
two readings. However, we adjusted for within-person variability in blood pressure 
and total cholesterol. Ignoring this variability would have lead to incorrect 
classification of persons with normal blood pressure as hypertensives and therefore 
influence prevalence estimates. Also, a higher blood pressure (≥ 95/160 mmHg) cut-
off was used for the analysis of determinants of hypertension, since this could 
minimize the number of falsely assignment hypertensives. The results are, however, 
similar. 
Another limitation is that we used self-reported data and did not include an 
examination of subjects’ medical records. The influence of misclassification is difficult 
to assess because over and under-reporting of cardiovascular risk factors and 
diseases occur.37 The use of information from self-reported medication has most likely 
not influenced our prevalence estimates, because agreement between 
self-reported antihypertensive drug use in this survey and the pharmacy records of 
antihypertensive drug dispensing is excellent.38
The Doetinchem cohort was a re-examination. It is possible that persons who 
participate in the re-examination are more conscious of their health (e.g. better 
compliance with drugs, better lifestyle, and/or more visits to a physician). If this is 
the case we underestimated the number treated and controlled hypertensives in the 
general population.  
We decided to consider only subjects whose risk of developing a cardiovascular 
disease within the next 10 years exceeding 20% as “untreated but should be treated”. 
However, according to the CBO guidelines13 when the cardiovascular risk is between 
10% and 20%, drug treatment is cost-effective and may therefore be considered. So,
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the eligible group for treatment is most likely larger than considered in this study. We 
did not include this group in our analysis because the guidelines leave this to the 
individual choice of the physician and patient.  
 
 
Conclusions 
 
Overall, the results suggest that approximately 14% of the Dutch population aged 30-
59 years has hypertension (blood pressure ≥ 140/90 mmHg). The situation is better 
for women than for men. There remains a considerable proportion of hypertensives 
who are eligible for treatment but are untreated (18%) and treated patients whose 
blood pressure is not controlled (46%). Although treatment improved slightly during 
the study period in Doetinchem, control of hypertension in our study is far from 
optimal. Owing to the strong association between blood pressure and cardiovascular 
disease, it is necessary to improve treatment and control rates of hypertension in the 
Netherlands. To improve the management of hypertension, physicians may focus on 
the subgroups, which are identified in this study.   
 
 
 
 
 
 
 
 
 
 
 
 
Undertreatment of hypertension 
29   
 References 
 
1. Brown MJ, Haydock S. Pathoaetiology, epidemiology and diagnosis of hypertension. Drugs 2000;59 
Suppl 2:1-12; discussion 39-40. 
2. Svardsudd K, Tibblin G. Mortality and morbidity during 13.5 years' follow-up in relation to blood 
pressure. The study of men born in 1913. Acta Med Scand 1979;205(6):483-92. 
3. Fiebach NH, Hebert PR, Stampfer MJ, et al. A prospective study of high blood pressure and 
cardiovascular disease in women. Am J Epidemiol 1989;130(4):646-54. 
4. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, 
Prolonged differences in blood pressure: prospective observational studies corrected for the regression 
dilution bias. Lancet 1990;335(8692):765-74. 
5. van der Giezen AM, Schopman-Geurts van Kessel JG, Schouten EG, et al. Systolic blood pressure 
and cardiovascular mortality among 13,740 Dutch women. Prev Med 1990;19(4):456-65. 
6. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. Jama 
1996;275(20):1571-6. 
7. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and 
of coronary heart disease. Br Med Bull 1994;50(2):272-98. 
8. Gueyffier F, Froment A, Gouton M. New meta-analysis of treatment trials of hypertension: improving 
the estimate of therapeutic benefit. J Hum Hypertens 1996;10(1):1-8. 
9. Neal B, MacMahon S, Chapman N. Effects of ACE-inhibitors, calcium channel blockers, and other 
blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Blood 
Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000;356(9246):1955-64. 
10. Klungel OH, de Boer A, Paes AH, et al. Undertreatment of hypertension in a population-based study 
in The Netherlands. J Hypertens 1998;16(9):1371-8. 
11. 1999 World Health Organization-International Society of Hypertension Guidelines for the 
Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999;17(2):151-83. 
12. Verschuren WMM, Leer van EM, Blokstra A, et al. Cardiovascular disease risk factors in The 
Netherlands. Neth J Cardiol 1993;4:205-10. 
13. Jacobsen BK, Thelle DS. Risk factors for coronary heart disease and level of education. The Tromso 
Heart Study. Am J Epidemiol 1988;127(5):923-32. 
14. Kraus JF, Borhani NO, Franti CE. Socioeconomic status, ethnicity, and risk of coronary heart disease. 
Am J Epidemiol 1980;111(4):407-14. 
15. CBO-consensus. Hoge bloeddruk. Herziening richtlijnen 2000 [in Dutch]. 
16. Klungel OH, de Boer A, Paes AH, et al. Estimating the prevalence of hypertension corrected for the 
effect of within-person variability in blood pressure. J Clin Epidemiol 2000;53(11):1158-63. 
17. Primatesta P, Brookes M, Poulter NR. Improved hypertension management and control: results from 
the health survey for England 1998. Hypertension 2001;38(4):827-32. 
18. de Gaudemaris R, Lang T, Chatellier G, et al. Socioeconomic inequalities in hypertension prevalence 
and care: the IHPAF Study. Hypertension 2002;39(6):1119-25. 
19. Gasse C, Hense HW, Stieber J, et al. Assessing hypertension management in the community: trends 
of prevalence, detection, treatment, and control of hypertension in the MONICA Project, Augsburg 1984-
1995. J Hum Hypertens 2001;15(1):27-36. 
20. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 
European countries, Canada, and the United States. Jama 2003;289(18):2363-9. 
21. De Henauw S, De Bacquer D, Fonteyne W, et al. Trends in the prevalence, detection, treatment and 
control of arterial hypertension in the Belgian adult population. J Hypertens 1998;16(3):277-84. 
22. Di Bari M, Salti F, Nardi M, et al. Undertreatment of hypertension in community-dwelling older 
adults: a drug-utilization study in Dicomano, Italy. J Hypertens 1999;17(11):1633-40. 
23. Shah S, Cook DG. Inequalities in the treatment and control of hypertension: age, social isolation and 
lifestyle are more important than economic circumstances. J Hypertens 2001;19(7):1333-40. 
24. NHG-Standaard Hypertensie. Huisarts Wet 1997; 40: 598-617 [in Dutch]. 
25. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. Jama 
2003;289(19):2560-71. 
26. Luscher TF, Vetter H, Siegenthaler W, et al. Compliance in hypertension: facts and concepts. J 
Hypertens Suppl 1985;3(1):S3-9. 
27. Balazovjech I, Hnilica P, Jr. Compliance with antihypertensive treatment in consultation rooms for 
hypertensive patients. J Hum Hypertens 1993;7(6):581-3. 
Chapter 2.1 
28. Haynes RB, Sackett DL, Gibson ES, et al. Improvement of medication compliance in uncontrolled 
hypertension. Lancet 1976;1(7972):1265-8. 
29. Peterson GM, McLean S, Millingen KS. Determinants of patient compliance with anticonvulsant 
therapy. Epilepsia 1982;23(6):607-13. 
30. Morisky DE, DeMuth NM, Field-Fass M, et al. Evaluation of family health education to build social 
support for long-term control of high blood pressure. Health Educ Q 1985;12(1):35-50. 
31. Eisen SA, Woodward RS, Miller D, et al. The effect of medication compliance on the control of 
hypertension. J Gen Intern Med 1987;2(5):298-305. 
32. Stockwell DH, Madhavan S, Cohen H, et al. The determinants of hypertension awareness, treatment, 
and control in an insured population. Am J Public Health 1994;84(11):1768-74. 
33. Wilber JA, Barrow JG. Hypertension--a community problem. Am J Med 1972;52(5):653-63. 
34. Klein LE. Compliance and blood pressure control. Hypertension 1988;11(3 Pt 2):II61-4. 
35. Trilling JS, Froom J. The urgent need to improve hypertension care. Arch Fam Med 2000;9(9):794-
801. 
36. Miller NH, Hill M, Kottke T, Ockene IS. The multilevel compliance challenge: recommendations for a 
call to action. A statement for healthcare professionals. Circulation 1997;95(4):1085-90. 
37. Klungel OH, de Boer A, Paes AH, et al. Cardiovascular diseases and risk factors in a population-
based study in The Netherlands: agreement between questionnaire information and medical records. 
Neth J Med 1999;55(4):177-83. 
38. Klungel OH, de Boer A, Paes AH, et al. Agreement between self-reported antihypertensive drug use 
and pharmacy records in a population-based study in The Netherlands. Pharm World Sci 
1999;21(5):217-20. 
 
 
 
 
30   
  
Chapter 3 
 
Pharmacogenetics and 
antihypertensive drugs 
 
   
    
  
Chapter 3.1 
 
Drug-gene interactions between 
genetic polymorphisms and 
antihypertensive therapy 
 
 
   
Chapter 3.1 
Abstract 
 
Genetic factors may influence the response to antihypertensive medication. A number 
of studies have investigated genetic polymorphisms as determinants of cardiovascular 
response to antihypertensive drug therapy. In most candidate gene studies, no such 
drug-gene interactions were found. However, there is observational evidence that 
hypertensive patients with the 460W-allele of the α-adducin gene have a lower risk of 
myocardial infarction and stroke when treated with diuretics compared with other 
antihypertensive therapies. With regard to blood pressure response, interactions were 
found between genetic polymorphisms in the endothelial nitric oxide synthase gene 
and diuretics, the α-adducin gene and diuretics, the α-subunit of G protein and β-
blockers, and the angiotensin converting enzyme (ACE) gene and angiotensin 
receptor II type 1 (AT1) receptor antagonists. Other studies found an interaction 
between ACE-inhibitors and the ACE insertion/deletion (I/D) polymorphism, which 
resulted in difference in AT1 receptor mRNA expression, left ventricular hypertrophy, 
and arterial stiffness between different genetic variants. Also, drug-gene interactions 
between calcium channel blockers and ACE I/D polymorphism regarding arterial 
stiffness have been reported. Unfortunately, the quality of these studies is quite 
variable. Given the methodological problems, the results from the candidate gene 
studies are still inconclusive and further research is necessary.  
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Introduction 
 
Hypertension is a major public health hazard because of its high prevalence, which is 
approximately 20% of the adult population in most developed countries1 and its high 
risk of cardiovascular diseases. Despite the availability of a variety of effective 
antihypertensive drugs, inadequate control of blood pressure is common in 
hypertensive patients, and is responsible for a large proportion of cardiovascular 
diseases in the population.2-4 The average response to antihypertensive drugs is 
similar across different classes of antihypertensives. For example, in the Veterans 
Affairs study,5 a randomized placebo-controlled clinical trail in which patients were 
randomly allocated to six different drugs or placebo, 31.7% of all hypertensive 
patients who were allocated to monotherapy with an antihypertensive drugs failed to 
achieve a normal diastolic blood pressure. When the initial treatment failed, 85.9% of 
these patients were randomized to another antihypertensive drugs which failed in 
37.8% of these patients.5 Although, the currently used ‘trial and error’ approach to 
antihypertensive drug therapy can be efficient in treating high blood pressure, it is not 
feasible with regards to long-term effects, such as myocardial infarction (MI) and 
stroke. Important factors in interpreting the variability in outcome of drug therapy 
include the patient's general health, prognosis, disease severity, quality of drug 
prescribing and dispensing, compliance with prescribed pharmacotherapy, and the 
genetic profile of the patient.6, 7
Multiple susceptibility genes and the environment explain the phenotype of 
essential hypertension. From family, twin, and adoption studies it has been estimated 
that 30% to 60% of the variation in blood pressure between individuals is caused by 
genetic factors.8 However, there is a small proportion of familial forms of hypertension 
that have a single gene (Mendelian) inheritance pattern. These include: apparent 
mineralocorticoid excess, glucocorticoid remediable aldosteronism, hypertensive 
forms of congenital adrenal hyperplasia, Liddle's syndrome, pseudohypoaldosteronism 
type II/Gordon’s syndrome, early-onset, autosomal dominant hypertension with 
severe exacerbation in pregnancy, and Bardet-Biedl syndrome types 2 and 4.9-11 
Pharmacogenetics focuses on the extent to which variability in genetic make-up is 
responsible for the observed differences in therapeutic response and adverse 
reactions between patients.6, 7 In other words, pharmacogenetics studies the 
interaction between drugs and genes, where interaction is defined as being present if 
the joint effect of a drug and genetic polymorphism is greater than the sum (additive 
scale) or product (multiplicative scale) of the individual effects of the drug and the 
genetic polymorphism. The purpose of pharmacogenetics is to understand the effects 
of genetic diversity on human response to drugs and other foreign substances and to 
use this information to avoid the occurrence of therapeutic failure and adverse drug 
reactions in susceptible persons.12 Drugs that are more specific for functional 
characteristics associated with an individual patient’s polymorphism may contribute to 
a better response and reduced toxicity of pharmacotherapy.  
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Genetic polymorphisms may influence drug response in three ways.13  
1. Through variation in pharmacokinetics that may pertain to absorption, but is mostly 
explained by altered metabolic clearance. Many pharmacokinetic drug-gene 
interactions are related to the cytochrome P450 (CYP) enzyme system.14 The majority 
of these enzymes are located in the endoplasmatic reticulum of the hepatocytes. This 
enzyme system can be modulated by genetic polymorphisms, causing some 
individuals to be poor (slow) metabolizers and others to be extensive (rapid) 
metabolizers. This is the case for many calcium channel blockers that are metabolized 
by CYP3A4, many lipophilic β-blockers by CYP2D6, and losartan and irbesartan by 
CYP2C9.15 However, it is unlikely that pharmacokinetic effects cause most of the 
antihypertensive drug-gene interactions.  
2.  Through altered pharmacodynamic drug-gene interactions. These involve, for 
example, gene products expressed as drug targets such as receptors and signal 
transduction molecules, which are relevant to the pharmacodynamics of drugs.  
3. Through genes that are in the causal pathway of the disease and are able to modify 
the effects of drugs.  
It is important to realize that most of the variation in blood pressure can be 
explained by a pharmacodynamic, rather than by pharmacokinetic, mechanism.16 This 
is most apparent in studies in which pharmacokinetic and pharmacodynamic 
assessments are available in the same subjects, and in which inter-subject variability 
can be expressed as a coefficient of variation.  
Six previous review articles presented pharmacogenetic concepts relevant to 
antihypertensive drug therapy. These articles included a brief overview of candidate 
genes studies with respect to blood pressure response and other cardiovascular 
responses to antihypertensive drug therapy.17-22 Our review extends the previous 
overviews and discusses some of the reasons for inconsistent results regarding drug-
gene interactions between genetic polymorphisms and antihypertensive drug therapy. 
Studies were identified in the Medline database from 1966 to October 2003 by 
combinations of the keywords: ‘antihypertensive drug’, ‘genetics’, and ‘polymorphism’ 
and by checking the references of all identified papers. All studies that reported data 
on genetic polymorphisms and response to antihypertensive drug therapy were 
included. Response to antihypertensive drugs was not pre-specified and could include 
blood pressure response, change in left ventricular mass, risk of MI and stroke, and 
other cardiovascular effects. 
 
  
Candidate gene studies and antihypertensive drugs 
 
Forty-one studies were found on the potential gene-drug interaction between genetic 
polymorphisms and antihypertensive drugs. Details of these studies are given in table 
1 and 2.  
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Table 1. The influence of genetic polymorphisms on the effect of antihypertensive medicine in patients 
with essential hypertension.  
 
Sample Duration  
of therapy 
Gene 
(location) 
Polymorphism Allelic association1 References 
Thiazide diuretic 
n=143 
Caucasian 
8wk ADD1 
(4p16.3) 
G460W 460W-allele associated 
with greater BP response 
23, 24
n=1038 
mixed 
4y  G460W 460W-allele associated 
with a lower risk of 
(combined) MI and stroke 
in comparison to other 
antihypertensive therapies 
(observational study) 
30
n=87 
Caucasian 
2mo  G460W 460W-allele associated 
with greater BP reduction 
29  
n=585 
mixed 
4wk  G460W No association (BP) 34
n=87 
Caucasian 
2mo ACE  
(17q23) 
I/D I-allele associated with a 
greater BP response 
29
n=376-585 
mixed 
4wk  I/D No association (BP) 34, 35
n=387-585 
mixed 
4wk GNB3  
(12p13) 
825C/T T-allele associated with 
greater BP response 
33
n=585 
mixed 
4wk ADRB1  
(10q24-q26) 
R389G No association (BP) 34
n=585  
mixed 
4wk ADRB2  
(5q31-q32) 
R16G No association (BP) 34
n=585  
mixed 
4wk LPL  
(8p22) 
S477Stop No association (BP) 34
n=585  
mixed 
4wk NOS2A  
(17p11-q12) 
E298D E-allele associated with 
greater DBP response 
34
      
β-blocker 
n=63-91 
Caucasian 
4wk AGT  
(1q42-q42) 
M235T No association (BP) 44
n=84-86 
Caucasian 
1-3mo  M235T No association (BP and 
LVM) 
45, 46
n=84-86 
Caucasian 
1-3mo  T174M No association (BP and 
LVM) 
45, 46
n=63-91 
Caucasian 
4wk ACE  
(17q23) 
I/D No association (BP) 44
n=50 
Caucasian 
15d  I/D No association (AT1R 
mRNA expression) 
47
n=84-86 
Caucasian 
1-3mo  I/D No association (BP and 
LVM) 
45, 46
n=84-86 
Caucasian 
1-3mo AGTR1  
(13q21-q25) 
1166A/C No association (BP and 
LVM) 
45, 46
n=147 
Caucasian 
4wk ADRB1  
(10q24-q26) 
G389R No association (BP and 
heart rate) 
48
n=40  
mixed 
>4wk  G389R R-allele associated with 
greater DBP reduction 
51
n=40  
mixed 
>4wk  S49G S-allele associated with a 
trend towards DBP 
reduction 
51
n=84-86 
Caucasian 
3mo CYP11B2 
(8q21-q22) 
-344C/T No association (BP and 
LVM) 
46, 49
n=97 
Caucasian 
3mo 74 SNPs2
ADRA2A 
 Association with: 
SBP (278G/T) and DBP 
59
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(10q24-q26) 
ADRB2  
(5q31-q32) 
AGT  
(1q42-q43) 
ADNRB3 
(13q22) 
NOS3  
(7q36) 
LIPC  
(15q21-q23) 
(1309G/A) 
SBP (1342G/C) and DBP 
(1817G/A) 
SBP (1015C/T) 
 
SBP and DBP (40G/A) 
 
SBP (498G/A) and DBP 
(2996A/G) 
DBP (110A/G) 
n=90 
Caucasian 
48wk BDKRB2 
(14q32) 
+9/-9 No association (LVM) 50
n=66 
Caucasian 
4wk GNAS  
(20q13) 
FokI (+/-) FokI +allele associated 
with greater BP reduction 
43
n=90 
Caucasian 
48wk TGFB1 
(19p13.2) 
915G/C No association (LVM) 103
      
ACE-inhibitor 
n=63-91 
Caucasian 
4wk AGT  
(1q42-q42) 
M235T No association (BP) 44
n=125 
Caucasian 
4wk  M235T 235T-allele associated with 
greater BP reduction 
61
n=1041 
mixed 
  M235T 235T-allele associated with 
a lower risk of stroke 
(observational study) 
62
n=63-91 
Caucasian 
4wk ACE  
(17q23) 
I/D No association (BP) 44
n=125 
Caucasian 
4wk  I/D No association (BP) 61
n=104 
Caucasian 
6mo  I/D D-allele associated with 
greater BP reduction 
64
n=50 
Japanese 
15d  I/D D-allele associated with 
greater AT1R mRNA 
expression 
47
n=54 
Japanese 
>2y  I/D I-allele associated with 
greater regression of LVH 
65
n=75 
Japanese 
6mo  I/D I-allele associated with 
greater regression of LVH 
67
n=60 
Japanese 
1y  I/D D-allele associated with 
positive effect on LVH and 
reduced diastolic filling 
63
n=57 
Japanese 
6wk  I/D I-allele associated with 
trend towards greater DBP 
reduction 
66
n=517 
Chinese 
6wk  I/D No association (BP) 75
n=82  
Japanese 
1h  I/D No association (BP and 
plasma renin activity)  
74
n=40 
Caucasian 
2mo AGTR1  
(13q21-q25) 
1166A/C 1166C-allele associated 
with greater BP reduction 
and arterial stiffness; no 
association heart rate 
68
n=125 
Caucasian 
4wk  1166A/C No association (BP) 61
      
AT1R antagonist 
n=84-86 
Caucasian 
1-3mo AGT  
(1q42-q42) 
M235T No association (BP and 
LVM) 
45, 46
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n=84-86 
Caucasian 
1-3mo  T174M 174M-allele associated 
with positive effect on 
LVM; no association BP 
45, 46
n=84-86 
Caucasian 
1-3mo ACE  
(17q23) 
I/D I-allele associated with 
greater DBP reduction; no 
association LVM 
45, 46
n=42 
Japanese 
12w  I/D I-allele associated with 
greater DBP reduction 
104
n=84-86 
Caucasian 
1-3mo AGTR1  
(13q21-q25) 
1166A/C 1166A-allele associated 
with a trend towards 
greater SBP reduction; no 
association LVM 
45, 46
n=84 
Caucasian 
3mo CYP11B2 
(8q21-q22) 
-344C/T -344T-allele associated 
with greater SBP 
reduction; no association 
LVM 
46, 49
n=84 
Caucasian 
12wk CYP2C9 
(10q24) 
*1 and *2 *1/*1 compared with 
*1/*2 associated with 
greater DBP reduction 
105
n=97 
Caucasian 
3mo 74 SNPs2
APOA1  
(11q23-q24) 
CYP11B2 
(8q21-q22) 
EDNRB  
(13q22) 
NOS3 (7q36) 
ACE (17q23) 
AGT  
(1q24-q43) 
LIPC  
(15q21-q23) 
 Association with: 
SBP and DBP (1449 A/G) 
 
SBP (267T/C) 
 
SBP (40G/A) 
 
SBP (498G/A) 
DBP (12257A/G) 
DBP (1198 C/T) 
 
DBP (110A/G) 
59
n=90 
Caucasian 
48wk BDKRB2 
(14q32) 
+9/-9 No association (LVM) 50
n=90 
Caucasian 
48wk TGFB1  
(19q13.1) 
915G/C C-allele associated with 
greater reduction LVM 
103
      
Calcium channel blocker 
n=63-91 
Caucasian 
4wk AGT  
(1q42-q42) 
M235T No association (BP) 44
n=50 
Caucasian 
15d ACE  
(17q23) 
I/D I-allele associated with 
reduced AT1R mRNA 
expression 
47
n=40 
Caucasian 
2mo AGTR1  
(13q21-q25) 
1166A/C 1166A-allele associated 
with greater reduction 
arterial stiffness; no 
association BP and heart 
rate 
77
 
1 Comparisons are versus untreated or placebo, unless otherwise specified. 
2 74 single nucleotide polymorphisms in 25 genes involved in BP regulation. 
d=days; h=hours; wk=weeks; y=years 
AT1=angiotensin II type 1; BP=blood pressure; DBP=diastolic blood pressure; I/D= 
insertion/deletion; LVH=left ventricular hypertrophy; LVM=left ventricular mass; MI=myocardial 
infarction; mRNA=messenger RNA; SBP=systolic blood pressure 
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Diuretics  
One of the first polymorphisms examined for blood pressure response in patients 
treated with diuretics was the G460W (a Gly to a Trp substitution at residue 460) α-
adducin polymorphism.23, 24 The human α-adducin 460W-allele can be considered as a 
candidate gene for hypertension, because it may affect blood pressure by increasing 
renal tubular reabsorption of sodium through the activation of Na+,K+-ATPase 
(adenosine triphosphatase). Linkage and association studies, performed with markers 
mapping in the region (loci) of the α-adducin locus and with the α-adducin G460W 
polymorphism, respectively, yielded positive associations.23 Compared with 
hypertensive patients who are homozygous for the 460G wild-type allele, 
hypertensive patients carrying at least one 460W-allele have a less steep pressure 
natriuresis slope. This means that they need a higher arterial pressure to excrete the 
same amount of sodium after saline infusion.25 Moreover, they have lower plasma 
renin activity,23 enhanced proximal tubular reabsorption,26 and a more pronounced 
blood pressure decrease after acute sodium depletion or long-term diuretic 
treatment.23 The 460W-allele of the α-adducin gene is associated with a higher affinity 
for the Na+,K+-ATPase pump than the 460G-allele.27 This last finding is particularly 
relevant because the same functional protein alteration has been demonstrated in 
both the rat and human ‘hypertensive’ α-adducin variant, suggesting that the protein 
plays a crucial role in Na+/K+ metabolism.27, 28 In two trials, the 460W-allele was 
associated with a greater blood pressure reduction in response to treatment with 
diuretics. In heterozygous (G/W) hypertensive patients a mean blood pressure 
decrease of 14.7 ± 2.2 mmHg was found versus 6.8 ± 1.4 mmHg in homozygous 
(G/G) hypertensive patients.23, 24  Recently, a second group of researchers also found 
an interaction between mean arterial pressure (diastolic blood pressure + (systolic 
blood pressure-diastolic blood pressure)/3) reduction and the G460W polymorphism. 
Homozygous (G/G) hypertensive patients had a reduction of 6 mmHg and patients 
with at least one 460W-allele had a reduction of 12 mmHg in mean blood pressure.29 
In another study the 460W-allele was associated with a lower risk (Odds ratio 
(OR)=0.49; 95%CI: 0.32-0.77) of MI and stroke in diuretic users compared with 
users of other antihypertensive drug therapies.30 
Recently, the ACE insertion/deletion (I/D) polymorphism was investigated for its 
role in blood pressure response to a diuretic (hydrochloorthiazide 25 mg). In this 
study a significant association was found between the ACE I/D polymorphism and 
response to hydrochlorothiazide. Hypertensive patients with the II genotype had a 
mean arterial pressure reduction of approximately 10 mmHg and those with the DD 
genotype a reduction of 3.8 mmHg.29
A third polymorphism that may influence the effect of a diuretic is the 825C/T 
(cytosine into a thymine) polymorphism (exon 10) of the gene encoding for the β3-
subunit of the G-protein. The G-protein mediate signal transduction across cell 
membranes.31 The 825T-allele of the β3-subunit of the G-protein polymorphism has 
been related to an RNA splice variant that results in the deletion of nucleotides 498-
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Table 2. The influence of genetic polymorphisms on the effect of antihypertensive medicine in 
non-hypertensive patients, but related diseases. 
 
Sample Duration  
of therapy 
Gene 
(location) 
Polymorphism Allelic association1 References 
β-blocker 
Nondiabetic 
nephropathy; 
n=81 Caucasian 
3-4y ACE  
(17q23) 
I/D D-allele associated 
with reduced 
glomerular filtration 
52
Chronic heart 
failure; n=328 
Caucasian 
2y  I/D D-allele associated 
with decreased 
chance of needing a 
heart transplantation 
53
      
ACE-inhibitor 
Proteinuric renal 
disease; n=36 
Caucasian 
12wk ACE  
(17q23) 
I/D No association 
(proteinuria) 
69
Diabetic 
nephropaty; 
n=35 Caucasian 
7y  I/D D associated with 
reduced glomerular 
filtration 
68
Chronic heart 
failure; n=34 
Caucasian 
6wk  I/D I-allele associated 
with greater BP 
reduction (captopril); 
no association 
(lisinopril) 
70
Post-PTCA; 
n=126 Japanese 
3-6mo  I/D I-allele associated 
with reduced chance 
of restenosis 
71
Nondiabetic 
nephropathy; 
n=81 Caucasian 
3-4y  I/D D-allele associated 
with reduced 
glomerular filtration 
52
Nondiabetic 
nephropathy; 
n=88 Caucasian 
4-12wk  I/D D-allele associated 
with reduced 
proteinuria (when 
there is a high salt 
excration) 
58
Post-coronary 
stents; n=345, 
Caucasian 
6mo  I/D I-allele associated 
with increased 
chance of restenosis 
72
Cerebrovascular 
disease 
(stroke/TIA); 
n=5688 mixed 
4wk  I/D No association 
(predicting 
cardiovascular risk of 
effect treatment) 
73
      
AT1R antagonist 
Diabetic 
nephropathy; 
n=45 Caucasian 
4mo ACE  
(17q23) 
I/D No association (BP 
and albuminuria) 
106
 
1 Comparisons are versus untreated or placebo, unless otherwise specified. 
d=days; wk=weeks; y=years 
AT1=angiotensin II type 1; BP=blood pressure; I/D=insertion/deletion; PTCA=percutaneous 
transluminal coronary angioplasty; TIA=transient ischaemic attack 
 
620 of exon 9 and structural changes in the β-subunit.32 Moreover, an enhanced 
signal was observed in lymphoblast lines from hypertensive individuals carrying the 
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825T-allele,31 which suggests that this genetic variation may indeed affect signal 
transduction. In one trial, a positive association was found between the 825T-allele 
and the effect of hydrochlorothiazide on blood pressure. Mean declines in systolic and 
diastolic blood pressures were 6 ± 2 and 5 ± 1 mmHg greater in TT than in CC 
homozygous patients, respectively.33  In the same study an association was found 
between thiazides and the 298E-allele of nitric oxide synthase gene on diastolic blood 
pressure with a larger sample size.34 Hypertensive patients homozygous for E-allele 
had a diastolic blood pressure reduction of 8.6 ± 0.4 mmHg compared to 7.1 ± 0.6 
mmHg for the other genotype groups. Their previously reported interaction with ACE 
gene35 could not be replicated with this larger sample size.34  
Recently, an alternatively spliced transcript of the β3-subunit of the G-protein 
referred to as Gβ3S2 was identified. Transcripts of the Gβ3S2 lack a 129 base pair of 
coding sequence of the β3-subunit of the G-protein. A close association between 
Gβ3S2 expression and T-allele status of the 825 C/T polymorphism of the β3-subunit 
of the G-protein was found. The data suggest that Gβ3S2 is a biologically active 
variant of the β-subunit of the G-protein, which may play a role in the manifestation 
of the complex phenotype associated with the 825C/T polymorphism.36
A polymorphism of the α-adducin gene may be used to identify patients with 
hypertension who are salt sensitive and respond relatively well to treatment with a 
diuretic. Nevertheless, two studies did not find an association between salt sensitive 
and this gene in young men37 or the general population.38 The β3-subunit of the G-
protein was also proposed as an candidate gene, but Ciechanowicz et al.39 could not 
find an association between polymorphism of the α-adducin gene and salt sensitivity 
of blood pressure. Furthermore, it has been suggested that polymorphisms of the 
angiotensin II type 1 receptor gene (AGTR1) and the γ-subunit of the epithelial Na+-
channel are also associated with salt sensitivity.40, 41 However, Giner et al. could not 
find an association.42 Whether genetic polymorphisms that are associated with salt-
sensitivity also modify the response to diuretics remains to be investigated. 
 
β-Blockers  
In only two of 11 studies was a drug-gene interaction found on blood pressure 
response to a β-blocker.43-51 This reduced response was attributed to a FokI +/- 
polymorphism encoding for the α-subunit of the G-protein. Good responders (62.5% 
had a FokI +allele) had a mean arterial blood pressure decrease of > 15 mmHg and 
poor responders (41.7% had a FokI +allele) had a decrease of < 11 mmHg.43 The α-
subunit of each heterotrimeric G-protein contains the guanine nucleotide-binding site, 
which has intrinsic guanosine triphosphatase activity and confers the functional 
specificity on each G-protein that allows it to discriminate among multiple receptors 
and effectors. In the cardiovascular system, the α-subunit of the G-protein couples 
β1- and β2-adrenoceptors in order to stimulate the cyclic adenosine monophosphate 
(cAMP) production. Johnson et al.51 found an interaction between β1-adrenergic 
receptor and metoprolol. Patients homozygygous for arginine at codon 389 had a 
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nearly 3-fold greater reduction in daytime diastolic blood pressure compared with 
those who carried the variant allele. 
In patients with nondiabetic nephropathy, the presence of the ACE D-allele was 
associated with a reduction of glomerular filtration.52 Another drug-gene interaction 
with the ACE D-allele was observed in patients with chronic heart failure. In this 
study,53 treatment with a β-blocker was associated with a decreased need for a heart 
transplantation.  
The A (adenine) into a C (cytosine) transversion at nucleotide position 1166 is 
located in the 3' untranslated region of the AGTR1 gene on chromosome 3q21-q25. 
Some studies have shown that it was associated with hypertension,54, 55 left 
ventricular hypertrophy (LVH),56 coronary heart disease, MI,57 and progression of 
diabetic nephropathy.58 The 1166A/C polymorphism of the AGTR1 gene was, however, 
not related to variation in blood pressure response or degree of LVH during β-blocker 
therapy in small groups of hypertensive patients.44, 45 
Recently, Liljedahl et al.59 tested a microarray-based minisequencing system on 
DNA samples of 97 hypertensive patients, of whom 49 were treated with atenolol. 
This group of researchers genotyped 74 Single Nucleotide Polymorphisms (SNPs) in 
25 genes that were involved in blood pressure regulation using stepwise multiple 
regression. Their results indicated drug-gene interactions between atenolol and 
several genes which resulted in a change in blood pressure, including: the 40G/A 
polymorphism of the endothelin receptor type B gene, the 278G/T and 1817G/A 
polymorphism of the adrenergic α1a-receptor gene, the 1342G/C and 1309G/A 
polymorphism of the adrenergic β2-receptor gene, the 498G/A and 2996A/G 
polymorphism of the endothelial nitric oxide synthase gene, and the 110A/G 
polymorphism of the lipase hepatic gene.59 However, this study included only a small 
number of patients and was focused on the applicability of the minisequencing system 
rather than on finding drug-gene interactions. Because of the large number of SNPs 
tested without adjustment for multiple testing and the small number of patients, this 
study could have resulted in a large number of false-positives and false-negative 
associations. The minisequencing method and study population was also used for the 
analysis of 30 SNPs in seven candidate genes of the renin-angiotensin system. In this 
study the researchers found that the -6A/G and M235T polymorphism of the 
angiotensinogen gene were associated with systolic blood pressure response.60   
 
ACE-inhibitors  
Most studies on interactions between ACE-inhibitors and genetic polymorphisms have 
concentrated on the renin-angiotensin system (RAS). One of the steps of the RAS 
system is the expression of angiotensinogen precursor in the liver. In response to 
lowered blood pressure it is cleaved by the enzyme renin. The resulting product, 
angiotensin I, is then cleaved by ACE to generate the physiologically active enzyme 
angiotensin II. This protein is involved in maintaining long-term blood pressure and in 
the pathogenesis of essential hypertension. 
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In one study, no drug-gene interaction was found between ACE-inhibitors and the 
M235T (methionine into a threonine) polymorphism of the angiotensinogen gene.44 
However, in a larger study an interaction was found.61 In this study, the reduction in 
systolic blood pressure was 20 ± 3 mmHg in patients with the TT genotype compared 
with 22 ± 2 mmHg in patients with MT genotype and 13 ± 4 mmHg in patients with 
the MM genotype. The reduction in diastolic blood pressure in patients carrying the TT 
genotype was 11 ± 3 mmHg compared with 14 ± 2 mmHg in patients with the MT
genotype, and 8 ± 2.5 mmHg in patients with the MM genotype.61 Another group of 
researchers found that ACE-inhibitor use compared with other antihypertensive drugs 
was associated with a lower risk of stroke among the TT genotype (OR=0.37; 95%CI: 
0.14-0.99) than among MT or MM genotype (OR=1.2; 95%CI: 0.88-2.40). No drug-
gene interaction on the risk of MI was found.62
Most studies have concentrated on investigating the association between the I/D 
polymorphism (intron 16) of the ACE gene and the response to an ACE-inhibitor. In 
12 out of 18 studies, an association could be found.47, 63-75 In one study, a greater 
blood pressure reduction with ACE-inhibitor therapy was observed in subjects with at 
least one copy of the D-allele. In this study, the reduction in systolic blood pressure in 
patients with the DD genotype was 5.6 ± 3.1 mmHg compared with 3.1 ± 1.1 mmHg 
with the II genotype and 3.6 ± 2.2 mmHg with the ID genotype. The reduction in 
diastolic blood pressure in patients with the DD genotype was 8.9 ± 6.0 mmHg 
compared with 5.5 ± 3.4 mmHg with the II genotype and 5.8 ± 4.0 mmHg with the ID 
genotype.64 In the other studies, the I-allele was associated with a reduced regression 
of LVH in patients with hypertension65, 66 and increased chance on restenosis in 
patients with coronair stents.72 The D-allele was associated with reduced AT1 receptor 
mRNA expression,47 left ventricular hypertrophy, reduced diastolic filling,63 greater 
reduction of glomerular filtration in diabetic and non-diabetic patients,52, 68 and less 
reduction of proteinuria in patients with nondiabetic nephropathy (primarily combined 
with a high excretion of salt).76
In two studies, the interaction between the 1166A/C polymorphism of the AGTR1 
gene and the response to ACE-inhibitors was investigated. In a small study, no 
interaction was found.61 In a larger study, the C-allele was associated with greater 
reduction of arterial stiffness and blood pressure by ACE inhibition. Patients with the 
AA genotype had a blood pressure reduction of approximately 6 mmHg and those with 
AC/CC genotype had a reduction of approximately 14 mmHg.77
 
Angiotensin II type 1 receptor antagonists  
Only one group has investigated the role of genetic polymorphisms and the response 
to an angiotensin II type 1 (AT1) receptor antagonist (irbesartan).44, 45, 48, 49, 58 The 
174M-allele of the angiotensinogen gene was associated with a positive effect of 
irbesartan on LVH. No interactions were found between the M235T polymorphism of 
the angiotensinogen gene or the –344C/T (cytosine to a thymine) polymorphism of 
the aldosterone synthase gene (CYP11B2) and irbesartan on reduction of LVH.45, 46, 49 
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However, the -344T-allele of the aldosterone synthase gene was associated with an 
increased reduction of systolic blood pressure after treatment with the AT1 receptor 
antagonist. Patients with TT genotype had a mean reduction in blood pressure of 21 ± 
19 mmHg compared with 14 ± 18 mmHg in patients with TC genotype and 0 ± 17 
mmHg in patients with CC genotype.49 Also the I-allele of the ACE gene was 
associated with a reduction of diastolic blood pressure. Patients with the II genotype 
had a reduction of 18 ± 12 mmHg compared with 8 ± 11 mmHg in patients with ID
genotype and 6 ± 9 mmHg in patients with DD genotype.45 Aldosterone synthase is a 
key rate-limiting enzyme for the biosynthesis of aldosterone. The –344C/T 
polymorphism is associated with elevated plasma aldosterone concentration through 
increased aldosterone synthesis.78 These results suggest that the –344T-allele is 
functionally associated with increased sodium reabsorption and thereby maintains 
blood pressure at a higher level due to volume expansion. 
Liljedahl et al. 59 tested a microarray-based minisequencing system on DNA 
samples of 97 hypertensive patients of whom 48 were treated with irbesartan. They 
found that lowering of blood pressure by irbesartan was modified by several 
polymorphisms, including: the 1449A/G polymorphism of the apolipoprotein A, the 
267C/T polymorphism of the cytochrome P450, family 11, subfamily B, polypeptide 2 
gene (CYP11B2), the 40G/A polymorphism of the endothelin receptor type B gene, 
the 498G/A polymorphism of the endothelial nitric oxide synthase gene, the 1015C/T 
polymorphism of the angiotensinogen gene, the 12257G/A polymorphism of the ACE 
gene, and the 110A/G polymorphism of the lipase hepatic gene.59  
 
Calcium channel blocker 
The influence of genetic polymorphisms on calcium channel blockers had been 
examined in three studies. In one study, an interaction was observed between 
calcium channel blockers and the ACE gene: patients with the I-allele had a reduced 
expression of AT1 receptor mRNA.47 Another study found a drug-gene interaction with 
the A-allele of the 1166A/C polymorphism of the AGTR1 gene, which lead to greater 
reduction of arterial stiffness.77 A drug-gene interaction between the M235T-allele of 
the angiotensinogen gene and calcium channel blockers could not be demonstrated 
regarding blood pressure response.44, 77   
 
 
Potential reasons for inconsistent findings 
 
Most of the studies exhibited inconsistent findings and did not yield conclusive results. 
In one out of four studies, for example, an interaction was found between the ACE 
gene and ACE-inhibitors regarding blood pressure response. The most promising 
result was the interaction between the α-adducin G460W polymorphism and blood 
pressure response and risk of MI and stroke in response to diuretics. However, these 
results need to be replicated before definitive conclusions can be made.  
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It is known that it may be problematic to demonstrate linkage or association 
consistently. For example, some groups were able to confirm an association between 
hypertension and the M235T polymorphism, while others could not.79-81 A meta-
analysis of 5,500 subjects reported a significant but weak association (OR=1.2; p < 
0.0001) between this polymorphism and hypertension.82 This is most likely the same 
for studies investigating the role of genetic polymorphisms and the response to 
antihypertensive treatment. For this reason, pharmacogenetic studies require a large
group of patients in order to have sufficient power to detect small genetic effects. This 
will reduce the likelihood of getting false-positive or false-negative results. For 
instance, Turner et al.34 found no interaction between the ACE gene and the effect of 
hydrochlorothiazide on blood pressure response, in contrast to their previous reported 
association with a smaller sample size.33, 35 The sample size in the studies 
investigating antihypertensive drug-gene interactions in hypertensive patients ranged 
from 40 to 1,048 persons. However, > 60% of the studies had less than 100 patients 
which is not sufficient for conclusive results when, besides a genetic factor, also an 
interaction is investigated. The number of patients needed to detect drug-gene 
interactions depends on the outcome studied (e.g. continuous vs. categorical), the 
contrast between responders and nonresponders in different genotype groups (the 
amount of interaction), and the precision of the measurements.83, 84  
 
Genetic diversity between populations 
Genetic diversity between populations can hinder replication of results. Gene variants 
that were selected during evolution to conserve salt, for example, may play a larger 
role in hypertensive patients with ancestors from Africa.18 In a study where the 
disease-causing allele is more prevalent, it might be easier to find an interaction. One 
examples which was investigated for antihypertensive drug-gene interaction is the 
frequency of the I-allele of the ACE gene which is different between Asian and 
Caucasian population, i.e. 62% versus 50%, respectively.61, 64, 66
 
Different study design 
There are often different inclusion criteria for different study population. If, for 
example, one study only includes patients with severe hypertension, it is possible that 
these patients have a genetic profile which differs from moderate hypertensive 
patients examined in another study. This might be the case when the study of 
Stavroulakis et al. (SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg)52 is compared with 
Hingorani et al. (SBP > 160 mmHg or DBP > 90 mmHg).61 Furthermore, differences in 
treatment regime were found between these studies. Both studies had a 4-week 
washout period, but in one study patients were given 20 mg fosinopril one daily64 
(defined daily dose [DDD] equivalent=1.33) while in the other study, patients were 
given 50 mg/day captopril or 10 mg/day enalapril or 10 mg/day lisinopril or 4 mg/day 
perindopril (all DDD equivalent=1).61 Another influence may be the variation in 
duration of therapy in different studies. The duration of therapy ranged from 15 days 
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to 7 years in studies which focused on antihypertensive drug-gene interactions in 
hypertensive patients.  
Different results may be explained by the use of different study designs, such as 
experimental (e.g. randomized clinical trail) and observational (e.g. cohort and case-
control) studies. In observational study designs for example confounding maybe a 
problem (e.g. confounding by indication). 
Another potential explanation for different results relates to the definition of 
outcome. For instance, Scarrione et al.29 used the reduction in mean blood pressure, 
while Turner et al.34 used systolic and diastolic blood pressure separately.  
 
Genetic polymorphism and disease-causing factors 
Most of the examined polymorphisms are probably not the disease-causing factors.69 
An example is the M235T polymorphism of the angiotensinogen gene. There is now 
evidence that an A for G nucleotide substitution in the promoter region of the 
angiotensinogen gene 6 nucleotide upstream from the start site of transcription is the 
functional mutation.85, 86 The A substitution alters the binding of a nuclear protein, 
resulting in increased gene transcription compatible with increased angiotensinogen 
levels. Fortunately, it has been suggested that the –6G/A polymorphism is nearly in 
complete linkage disequilibrium (LD) with the M235T polymorphism.82, 87 The same 
holds for the I/D polymorphism in the ACE gene. The I/D polymorphism predicts 
approximately half of the interindividual variability in serum88, 89 and tissue.90 Thus, 
the probability that the ACE gene is not in linkage equilibrium with the functional 
polymorphism is considered small.89, 91, 92  
 
 
Considerations for the design of a pharmacogenetic study 
 
There are several ways to design studies to investigate interactions between 
antihypertensive drugs and genetic polymorphisms. All studies performed to date 
investigated (allelic) polymorphisms. This sort of study provides the most powerful 
approach to identify genes of small effect in complex traits93 because the markers that 
are used are either very close to the susceptibility locus or lie in the gene of interest 
itself. It is difficult to perform a linkage study, because a high number of patients 
would be needed and only relatives who use the same antihypertensive drugs can be 
included. In the future, genome-wide association studies using SNPs will become 
possible, which will make it available to use unrelated cases and controls to map 
regions of the genome, and eventually the whole genome.  
It is possible to consider different endpoints when investigating hypertension. For 
example, studies could consider long-term outcomes such as MI and/or stroke, 
intermediate-term outcomes such as atherosclerosis and/or LVH, or short-term 
outcomes such as blood pressure. Another option is to investigate adverse effects of 
antihypertensive drugs or adherence to antihypertensive medication. Moreover, there 
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are several potential inclusion criteria and there is no clear indication whether it is, for 
instance, best to choose mild or severe hypertension. It is important to consider the 
appropriate group of controls because a strong difference in response can results in 
spurious drug-gene interactions. 
The number of markers and the question which markers an investigator wants to 
test also need to be considered. There are biallelic (SNPs and I/D polymorphisms) and
microsatellite markers (tandem repeats). Biallelic markers are relatively less 
polymorphic, but they are more abundant and accessible. The number of markers 
depends on the amount of LD in the candidate gene in the study population. LD 
occurs when two particular alleles at loci on the chromosome go together more often 
then may be expected from independent segregation in a population. LD can be 
determined with a small pilot sample. This can help to optimize marker selection and 
provide information for haplotype analysis.94 Genotyping more markers gives more 
information and thus more power. It is, nonetheless, more expensive and time 
consuming and the sample size has to be increased because more genotypes groups 
are identified. When more markers are tested, adjustment should be made for 
multiple testing. It is best to investigate only candidate genes, which can be linked to 
a biological system. For antihypertensive response, for instance, genes in the renin-
angiotensin system are prominent, and other regulatory mechanisms of pressure-
natriuresis are important because of their role in blood pressure homeostasis.  
A more crucial issue is whether checking for population stratification is needed. 
Population stratification refers to a form of confounding. The bias from population 
stratification is the distortion in the association between the genetic variant and the 
outcome that can occur when the variant is associated with an unknown risk factor 
which varies by ethnicity. Population stratification may also be important in drug 
response. For instance, African Americans may react differently to a specific 
antihypertensive drugs class compared with Caucasians.95-98 The impact of population 
stratification is, however, not yet clear. Some conditions must be met before a 
substantial bias occurs: (I) there must be substantial variation across ethnicities in 
the allele frequency of the relevant gene; (II) there must be substantial variation in 
disease rates; (III) allele frequencies must correlate with adjusted disease rates 
between ethnic groups; and (IV) adjustment for ethnicity must reduce the relevant 
effect.99 At present it is still unclear whether population stratification biases results in 
a substantial way.94, 100 To minimize the effect of population stratification, a solution 
could be the typing of additional markers unrelated to the outcome101 or match for 
ethnicity.100, 102  
 
 
Future prospects 
 
Although there are many difficulties to overcome, pharmacogenetics may yield 
successful strategies to optimize drug therapy. Several potential candidate genes are 
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currently under investigation for their potential to modify response to 
antihypertensive drugs. Findings from previous studies require conformation in other 
studies to be able to make definitive conclusions about current positive drug-gene 
interactions. It is also important that research groups collaborate more it order to 
facilitate the conduct of a meta-analysis for conclusive results. With the development 
of efficient methods for analyzing massive amounts of data, pharmacogenetic studies
may eventually lead to the optimization of antihypertensive drug therapy based on 
genetic profiles of patients. 
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Abstract 
 
Aim: To investigated whether the insertion/deletion (I/D) polymorphism of the 
angiotensin converting enzyme (ACE) gene modified the adherence to ACE-inhibitors 
as measured by the discontinuation of an ACE-inhibitor, or the addition of another 
antihypertensive drug.  
Methods: This was a cohort study among 239 subjects who started ACE-inhibitor 
therapy. A Cox proportional hazard model was used to calculate relative risk (RR).  
Results: During follow-up there was no significant difference between subjects with the 
DD, ID, or II genotype (DD vs. II; RR=1.17; 95%CI: 0.78-1.77 and ID vs. II; 
RR=1.06; 95%CI: 0.73-1.55) in adherence.  
Conclusion: The I/D polymorphism of the ACE gene does not influence the adherence 
to ACE-inhibitors. 
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Introduction 
 
Hypertension is a major public health hazard and despite the availability of a variety of 
effective antihypertensive drugs inadequate control of blood pressure is common in 
hypertensive patients. One of the factors in interpreting the variability in outcome of 
drug therapy includes the genetic profile of a patient.1
A candidate gene for the control of blood pressure is the angiotensin converting 
enzyme (ACE) gene. Individuals with the DD genotype display twice as high serum 
ACE concentrations as individuals with the II genotype,2 but without clear correlation 
to blood pressure.2 The I/D polymorphism of the ACE gene has been associated with 
differential blood pressure responses to ACE-inhibitors. However, the results have been 
controversial.3-6
Given the controversial results, we investigated whether the I/D polymorphism of 
the ACE gene was associated with the response to ACE-inhibitor therapy as measured 
by the discontinuation of an ACE-inhibitor, or addition of another antihypertensive drug 
class.  
 
 
Methods 
 
Setting 
The Rotterdam Study started in 1990 as a population-based prospective follow-up 
study. In total, 7,983 residents of the suburb Ommoord in Rotterdam aged 55 years or 
over participated. The baseline measurements took place until 1993. The design of this 
population-based study has been described elsewhere.7 Pharmacy records were 
available for approximately 99% of the cohort as of January 1st, 1991.  
 
Cohort and outcome definition 
For the analysis, we included patients who had at least 6 months of medication history 
at the pharmacy before starting with an ACE-inhibitor and who did not use 
antihypertensive drugs during that period. We excluded persons with only one ACE-
inhibitor prescription. 
To study the potential interaction between the I/D polymorphism and response to 
ACE-inhibitors, we used two proxy outcomes. The first outcome was defined as the 
discontinuation of ACE-inhibitors for ≥ 180 days. The second outcome was addition of 
another antihypertensive drug to the ACE-inhibitor therapy. Subjects were followed 
until the outcome of interest, death, moving outside of the study area, or the end of 
the study period, whichever came first.  
 
Genotype  
The I and D-allele of the ACE genotype were identified on the basis of polymerase 
chain reaction (PCR) amplification of the respective fragments from intron 16 of the
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ACE gene and size fractionation and visualization by electrophoresis as described 
before.8
 
Analysis 
We used ANOVA (continuous variables) and Chi-square testing (categorical variables) 
to compare baseline characteristics of people with different genotypes. For the 
outcome of interest, a Cox proportional hazard model was used to calculate the 
relative risk (RR) and 95% confidence interval (95%CI) of discontinuation of an ACE-
inhibitor or addition of another antihypertensive drug.  
 
 
Results     
 
Between January 1st, 1991 and December 31st, 1999, 1,488 subjects were identified as 
ACE-inhibitor users and 239 subjects had not used antihypertensive medication 
between January 1st and July 1st, 1991 prior to the start of ACE-inhibitor medication. 
 
Cohort study among starters of ACE-inhibitors 
In total, 65, 117, and 57 had the DD, ID, and II genotypes, respectively. Different 
ACE-inhibitors were used as a first prescription including: enalapril (48.3%), lisinopril 
(16.8%), captopril (9.7%), quinapril (8.8%), perindopril (6.7%), fosinopril (6.3%), 
ramipril (3.0%), and cilazapril (0.4%). The distribution of age, gender, systolic blood 
pressure, diastolic blood pressure, smoking, and body mass index (BMI) were similar 
between the three genotype groups (see table 1).  
 
Table 1. Baseline characteristics. Values are presented as means (± SD), or number (%). 
 
Variable DD (n=65) ID (n=117) II (n=57) P 
Gender, F 36 (55.4%) 67 (57.3%) 32 (56.1%) 0.97 
Age, y 68.7± 9.7 69.2 ± 7.4 69.3 ± 8.2 0.90 
SBP1, mmHg 148.6 ± 20.9 154.7± 22.4 150.4 ± 22.0 0.21 
DBP1, mmHg 78.7 ± 10.6 80.3 ± 12.9 79.1 ± 9.8 0.66 
Smoking     
current 12 (18.5%) 33 (29.2%) 13 (22.8%) 0.53 
past 31 (47.7%) 46 (40.7%) 23 (40.4%)  
never 22 (33.8%) 34 (30.1%) 21 (36.8%)  
BMI, kg/m2 26.5 ± 3.2 26.4 ± 3.7 26.8 ± 4.0 0.96 
Diabetes mellitus, yes 11 (16.9%) 21 (17.9%)   7 (12.3%) 0.76 
MI, yes   6 (9.2%) 16 (13.7%)   2 (3.5%) 0.11 
 
1 Only persons with a blood pressure measurement before they started an ACE-
inhibitor therapy were included (n=211)  
 
The Kaplan-Meier function showed that there were no significant differences in the 
rate of discontinuation of ACE-inhibitors or addition of other antihypertensive 
medication (DD vs. II; RR=1.17; 95%CI: 0.78-1.77 and ID vs. II; RR=1.06; 95%CI: 
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0.73-1.55) (see figure 1). During the entire follow-up there was no significant 
difference between the three genotypes. The results were similar when the outcomes 
of discontinuation and addition of other antihypertensive drugs were analyzed 
separately (data not shown). Excluding of stoppers (n=38) did not effect our findings. 
The effect was not caused by a difference in the average last prescribed daily dose 
before a censoring event (0.76 ± 0.38, 0.83 ± 0.64, and 0.78 ± 0.37 for the DD, ID, 
and II genotype; p=0.63).  
 
Figure 1. Kaplan-Meier function of addition of other antihypertensive medication and/or 
stopping of an ACE-inhibitor stratified by ACE genotype (adjusted for gender, body mass index, 
systolic blood pressure diastolic blood pressure, myocardial infarction, diabetes mellitus, 
smoking, and death). 
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Discussion 
 
Our findings suggest that the ACE I/D polymorphism in starters of ACE-inhibitors does 
not influence the response when evaluated by discontinuation of ACE-inhibitors and/or 
addition of other antihypertensive drugs.  
Previously, four other studies investigated the role of the ACE gene in the response 
of blood pressure to ACE-inhibitors, but the results were inconclusive.3-6 Our study 
corroborates the results of two of four studies.5, 6 However, we used a proxy for blood 
pressure response instead of actual blood pressure measurements. Although, 
insufficient blood pressure control and side-effects account for most of the treatment 
switching,9 our proxy might not be good for measuring the nonsatisfactory response of 
blood pressure to ACE-inhibitors. For example, our results could be influenced by 
adverse reactions to ACE-inhibitors, like dry cough. The role of the ACE gene in the
occurrence of cough is, however, still unclear.10, 11 It is also possible, that due to 
satisfactory blood pressure response a physician advices a patient to stop using 
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antihypertensive medication. However, this is a rare occurrence and we saw no 
difference between switchers and stoppers.  
This study suggests that the ACE I/D polymorphism of the ACE gene does not 
influence the adherence to ACE-inhibitors.  
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Chapter 4.2 
Abstract 
 
Background: Despite the availability of a variety of effective drugs, inadequate control 
of blood pressure is common. There have been some indications that the angiotensin 
converting enzyme (ACE) gene modifies the response to antihypertensive drugs, 
although, the results were inconclusive. 
Aim: To investigate whether the insertion/deletion polymorphism of the ACE gene 
modifies blood pressure difference among subjects using diuretics, β-blockers, calcium 
channel blockers, or ACE-inhibitors. 
Methods: Data were used from the Rotterdam Study, a population-based prospective 
cohort study in the Netherlands, which started in 1990 and included 7,983 subjects 
aged 55 years or older. Data from three subsequent cross-sectional investigations was 
used. Subjects were included if they had a high blood pressure during ≥ 1 
examinations and/or used monotherapy with a diuretic, β-blocker, calcium channel 
blocker, or ACE-inhibitor. A marginal generalised linear model was used to assess the 
association between the mean difference in systolic/diastolic blood pressure and 
antihypertensive classes stratified by the three genotypes.  
Results: In total, 3,025 hypertensive individuals were included, totalling 6,500 
measurements of blood pressure. Of these, 28.3%, 51.4%, and 20.3% had the DD, 
ID, and II genotypes, respectively. The mean difference in systolic blood pressure 
between the II and DD genotype was 0.23 mmHg (95%CI: -5.48-5.94) for diuretic,    
–2.41 mmHg (95%CI: -6.72-1.90) for β-blocker, 2.12 mmHg (95%CI: -4.64-8.89) for 
calcium channel blocker, and –2.01 mmHg (95%CI: -9.82-5.79) for ACE-inhibitor 
users.   
Conclusion: The adjusted mean difference in diastolic and systolic blood pressure 
among diuretic, β-blocker, calcium channel blocker, or ACE-inhibitor users was not 
modified by the ACE insertion/deletion polymorphism.  
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Introduction 
 
The renin-angiotensin system (RAS) regulates blood pressure and fluid homeostasis. 
Angiotensin converting enzyme (ACE), which is one of the enzymes of the RAS, 
converts angiotensin I to the vasoactive angiotensin II and inactivates bradykinin. An 
insertion/deletion (I/D) polymorphism of the 187-bp Alu element in intron 16 of the 
ACE gene predicts approximately half of the inter-individual variability in serum ACE 
levels.1 In general, individuals with the DD genotype have serum ACE levels which are 
twice as high as individuals with the II genotype,1 although, there is no clear 
correlation to blood pressure.2  
Predicting the effect of a particular antihypertensive agent in an individual patient 
is difficult. To overcome this problem researchers are currently investigating which 
genes influence the response to various antihypertensive drugs.  
Some studies have investigated the effect of the ACE I/D polymorphism on blood 
pressure response in patients treated with ACE-inhibitors3-11 and, less so, in patients 
treated with β-blockers.4,12 The latter reduces angiotensin II levels by inhibiting the β-
adrenergic mediated renin release from the kidneys.13 With regard to ACE-inhibitor 
users, three studies indicated that the D-allele had a stronger blood pressure lowering 
effect,8-10 while two studies indicated the I-allele,6,7 and four studies found no drug-
gene effect.3-5,11 No drug-gene interaction was found in studies with β-blocker users.4,12 
Due to conflicting results, it is still unclear whether the I/D polymorphism of the ACE 
gene influences the response to ACE-inhibitors or β-blockers.  
Diuretics and calcium channel blocker are also influenced by the RAS i.e. by a 
counter regulatory system. For example, diuretic therapy leads to salt loss, which in 
turn, results in volume depletion, causing an increase in the plasma renin activity.14 
Calcium channel blockers block the inward movement of calcium by binding to L-type 
calcium channels in the heart and in smooth-muscle of the coronary and peripheral 
vasculature. This could result in an activation of the RAS.15 
The purpose of this study was to evaluate the relationship between the I/D 
polymorphism of the ACE gene on the mean difference in systolic blood pressure (SBP) 
and diastolic blood pressure (DBP) among diuretics, β-blockers, calcium channel 
blockers, or ACE-inhibitors users.  
 
 
Methods 
 
Setting 
The Rotterdam Study started in 1990 as a population-based prospective follow-up 
study. All 10,275 residents of the suburb Ommoord in Rotterdam aged 55 years or 
older were invited to participate. The aim of the Rotterdam Study is to investigate 
determinants of disease occurrence and progression in the elderly. Our study was 
67 
Chapter 4.2 
approved by the Medical Ethics Committee of Erasmus University and conducted in 
compliance with their requirements. In total, 7,983 (78%) subjects gave written 
informed consent and of 6,869 (86%) the ACE genotype was assessed. The baseline 
measurements took place until 1993. The design of this population-based study has 
been described elsewhere.16  
The baseline examination included several details, such as an interview on 
demographics, current health status, medical history, family history of diseases, 
smoking habits, and current use of medication. During a physical examination, blood 
pressure, weight, and height were measured and blood was drawn for DNA extraction. 
Blood pressure was measured in sitting position at the right upper arm with a random-
zero sphygmomanometer. The average of the two measurements, separated by a 
count of pulse rate, was used in the analysis. All participants were subsequently 
examined in follow-up examination rounds every 2-3 years (1993-1995, 1997-1999). 
Blood pressure data from all three examinations were used in this study. 
Pharmacy records were available for approximately 99% of the cohort as of 
January 1st, 1991. These records include the name of the drug, the day of dispensing, 
the dosage form, the number of units dispensed, the prescribed daily dose, and the 
Anatomical Therapeutic Chemical code of the drug.17
 
Cohort and outcome definition 
The study population included all individuals with hypertension in the Rotterdam Study 
for whom the ACE genotype was assessed and where 1 or more blood pressure 
measurements were available. We defined hypertension as ≥ 1 blood pressure 
measurement during follow-up, which met one of the following criteria: SBP ≥ 160 
mmHg, and/or DBP ≥ 95 mmHg. Subjects who used, antihypertensive drugs during 
follow-up were also defined as hypertensive. When a blood pressure measurement 
occurred, we assessed whether a prescription was filled by the pharmacy on this date. 
Hereto, the length of each prescription was calculated by dividing the number of 
dispensed tablets or capsules by the prescribed daily number. When the blood 
pressure measurement date fell within the usage period, the patient was considered as 
currently exposed. When > 1 antihypertensive drug class was used at the time of the 
blood pressure measurement the measurement was excluded. Antihypertensive drug 
treatment was classified in four groups i.e. diuretics, β-blockers, calcium channel 
blockers, or ACE-inhibitors. Subjects could switch between no treatment and different 
antihypertensive drug classes and between different antihypertensive drug classes. 
Due to the small numbers for the other antihypertensive drug classes, only subjects 
using diuretics, β-blockers, calcium channel blockers and ACE-inhibitors were included 
in the analysis. Pharmacy records were available as of January 1st, 1991. Nevertheless, 
blood pressure measurements from 1990 were included if an individual did not use an 
antihypertensive drug according to self-reported questionnaire information and did not 
start antihypertensive therapy before July 1st, 1991 according to the pharmacy 
dispensing records. The end of the study period was set at December 31st, 1999.  
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Potential confounders and effect modifiers 
The potential confounders considered were age, sex, body mass index (BMI), defined 
daily dose (DDD), which (re-)examination (1st, 2nd, or 3rd), smoking at baseline, history 
of myocardial infarction, diabetes mellitus at baseline, use of nitrates, use of statins, 
use of NSAID’s, use of another antihypertensive drug class two weeks prior to the 
blood pressure measurement, use of an antihypertensive drug for six of the eight 
weeks prior to the blood pressure measurement, and the cumulative number of days 
an antihypertensive drug was used. History of myocardial infarction was self-reported 
and confirmed by a physician or demonstrated on the baseline ECG. To compare 
dosages of different antihypertensive drugs in our analysis, we used the prescribed 
daily dose (PDD), expressed as the number of DDDs per day. The DDD is defined as 
the average daily dose for the main indication in an adult of 70 kg.18 DDDs provide a 
fixed unit of measurement independent of price and formulation, enabling the 
researcher to assess trends in drug consumption and to perform comparisons between 
population groups.  
Smoking was also considered as an effect-modifier, since smoking and the D-allele 
have been associated with increased generation of angiotensin II.19
 
Genotype  
The I and D-allele of the ACE gene were identified on the basis of polymerase-chain-
reaction (PCR) technique in accordance with the method described by Lindpainter et 
al.,17 with some modifications. Because the D-allele in heterozygous samples is 
preferentially amplified, there is a tendency of misclassification for about 4-5% of the 
ID to DD genotypes. For this reason, a second PCR was performed with a primer pair 
that recognises an insertion specific sequence (5’ TGG GAC CAC AGC GCC CAC TAC 3’ 
and 5’ TCG CCA GCC CTC CCA TGC CCA TAA 3’). The reaction yielded a 335-bp 
amplicon only if the I-allele was present. Two independent investigators read pictures 
from each gel and all ambiguous samples were analysed a second time. 
 
Analysis 
We used ANOVA (continuous variables) and Chi-square testing (categorical variables) 
to compare baseline characteristics of people with different genotypes. To compare the 
difference in DDDs for each examination, an ANOVA was used, stratified by genotype. 
A marginal generalised linear model (GEE) was used to investigate any association 
between I/D polymorphism of the ACE gene and antihypertensive treatment for two 
outcomes: mean difference in systolic blood pressure (SBP) and diastolic blood 
pressure (DBP). A p-value of ≤ 0.05 was considered statistically significant. Since 
subjects could have one, two, or three measurements, the GEE model was used to 
account for intraperson correlations among repeated measurements. The covariance 
matrix of the repeated dependent measurements was unstructured and data were 
analysed using SAS statistical software and corrected for potential confounders.  
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We performed two separate analyses. In the first analysis we compared the mean 
systolic and diastolic blood pressure levels between the different genotype groups (DD, 
ID, and II) for untreated and treated patients. In this analysis the reference group 
comprised of untreated subjects with the DD genotype. In the second analysis we 
focused on the drug-gene interaction. In this analysis we compared the mean systolic 
and diastolic blood pressure levels between the different genotype groups for subjects 
using the same antihypertensive drug class. The reference group comprised of subjects 
with the DD genotype who had a prescription of the antihypertensive drug class in 
question. The mean SBP and DBP of treated subjects was defined as the mean SBP or 
DBP of subjects who used the antihypertensive drug class in question minus the mean 
SBP or DBP in untreated subjects with the same genotype. 
 
 
Results 
 
Of the 6,869 subjects, who participated in the Rotterdam Study between January 1st, 
1990 and December 31st, 1999 3,025 were classified as hypertensive. These 3,025 
subjects had a total of 6,500 blood pressure measurements. In total, 28.3%, 51.4%, 
and 20.3% had the DD, ID, and II genotypes, respectively. Of these 3,025 persons, 
431 subjects used diuretics (603 measurements), 745 used β-blockers (1,078 
measurements), 306 used calcium channel blockers (400 measurements), and 317 
used ACE-inhibitors (420 measurements). A person may switch from one 
antihypertensive drug class to another. Baseline characteristics at the first examination 
are presented in table 1. The mean DDD at baseline for diuretics was 0.81 ± 0.44, for 
β-blockers 0.67 ± 0.17, for calcium channel blockers 0.79 ± 0.43, and for ACE-
inhibitors 1.01 ± 0.63, respectively. During the first examination round, 855 subjects 
were treated with an antihypertensive drug. During the three examination rounds 
there was no statistically significant difference in the DDDs between the different 
genotype groups for any of the different antihypertensive drug classes.  
In the univariate analysis without correction for potential confounders, none of the 
antihypertensive drug classes were associated with a significant decrease in the mean 
difference in SBP or DBP for the three genotype groups (data not shown). After 
adjustment for potential confounders, the ACE gene did not significantly influence the 
mean difference in SBP (ID vs. DD=0.42 mmHg; 95%CI: -5.18-6.01 and II vs. DD=-
1.67 mmHg; 95%CI: -9.60-6.27) or the mean difference in DBP (ID vs. DD=-0.21 
mmHg; 95%CI: -3.24-2.82 and II vs. DD=-0.84 mmHg; 95%CI: -5.19-3.51) when all 
antihypertensive drugs were combined. The adjusted mean difference in SBP and DBP 
is shown in figures 1 and 2 with the mean SBP or DBP levels in untreated subjects with 
the DD genotype as a reference. Diuretics users with the DD genotype had a 5.19 
mmHg (95%CI: -10.16-0.78) lower mean SBP and a 0.44 mmHg (95%CI: -3.76-2.88) 
lower mean DBP compared to untreated subjects with the DD genotype. 
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Table 1. Baseline characteristics of all patients at the first examination. Values are presented as 
means (± SD), or number (%). 
 
 Untreated  Treated  
Variable DD ID II  DD ID II  
 (n=452) (n=896) (n=357)  (n=265) (n=415) (n=175)  
Gender, male 172 
(38.1%) 
370 
(41.3%) 
139 
(38.9%) 
 93 
(35.1%) 
168 
(40.5%) 
61 
(34.9%) 
 
Age, years 70.1 ± 
8.9 
69.8 ± 
8.4 
69.2 ± 
8.5 
 71.4 ± 
9.1 
71.3 ± 
8.9 
70.3 ± 
9.35 
 
SBP, mmHg 154.6 ± 
21.8 
153.4 ± 
21.3 
152.2 ± 
22.8 
 145.1 ± 
22.1 
145.3 ± 
23.3 
142.5 ± 
23.3 
 
DBP, mmHg 79.0 ± 
11.9 
78.7 ± 
12.2 
79.8 ± 
12.4 
 75.2 ± 
10.9 
76.1 ± 
11.9 
74.7 ± 
13.2 
 
BMI, kg/m2 26.5 ± 
3.5 
26.3 ± 
3.5 
26.3 ± 
3.4 
 27.0 ± 
3.9 
27.2 ± 
3.7 
27.3 ± 
4.1 
 
Diabetes mellitus 51 
(11.6%) 
104 
(12.0%) 
42 
(12.1%) 
 27 
(10,3%) 
72 
(17.4%) 
24    
(14.0 %) 
* 
Smoking         
Current 74 
(16.7%) 
195 
(22.1%) 
73 
(20.7%) 
 39 
(15.0%) 
113 
(43.5%) 
108 
(41.5%) 
 
Past 196 
(44.2%) 
358 
(40.5%) 
157 
(44.6%) 
 70  
(17.0 %) 
184 
(44.7%) 
158 
(38.3%) 
 
Never 173 
(39.1%) 
330 
(37.4%) 
122 
(34.7%) 
 31 
(17.9%) 
77 
(44.5%) 
65 
(37.6%) 
 
Diuretics     77 
(33.6%) 
104 
(45.4%) 
48 
(21.0%) 
 
β-blockers     116 
(30.3%) 
179 
(46.9%) 
87 
(22.8%) 
 
Calcium channel 
blocker 
    34 
(27.4%) 
69 
(55.6%) 
21 
(16.9%) 
 
ACE-inhibitor     38 
(31.7%) 
63 
(52.5%) 
19 
(15.8%) 
 
 
* = Significantly different in treated or untreated group (p < 0.05) 
 
In addition, we investigated whether there was an interaction between the ACE I/D 
polymorphism and diuretics, β-blockers, calcium channel blockers, or ACE-inhibitors 
users (figure 3). The reference group in this analysis was the mean SBP or DBP of 
subjects with the DD genotype of the investigated antihypertensive drug class. Diuretic 
users with the II genotype had a 0.23 mmHg (95%CI: -5.48-5.94) higher mean SBP 
and a 0.81 mmHg (95%CI: -4.14-2.52) lower mean DBP compared to diuretic users 
with the DD genotype. After adjustment for the covariates, there was only a trend 
towards an association with the II genotype versus the DD genotype when treated with 
a β-blocker (p=0.096). However, there was no dose response relationship with regard 
to blood pressure with the I-allele.   
In addition, because a previous study in the Rotterdam Study found a smoking-
dependent effect of the ACE gene on blood pressure in current smokers,20 we assessed 
the drug-gene interactions in smokers. No drug-gene interaction was found with any of 
the antihypertensive drug classes in current smokers (data not shown).   
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Figure 1. Adjusted mean systolic blood pressure among antihypertensive drug users and 
subjects who were not treated for the 3 ACE genotypes with as reference untreated subjects 
with the DD genotype.  
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Figure 2. Adjusted mean diastolic blood pressure among antihypertensive drug users and 
subjects who were not treated for the 3 ACE genotypes with as reference untreated subjects 
with the DD genotype.  
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Figure 3. Adjusted mean systolic and diastolic blood pressure among antihypertensive drug 
users with as reference the DD genotype of the antihypertensive drug classes. 
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Discussion 
 
Our findings in a Caucasian population suggest that the ACE I/D polymorphism does 
not influence the mean SBP or DBP difference in users of diuretics, β-blockers, calcium 
channel blockers, or ACE-inhibitors, even after adjusting for DDDs and other potential 
confounders.  
Previous studies investigating the interaction between the I/D polymorphism and 
antihypertensives on blood pressure response have been inconclusive.3-12 Of the eight 
studies that investigated the interaction between the ACE gene and ACE-inhibitors on 
SBP and DBP in hypertensive patients, three suggested that the D-allele had a 
stronger drug effect,8-10 while two studies indicated the I-allele,6,7 and four studies 
found no difference between the two alleles.3-5,11 Regarding β-blockers, two studies 
found no drug-gene interaction on blood pressure4,12 and one study found an 
interaction with thiazide diuretics.21 In this study diuretics users with one or two copies 
of the I-allele of the ACE gene and one copy of the 460Trp-allele of the α-adducin gene 
showed the largest blood pressure decrease.  
The main difference between these studies and the current study was that the 
latter was an observational study and previous studies were non-randomized trials. In 
trials, treatment groups can be standardized with respect to dose, medication, duration 
of therapy, time between blood pressure measurement, and medication intake. In 
addition, it is possible that, in the current study, the medication taken at the time of 
the blood pressure measurement was not the initial drug chosen, but rather represents 
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an alternative drug which, through a process of trial and error, was found to be the 
most effective. The potential overrepresentation of “good responders” increased the 
chance of finding a drug-gene interaction.  
A strength of an observational study is that it resembles more closely daily clinical 
practice and the analysis can be adjusted to account for potential confounders like 
dose and duration of therapy. Another strength of the current study was the large 
sample size. 
A limitation of the current study is that no (pretreatment) baseline measurement 
immediately preceding the commencement of an antihypertensive drug was available 
and measurements were only taken every 2-3 years. This made it impossible to 
calculate the immediate drug effect after administration of an antihypertensive drug. 
Therefore, short-lived and temporary interactions would be missed in this study. Other 
limitations were the absence of a clinically confirmed diagnosis of hypertension and the 
overrepresentation of subjects with isolated systolic hypertension (approximately 50% 
of the untreated patients). As the mean of the treated patients is above 70 years of 
age, it is reasonable to assume that also in this group there is an overrepresentation of 
patients with isolated systolic hypertension. Thus, the results can not be generalized to 
all patients with hypertension.  
Another potential limitation of our study is that we studied only one genetic 
polymorphism, which is linked to the serum ACE activity, but it is controversial in 
hypertension. Zhu et al.22 found two other ACE gene mutations, which were linked with 
blood pressure and ACE serum levels. Therefore, it might be necessary to type 
additional markers. Finally, observational studies may be vulnerable to selection, 
information, and confounding bias. Confounding is very unlikely given that the data 
were adjusted for potential confounders, but it is impossible to adjust for other 
unmeasured confounders. Race could have been an additional confounder, however, 
given that less than 1% of the subjects had a different ethnic background, it is unlikely 
that this biased our results. Since our study population consisted of > 99% of 
Caucasians, our results can only be generalized to Caucasians. There are other 
additional variables, e.g. exercise, which have an impact on blood pressure. Therefore, 
it is possible that we over or underestimated the blood pressure lowering effect of the 
antihypertensive drug classes. However, since this is likely the same for the different 
genotypes this has not influenced the results of the drug-gene interaction. In addition, 
difference in blood pressure between treated patients and untreated patients could be 
the result of confounding by indication. As a physician is free to choose a specific 
antihypertensive drug or no treatment, specific patient characteristics may have 
influenced this decision. Therefore, we also investigated the mean difference in blood 
pressure between users of the same antihypertensive drug therapy, as they were most 
likely to have the same patient characteristics. Information bias is also unlikely, as 
data on drug exposure were prospectively gathered via computerised pharmacies in a 
similar and unbiased fashion for all subjects. It is, however, possible that we under- or 
overestimated baseline characteristics for which we used self-reported data. In 
74 
ACE I/D polymorphism, antihypertensive therapy and blood pressure 
addition, we assumed that all prescribed pills were taken and thereby may have 
overestimated compliance. As this is likely the same for all three genotypes, this 
unlikely to have biased our result. Additionally, selection bias is unlikely, because this 
study was population-based and loss to follow-up was negligible.  
 
 
Conclusion 
 
Notwithstanding the caveats, the study suggests that the ACE I/D polymorphism of the 
ACE gene does not influence the mean blood pressure difference among users of low-
ceiling diuretics, β-blockers, calcium channel blockers, or ACE-inhibitors. Although, it 
seems that the ACE I/D polymorphism does not have a clinical relevance in the 
response to antihypertensive drugs, further investigations with this polymorphism on 
short and long-term outcomes will be needed to make definitive conclusions.  
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Abstract 
 
Introduction: Despite the availability of a variety of effective antihypertensive drugs, 
inadequate control of blood pressure is common in hypertensive patients.  
Aim: To investigate whether the α-adducin G460W or angiotensinogen M235T 
polymorphism modifies the mean difference in blood pressure in subjects using 
antihypertensive drugs. 
Methods: Data were used from the Rotterdam Study, a population-based prospective 
cohort study in the Netherlands. This study started in 1990 and included 7,983 
subjects of 55 years or older. Data from three examination rounds were used. Subjects 
were included if their blood pressure was elevated at one or more examinations and/or 
a diuretic, β-blocker, calcium channel blocker, or ACE-inhibitor was used. A marginal 
generalised linear model (GEE) was used to assess the drug-gene interaction.  
Results: In total, 3,025 hypertensives were included. No drug-gene interaction on 
blood pressure levels was found. The mean difference in systolic blood pressure 
between subjects with the W-allele and GG genotype of the α-adducin gene was for 
diuretic users 1.25 mmHg (95%CI: -2.86-5.35), for β-blocker users 0.02 mmHg 
(95%CI: -3.39-3.42), for calcium channel blocker users –0.70 mmHg (95%CI: -5.61-
4.21), and for ACE-inhibitors user –3.50 mmHg (95%CI: -9.02-2.02). The mean 
difference in systolic blood pressure between subjects with the TT and MM genotype 
was for diuretic users –2.33 mmHg (95%CI: -8.32-3.66), for β-blocker users –0.06 
mmHg (95%CI: -4.91-4.79), for calcium channel blocker users 0.59 mmHg (95%CI:   
-5.95-7.13), and for ACE-inhibitor users -2.33 mmHg (95%CI: -9.66-5.01). 
Conclusion: The G460W and the M235T polymorphism did not modify differences in 
blood pressure levels among subjects who used diuretics, β-blockers, calcium channel 
blockers, or ACE-inhibitors. 
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Introduction 
 
Hypertension is the most prevalent cardiovascular risk factor in the industrialized 
world. Despite the availability of a variety of effective antihypertensive drugs, 
inadequate control of blood pressure is common in hypertensive patients. This is 
caused by environmental and genetic factors. 
A number of studies have investigated genetic polymorphisms as determinants of 
cardiovascular response to antihypertensive drug therapy, e.g. the G460W 
polymorphism of the α-adducin (ADD1) gene and the M235T polymorphism of the 
angiotensinogen (AGT) gene. In four studies, the interaction between the ADD1 
G460W polymorphism and antihypertensive drugs on blood pressure response was 
evaluated.1-4 Three studies, with partly the same study population, found a greater 
blood pressure reduction with the 460W-allele than with the 460G-allele,1-3 while 
another study could not replicate this finding4. All these studies were non-randomized 
trials. Three research groups studied the influence of the M235T polymorphism of the 
AGT on the blood pressure response to antihypertensive medication.5-7 Two of these 
studies where non-randomized trials5, 7 and the other study was a placebo-controlled 
crossover.6 Hypertensive subjects with the 235T-allele when treated with ACE-
inhibitors had a greater blood pressure reduction in one study,5 but this could not be 
reproduced in another study.6 No drug-gene interactions were found with β-blockers or 
calcium channel blockers.6, 7
The purpose of this study was to evaluate the relationship between the G460W 
polymorphism of the α-adducin gene and the M235T polymorphism of the 
angiotensinogen gene on mean systolic and diastolic blood pressure difference in 
hypertensive patients treated with diuretics, β-blockers, calcium channel blockers, or 
ACE-inhibitors.  
 
 
Methods 
 
Setting 
The Rotterdam Study started in 1990 as a population-based prospective follow-up 
study. All 10,275 residents of the suburb Ommoord in Rotterdam aged 55 years or 
older were invited to participate. In total, 7,983 (78%) subjects gave written informed 
consent and of 86% of them blood samples were available for genotyping. The 
baseline measurements took place until 1993 and the design has been described 
elsewhere.8 The baseline examination included several details, such as an interview on 
demographics, current health status, medical history, family history of diseases, 
smoking habits, and current use of medication. During a physical examination, blood 
pressure, weight, and height were measured and blood was drawn for DNA extraction. 
Blood pressure was measured in sitting position at the right upper arm with a random-
zero sphygmomanometer. The average of the two measurements, separated by a 
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count of pulse rate, was used in the analysis. All participants were subsequently 
examined in follow-up examination rounds every two to three years (1993-1995, 
1997-1999).  
Pharmacy records were available for approximately 99% of the cohort as of 
January 1st, 1991. These records include the name of the drug, the day of dispensing, 
the dosage form, the number of units dispensed, the prescribed daily dose, and the 
Anatomical Therapeutic Chemical code of the drug.9
 
Cohort and outcome definition 
The study population included all hypertensive individuals in the Rotterdam Study for 
whom the AGT M235T or ADD1 G460W genotype was assessed. Hypertension was 
defined as one or more blood pressure measurements with a systolic blood pressure 
(SBP) above 160 mmHg and/or diastolic blood pressure (DBP) above 95 mmHg, and/or 
use of one antihypertensive drug at the time of a blood pressure measurement 
(monotherapy). When a blood pressure measurement occurred, we assessed whether 
a prescription was filled by the pharmacy on this date. When the blood pressure 
measurement date fell within the usage period, the patient was considered currently 
exposed. Due to the small numbers for the other antihypertensive drug classes, only 
subjects using diuretics, β-blockers, calcium channel blockers, and ACE-inhibitors were 
included in the analysis. In addition, blood pressure measurements were excluded 
when combinations of different antihypertensive drugs classes were used on the date 
of the blood pressure measurement. Pharmacy records were available as of January 
1st, 1991, nevertheless, blood pressure measurements from 1990 were included if an 
individual did not use an antihypertensive drug according to self-reported 
questionnaire information and did not start antihypertensive therapy before July 1st, 
1991. The end of the study period was set at December 31st, 1999.  
In addition, we distinguished between starters and continuous users. Starters were 
defined as hypertensives who did not have a prescription before July 1st, 1991 and 
used their antihypertensive medication, less then six of the eight weeks prior to their 
blood pressure measurement. In addition, starters had to have at least a 30 days gap 
between the start date of prescription, which was used at the date of the blood 
pressure measurement, and the end date of the previous prescription.  
 
Potential confounders  
The potential confounders considered were age, sex, body mass index (BMI), defined 
daily dose (DDD), (re-)examination round, smoking at baseline, salt intake at baseline 
(g/day), history of myocardial infarction, diabetes mellitus at baseline, use of nitrates, 
use of statins, use of NSAID’s, use of another antihypertensive drug class two weeks 
prior to the blood pressure measurement, use of an antihypertensive drug for six of 
the eight weeks prior to the blood pressure measurement, and the cumulative number 
of days an antihypertensive drug was used.   
82 
ADD1 G460W and AGT M235T polymorphism, antihypertensive therapy, and blood pressure 
History of myocardial infarction was self-reported confirmed by a physician or 
demonstrated on the baseline ECG. To compare dosages of different antihypertensive 
drugs in our analysis, we used the prescribed daily dose (PDD), expressed as the 
number of DDDs per day. The DDD is defined as the recommended dose for the main 
indication in an adult of 70 kg.9
 
Genotype  
Genomic DNA was extracted from whole blood samples using standard methods, 
described previously.10 Samples were genotyped with TaqMan allelic discrimination 
Assays-By-Design (Applied Biosystems, Foster City, CA). Forward and reverse primer 
sequences were 5’ GAG AAG ACA AGA TGG CTG AAC TCT 3’ and 5’ GTC TTC GAC TTG 
GGA CTG CTT 3’ and the minor groove binding probes were 5’ ATT CTG CCA TTC CTC 
3’ (VIC) and 5’ ATT CTG CCA TTC CTC 3’ (FAM) for the ADD1 gene. Forward and 
reverse primer (anti sense strand) sequences were 5’ AGG TTT GCC TTA CCT TGG AAG 
TG 3’ and 5’ GCT GTG ACA GGA TGG AAG ACT 3’ and the minor groove binding probes 
were 5’ CTG GCT CCC ATC AGG 3’ (VIC) and 5’ CTG GCT CCC GTC AGG 3’ (FAM) for 
the AGT gene. The assays utilized 5 nanograms of genomic DNA and 2 microliter 
reaction volumes. The amplification and extension protocol was as follows: an initial 
activation step of 10 min at 95 deg preceded 40 cycles of denaturation at 95 deg for 
15 s and annealing and extension at 50 deg for 60 s. allele-specific fluorescence was 
then analyzed on an ABI Prism 7900HT Sequence Detection System with SDS v 2.1 
(Applied Biosystems, Foster City, CA). 
 
Analysis 
We used ANOVA (continuous variables) and Chi-square testing (categorical variables) 
to compare baseline characteristics of people with different genotypes. ANOVA was 
used to compare, for each examination, the difference in DDD between the genotype 
groups, stratified by genotype groups. A marginal generalised linear model (GEE) was 
used to investigate the potential interaction between the α-adducin G460W and 
angiotensinogen M235T polymorphism and response to antihypertensive treatment for 
two outcomes: mean difference in SBP and DBP.  
We compared the mean SBP and DBP levels between the different genotype groups for 
subjects using the same antihypertensive drug class. The mean SBP and DBP of 
treated subjects was defined as the mean SBP and DBP of subjects who used the 
antihypertensive drug class in question minus the mean SBP or DBP in untreated 
subjects with the same genotype. The GEE model was used to account for intraperson 
correlations between repeated measurements. The covariance matrix of the repeated 
dependent measurements was unstructured and data were analysed using SAS 
statistical software and adjusted for potential confounders (SAS version 8.2). 
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Results 
 
Alpha-Adducin gene (ADD1) G460W polymorphism 
Between January 1st, 1990 and December 31st, 1999, 6,500 blood pressure 
measurements of 3,025 hypertensive individuals were included. In 91% of the 
hypertensive individuals the ADD1 genotype could be assessed. In total, 396 
individuals used diuretics (559 measurements), 685 β-blockers (997 measurements), 
281 calcium channel blockers (366 measurements), and 294 ACE-inhibitors (389 
measurements). Baseline characteristics of all subjects stratified by the ADD1 
genotype are presented in table 1. There was a significant difference in SBP levels 
between the genotype groups in treated subjects during the first examination. 
 
Table 1. Baseline characteristics of all patients at the first examination stratified by α-adducin 
genotype. Values are presented as means (± SD), or number (%) 
 
 Untreated Treated 
Variable GG W-allele   GG W-allele   
  (n=950) (n=602)   (n=469) (n=316)   
Gender, M 389 (40.9%) 246 (40.9%)   178 (38.0%) 132 (41.8%)   
Age, years 69.9 ± 8.6 69.2 ± 8.3   70.7 ± 9.1 71.6 ± 8.8   
SBP, mmHg 153.0 ± 21.9 152.9 ± 21.3   146.0 ± 22.7 142.5 ± 23.4 ** 
DBP, mmHg 78.9 ± 12.0 78.6 ± 11.9   76.0 ± 11.8 74.9 ± 11.8   
BMI, kg/m2 26.4 ± 3.5 26.2 ± 3.4   27.1 ± 3.8 27.3 ± 3.9   
Diabetes mellitus 109 (11.7%) 72 (12.8%)   67 (14.4%) 44 (14.1%)   
Smoking           
Current 187 (20.0%) 129 (21.8%)   70 (15.0%) 59 (19.0%)   
Past  393 (42.1%) 259 (43.7%)   213 (45.7 %) 134 (43.2%)   
Never 354 (37.9%) 205 (34.6%)   183 (39.3%) 117 (37.7%)   
Diuretic      125 (36.7%) 87 (27.5%)   
β-blocker      203 (43.3%) 147 (46.5%)   
Calcium channel 
blocker      72 (15.4%) 43 (13.6%)   
ACE-inhibitor       69 (14.7%) 39 (12.3%)   
 
* = Significantly different in treated or untreated group (p < 0.10) 
** = Significantly different in treated or untreated group (p < 0.05) 
 
The mean DDD at baseline for users of diuretics was 0.81 ± 0.46, for β-blockers 
0.68 ± 0.35, for calcium channel blockers 0.77 ± 0.34, and for ACE-inhibitors 1.11 ± 
0.65. There was no statistically significant difference in DDDs during follow-up between 
the different genotypes (data not shown). 
Due to the small number of subjects with the WW genotype (7.5% of the 
individuals) this group was combined with the GW genotype group in the analysis. 
After adjustment for potential confounders, the mean difference in SBP and DBP was 
compared between the two genotype groups for the different antihypertensive drug 
classes during the three examination rounds (see figure 1). Among starters of diuretic 
therapy (n=57) there was no drug-gene interaction on the mean difference in SBP 
(p=0.81) and DBP (p=0.88). There was also no drug-interaction among starters of β-
blocker therapy (n=63) (SBP p=0.95 and DBP p=0.75). However, we could only 
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include a small number of measurements. The number starters of calcium channel 
blockers therapy (n=23) and ACE-inhibitors therapy (n=15) were too small to 
examine. 
 
Figure 1. Adjusted mean difference in systolic and diastolic blood pressure among 
antihypertensive drug users with the GG genotype of the α-adducin gene compared to subjects 
with the W-allele of α-adducin gene. 
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Angiotensinogen gene (AGT) M235T polymorphism 
For the AGT gene 91% of the genotypes could be ascertained. In total, 395 individuals 
used diuretics (559 measurements), 689 β-blockers (1,002 measurements), 282 
calcium channel blockers (367 measurements), and 293 ACE-inhibitors (388 
measurements), respectively. Baseline characteristics for all subjects stratified by AGT 
genotypes are presented in table 2. There was no significant difference in baseline 
characteristics between the different genotype groups during the first examination. 
Although, there was some indication that untreated subjects with the MT genotype had 
a higher SBP level compared to the other genotypes. There was no statistically 
significant difference in DDDs for the different genotypes.  
The adjusted difference in blood pressure when treated with diuretics, β-blockers, 
calcium channel blockers, or ACE-inhibitors is presented in figure 2. Also, with this 
polymorphism no statistically significant drug-gene interaction was found. There was 
no drug-gene interaction for starters of diuretic (SBP p=0.88 and DBP p=0.65) or β-
blocker therapy (SBP p=0.72 and DBP p=0.41).  
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Table 2. Baseline characteristics of all patients at the first examination stratified by 
angiotensinogen genotype. Values are presented as means (± SD), or number (%). 
 
 Untreated  Treated  
Variable MM MT TT   MM MT TT   
  (n=541) (n=755) (n=252)   (n=280) (n=397) (n=113)   
Gender, M 
 
207 
(38.3%) 
325 
(43.0%) 
102 
(40.5%)   
111 
(39.6%) 
152 
(38.3%) 
49 
(43.4%)   
Age, years 
 
69.4 ± 
8.3 
70.0 ± 
8.6 
68.8 ± 
8.4   
71.0 ± 
8.9 
70.9 ± 
8.8 
70.5 ± 
9.4   
SBP, mmHg 
 
151.3 ± 
21.9 
154.0 ± 
21.7 
152.8 ± 
21.0 * 
142.8 ± 
22.6 
145.7 ± 
23.0 
144.6 ± 
23.3   
DBP, mmHg 
 
78.4 ± 
12.0 
79.0 ± 
12.1 
78.7 ± 
11.8   
75.3 ± 
11.6 
75.3 ± 
11.7 
77.6 ± 
12.7   
BMI, kg/m2 
 
26.4 ± 
3.6 
26.3 ± 
3.4 
26.4 ± 
3.2   
27.4 ± 
4.1 
27.0 ± 
3.6 
27.0 ± 
3.9   
Diabetes mellitus 
 
61 
(11.5%) 
90 
(12.3%) 24 (9.7%)   
39 
(13.9%) 
56 
(14.3%) 
16  
(14.4 %)   
Smoking               
Current 
 
100 
(18.9%) 
152 
(28.8%) 
61 
(24.5%)   
39 
(14.1%) 
73 
(18.6%) 
20 
(17.9%)   
Past  
 
223 
(42.2%) 
327 
(43.8%) 
101 
(40.6%)   
131 (47.5 
%) 
171 
(43.5%) 
47 
(42.0%)   
Never 
 
205 
(37.5%) 
267 
(35.8%) 
87 
(34.9%)   
106 
(38.4%) 
149 
(37.9%) 
45 
(40.2%)   
Diuretic 
        
84 
(30.0%) 
106 
(26.7%) 
23 
(20.4%)   
β-blocker 
        
118 
(42.1%) 
185 
(46.6%) 
49 
(43.4%)   
Calcium channel 
blocker        
39 
(13.9%) 
57 
(14.4%) 
19 
(16.8%)   
ACE-inhibitor 
         
39 
(13.9%) 
49 
(12.3%) 
22 
(19.5%)   
 
* = Significantly different in treated or untreated group (p < 0.10) 
** = Significantly different in treated or untreated group (p < 0.05) 
 
In addition, we assessed the effect of drug-gene-gene interactions between the ACE 
I/D polymorphism, AGT M235T polymorphism, and ADD1 G460W polymorphism and 
antihypertensive drugs on blood pressure. None of the drug-gene-gene combinations 
(AGT-ADD1 or AGT-ACE or ADD1-ACE) modified the mean difference in SBP or DBP 
level.  
 
 
Discussion 
 
This study suggests that there is no interaction between the G460W polymorphism of 
the α-adducin gene or the M235T polymorphism of the angiotensinogen gene and the 
use of monotherapy with a diuretic, β-blocker, calcium channel blocker, or ACE-
inhibitor on SBP and DBP levels. Furthermore, combinations of these two 
polymorphisms and the I/D polymorphism of the ACE gene did not result in significant 
drug-gene-gene interactions. 
86 
ADD1 G460W and AGT M235T polymorphism, antihypertensive therapy, and blood pressure 
Figure 2. Adjusted mean difference in systolic and diastolic blood pressure among 
antihypertensive drug users with the TT and MT genotype of the angiotensinogen gene 
compared to the MM genotype of the angiotensinogen gene. 
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The G460W and M235T polymorphisms were logical candidates to investigate as 
polymorphisms that might influence antihypertensive drug response. Studies with the 
Milan hypertensive rat and humans with essential hypertension suggest that genetic 
alterations in α-adducin may contribute to hypertension.11-13 The α-adducin gene may 
affect blood pressure by increasing renal tubular reabsorption of sodium through the 
activation of Na+,K+-ATPase (adenosine triphosphatase) and the 460W-allele of the α-
adducin gene is associated with a higher affinity for the Na+,K+-ATPase pump than the 
460G-allele.14 Angiotensinogen is the inactive precursor of the potent vasoactive and 
salt-retaining hormone angiotensin II and thus a major component of the renin-
angiotensin system. The M235T polymorphism of the angiotensinogen gene has an 
effect on plasma angiotensinogen concentration. Subjects with two copies of the 235T-
allele have 15% to 40% higher levels compared with subjects with two copies of the 
235M-allele.15 In a meta-analysis the M235T polymorphism was significantly associated 
with hypertension.16 Persons with a copy of the T-allele had a higher risk of 
hypertension. In our study, subjects with the T-allele had a higher SBP level compared 
to the subjects with MM genotype at baseline. 
Previous studies investigating the interaction between the G460W polymorphism of 
the α-adducin gene or M235T polymorphism of the angiotensinogen gene and 
antihypertensive drugs on blood pressure response have been inconclusive. In a study 
of Italian families, there was evidence that the G460W polymorphism predicted a 
twofold mean difference in blood pressure response to hydrochlorothiazide among 
hypertensive subjects when treated for 4 weeks,1-3 although, this could not be
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replicated in another and larger study.4 We did observe a significant difference 
between the genotype groups in SBP in treated groups during the first examination, 
but this disappeared when we analyzed the complete data.  
In our study, we had only measurements every three years and could not 
investigate the immediate effect on blood pressure response after administration of an 
antihypertensive drug and therefore calculated the difference in blood pressure 
between genotype groups. It is possible that previously reported drug-gene interaction 
were the results of a temporary difference between the genotype groups, which 
occurred shortly after administration of an antihypertensive drug and therefore missed 
in our study. However, no drug-gene interaction was found in our group of “starters”.  
The main difference between the previous studies and ours, is that we conducted 
an observational study and the other studies were trials. The advantage of an 
observational study is that it resembles daily clinical practice. A limitation of 
observational studies is that they are vulnerable to confounding. For example, 
confounding by indication might have biased our results. As a physician was free to 
choose whether a patient receives a antihypertensive drug and which, specific patients 
characteristics might have influenced this decision. However, the drug-gene interaction 
between subjects using the same antihypertensive class is most likely not influenced 
by this bias, since users of the same antihypertensive drug class have most likely the 
same characteristics and the physician is unaware of a subjects’ genotype. In addition, 
we adjusted for potential confounders, such as dose, BMI, and salt-intake. Another 
limitation is the overrepresentation of patients with isolated systolic hypertension. In 
addition, it is possible that the medication taken during the blood pressure 
measurement was not the initial drug chosen, but rather represents an alternative 
drug, which through a process of trail and error was found to be the most effective. 
However, the potential overrepresentation of “good responders” increased our chance 
of finding a drug-gene interaction.  
Notwithstanding these caveats, this study suggests that in daily practice the 
G460W polymorphism of the ADD1 gene and M235T polymorphism of the AGT gene do 
not influence differences in blood pressure levels among users of low-ceiling diuretics, 
β-blockers, calcium channel blocker, or ACE-inhibitors.  
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Abstract 
 
Despite the availability of effective antihypertensive drugs, there is a large variation in 
response to these drugs. This study investigates whether polymorphisms in the 
angiotensin converting enzyme (I/D), angiotensinogen (M235T), α-adducin (G460W), 
angiotensin II type 1 receptor (1166A/C), or G protein β3-subunit (825C/T) gene 
modify the mean difference in blood pressure levels among diuretic, β-blocker, or ACE-
inhibitor users. Data were used from the Doetinchem Cohort Study, and blood pressure 
data was collected from GPs (1987-1997). A marginal generalised linear model (GEE) 
was used to assess the gene-drug interaction on the mean difference in 
systolic/diastolic blood pressure. In total, 625 hypertensive individuals were included 
with a total of 5,262 measurements of blood pressure. Only the interaction between 
diuretic use and the GNB3 825C/T polymorphism was significant (C-allele versus TT; 
difference in systolic blood pressure=4.33 mmHg; 95%CI: 0.14-8.54). Thus, the mean 
systolic blood pressure level among diuretic users may be modified by the GNB3 
825C/T polymorphism. 
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Introduction 
 
Hypertension is an important public health problem. Evidence from randomized trials 
has shown that drug treatment reduces the risk of cardiovascular morbidity and 
mortality.1, 2 Despite the availability of a variety of effective drugs, inadequate control 
of blood pressure is still common in hypertensive patients.3 Among the possible causes 
are, besides environmental, certain genetic characteristics that could have modified 
the response to antihypertensive drugs. 
Blood pressure levels are homeostatically maintained through complex interactions 
between environmental and genetic factors. Antihypertensive drugs lower blood 
pressure by acting on specific targets within this system. Obvious candidate genes for 
antihypertensive drug-gene interactions are those that code for components of a 
system, which is pharmacology influenced by an antihypertensive drug. Other 
candidates genes are those that code for components of counter-regulatory systems.  
Examples of candidate genes for blood pressure lowering drugs are those in the 
renin-angiotensin system, for example: angiotensinogen (AGT), angiotensin converting 
enzyme (ACE), and angiotensin II receptor type 1 (AGTR1). Plasma AGT is significantly 
elevated in patients with the AGT 235T-allele4, and serum ACE is significantly higher in 
subjects with the ACE D-allele.5 Candidate genes related to other blood pressure 
regulating systems are α-adducin (ADD1) and β3-subunit of G-protein (GNB3). ADD1 
may affect blood pressure by modulating renal tubular reabsorption of sodium through 
the activation of Na+,K+-ATPase (adenosine triphosphatase) with the 460W-allele 
exhibiting higher affinity for the Na+,K+-ATPase pump.6 The 825T-allele of GNB3 gene 
is associated with a shortened splice variant of the GNB3 protein that gives rise to 
enhanced signal transduction via pertussis toxin-sensitive G-proteins.7
Several non randomized trials have studied the influence of these genes on the 
response to antihypertensive medication,8 but with conflicting results and as far as we 
known, the effect of these genes in daily practice has never been evaluated. Therefore, 
the purpose of the present study was to evaluate the relationship between the I/D 
(ACE), M235T (AGT), G460W (ADD1), 1166A/C (AGTR1), and 825C/T (GNB3) 
polymorphism on the mean difference in blood pressure levels among subjects using 
diuretics, β-blockers, or ACE-inhibitors in daily practice. 
 
 
Materials and Methods 
 
Setting 
Data from the Doetinchem Cohort Study was used; a population-based prospective 
study on cardiovascular disease risk factor conducted in the Netherlands.9 The baseline 
examination was carried out from 1987 to 1992 in men and women aged 20-59 years, 
living in Doetinchem, a Dutch town with circa 40,000 inhabitants.  
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Data collection  
At the start of the Doetinchem Cohort Study, the respondents completed a 
questionnaire that contained questions on demographic variables, cardiovascular 
diseases, and risk factors. In addition, weight, and height were measured and blood 
was drawn for total and high-density lipoprotein (HDL) cholesterol determination and 
DNA extraction. The design of this study has been described elsewhere.9 In addition, 
blood pressure data was collected from general practitioners from 1987 to 1997.    
Pharmacy records were available for approximately 76% of the Doetinchem cohort 
as of January 1st, 1987. These records include the name of the drug, the day of 
dispensing, the dosage form, the number of units dispensed, the prescribed daily dose 
and the Anatomical Therapeutic Chemical code of the drug.10
 
Cohort and outcome definition 
Hypertensive patients were only included if their genotypes could be assessed, 
additional blood pressure measurements from the GPs were available, and pharmacy 
data were available. In addition, during follow-up individuals had to have one or more 
blood pressure measurements which met one of the following criteria: systolic blood 
pressure (SBP) ≥ 160 mmHg, and/or diastolic blood pressure (DBP) ≥ 95 mmHg, 
and/or the use of 1 antihypertensive drug class at the time of a blood pressure 
measurement (monotherapy). Only subjects using low-ceiling diuretics, β-blockers, or 
ACE-inhibitors were included in the analysis, because of the small numbers for the 
other antihypertensive drug classes. Measurements were excluded when a combination 
of antihypertensive drugs was used. The end of the study period was set at December 
31st, 1997. 
 
Potential confounders and effect modifiers 
As potential confounders we considered age, gender, body mass index, defined daily 
dose (DDDs), smoking at baseline, history of myocardial infarction, diabetes mellitus at 
baseline, use of nitrates, use of statins, use of NSAIDs, total/hdl cholesterol level, low-
salt diet, low-cholesterol diet, the use of another antihypertensive drug class two 
weeks prior to the blood pressure measurement, the use of an antihypertensive drug 
six of the eight weeks prior to the blood pressure measurement, and the date of the 
measurement. To compare dosages of different antihypertensive drugs in our analysis, 
we used the prescribed daily dose (PDD), expressed as the number of DDDs per day. 
The DDD is defined as the recommended dose for the main indication in an adult of 70 
kg.11
 
Genotype  
Genomic DNA was isolated from peripheral blood according to standard procedures. 
The genotyping procedure of the ADD1 G460W,12 ACE I/D,5 AGT M235T,13 GNB3 
825C/T,14 and AGTR1 1166A/C,15 polymorphism were previously described.  
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Analysis 
We used ANOVA (continuous variables) and Chi-square testing (categorical variables) 
to compare baseline characteristics of people with different genotypes. A marginal 
generalized linear model (GEE) was used to study the potential interaction between the 
genetic polymorphisms of interest and response to antihypertensive treatment for two 
outcomes: mean difference in SBP and DBP. We compared the mean SBP and DBP 
levels between the different genotype groups for subjects using the same 
antihypertensive drug class. To test for the interaction between the polymorphism in 
question (e.g. ACE I/D polymorphism) and the use of an antihypertensive drug class in 
question (e.g. ACE-inhibitors) two dummy variables were added to the model: ACE 
genotype (ID and II) x the use of ACE-inhibitors during the blood pressure 
measurement (0/1). The reference group consisted of subjects with the DD genotype, 
who had a prescription of the antihypertensive drug class in question. The mean blood 
pressure of treated subjects was defined as the mean blood pressure of subjects who 
used the antihypertensive drug class in question minus the mean blood pressure in 
untreated subjects with the same genotype. For the drug-gene-gene interaction, we 
combined the genotypes of two of the five polymorphisms. For this analysis, we added 
three dummy variables to the model i.e. the drug-gene combinations (e.g. ACE+ADD1: 
I-allele+T-allele, I-allele+MM, and D-allele+T-allele) x the use of the antihypertensive 
drug class in question (0/1). The GEE was used to account for intraperson correlations 
among repeated measurements. To compare the difference in DDD, the model was 
used stratified for the different genotypes. The covariance matrix of the repeated 
dependent measurements was exchangeable and data were analysed using SAS 
statistical software and adjusted for potential confounders. 
 
 
Results 
 
Between 1987 and 1997, 5,262 blood pressure measurements of 625 individuals were 
included. During follow-up, 106 subjects used diuretics (743 measurements), 229 used 
β-blockers (1,480 measurements), and 77 used ACE-inhibitors (495 measurements). 
In 99.4% of the hypertensive individuals, genotypes were assessed for the ACE gene, 
99.9% for the ADD1 gene, 99.9% for the AGTR1 gene, 99.3% for the GNB3 gene, and 
99.9% for the AGT gene. Characteristics for the 625 subjects stratified by treatment or 
no treatment during the first examination are presented in table 1. Subjects in the 
treated group were older and the percentage of diabetics, female subjects, subjects 
receiving a low-salt diet or a low-cholesterol diet was higher compared to the 
untreated group.  
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Table 1. Baseline characteristics of all subjects at the first examination stratified by treatment. 
 
Variable Untreated Treated   
  (n=490) (n=135)   
Gender, M 279 (56.9%) 57 (42.2%) ** 
Age, years 47.7 ± 9.1 52.1 ± 7.6 ** 
SBP, mmHg 151.4 ± 18.3 144.2 ± 20.4 ** 
DBP, mmHg 96.2 ± 10.0 90.5 ± 10.1 ** 
BMI kg/m2 28.0 ± 4.5  27.5 ± 3.9   
Totaal/HDL cholesterol 
ratio  5.5 ± 1.9  5.8 ± 2.2   
Diabetes mellitus 15 (3.1%) 14 (10.4%) ** 
Myocardial infarction 7 (1.4%) 1 (0.7%)   
Diet for high BP 56 (11.5%) 33 (24.4%) ** 
Diet for high cholesterol 35 (7.1%) 24 (17.8%) ** 
Smoking       
current 167 (34.1%) 48 (35.6%)   
past 151 (30.8%) 33 (24.4%)   
never 172 (35.1%) 54 (40.0%)   
Ethnicity, caucasian 477 (97.3%) 131 (97.8%)   
        
ACE: DD/ID/II 160/212/114 36/72/27   
ADD1: W-allele/GG 1 312/92 92/43   
AGTR1: C-allele/AA 2 237/66 66/69   
GNB3: C-allele/TT 3 220/63 63/71   
AGT: T-allele/MM 4 164/325 51/84   
        
Diuretic   39 (33.9%)   
Beta-blocker   86 (63.7%)   
ACE-inhibitor   10 (7.4%)   
 
** P < 0.001 
1 W-allele: WW+GW genotype  
2 C-allele: CC+CA genotype  
3 C-allele: CC+CT genotype  
4 T-allele: TT+MT genotype 
 
 Owing to the small sample size, two genotype groups were combined in the 
analysis for most genes, namely the TT (6.0% of the individuals) and GT genotype of 
ADD1 gene, the CC (10.2% of the individuals) and AC genotype of AGTR1 gene, the 
CC (4.6% of the individuals) and CT genotype of GNB3 gene, and the TT (1.0% of the 
individuals) and GT genotype of AGT gene. The unadjusted difference in SBP and DBP 
was for diuretics users -3.15 mmHg (95%CI: -4.70--1.60) and -3.92 mmHg (95%CI:  
-4.75--3.10), for β-blockers users -2.53 mmHg (95%CI: -3.78--1.27) and -2.13 
mmHg (95%CI: -2.80--1.46), for ACE-inhibitors users 0.35 mmHg (95%CI: -1.62-
2.32) and 0.48 mmHg (95%CI: -0.55-1.52).  
The mean difference in DDDs between genotypes for users of diuretics, β-blockers, 
and ACE-inhibitors adjusted for potential confounders is presented in table 2. There 
was no statistically significant difference in DDDs between the different genotype 
groups.  
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Table 2. Adjusted DDDs for antihypertensive drug users. 
 
  Diuretic Beta-blocker ACE-inhibitor 
ACE: ID versus DD -0.04 (-0.32-0.24)  0.06 (-0.04-0.15)  0.00 (-0.38-0.37) 
ACE: II versus DD  0.09 (-0.26-0.44)  0.08 (-0.02-0.19)  0.01 (-0.42-0.44) 
ADD1: W-allele versus GG -0.10 (-0.33-0.13)  0.00 (-0.08-0.09)  0.05 (-0.23-0.33) 
AGTR1: C-allele versus AA  0.12 (-0.13-0.37)  0.01 (-0.07-0.08)  0.05 (-0.24-0.37) 
GNB3: C-allele versus TT  0.01 (-0.21-0.24) -0.08 (-0.15-0.00)  0.17 (-0.12-0.44) 
AGT: T-allele versus MM -0.08 (-0.34-0.18) -0.01 (-0.08-0.07)  0.20 (-0.13-0.53) 
 
After adjustment for potential confounders, the mean difference in SBP and DBP 
for users of diuretics, β-blockers, and ACE-inhibitors was compared between the 
genotype groups (see figure 1a-c). The only statistically significant drug-gene 
interaction was between diuretic users and GNB3 on SBP level (4.33 mmHg; 95%CI: 
0.14-8.54). This interaction was not found for the mean difference in DBP (0.51 
mmHg; 95%CI: -1.13-2.15). In addition we also adjusted for persons who used 
another antihypertensive drug prior to the use of a diuretic (n=243 switchers). The 
reduction for SBP after this adjustment was 4.74 mmHg (95%CI: 0.69-8.78) and for 
DBP 0.51 mmHg (95%CI: -1.69-2.70). 
 
Drug-gene-gene-interactions 
To assess drug-gene-gene interactions, the mean difference in blood pressure was 
compared between combinations of two of the five genes. Owing to the small sample 
size, the genotype of the ID and II of the ACE gene were combined and it was 
impossible to combine more then two genes together.  
 
Figure 1a.  Adjusted mean difference in systolic or diastolic blood pressure among diuretic 
users. The diamonds with bars depict the mean difference in blood pressure ± 95%CI. 
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Figure 1b. Adjusted mean difference in systolic or diastolic blood pressure among β-blocker 
users. The diamonds with bars depict the mean difference in blood pressure ± 95%CI. 
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Figure 1c. Adjusted mean difference in systolic or diastolic blood pressure among ACE-inhibitor 
users. The diamonds with bars depict the mean difference in blood pressure ± 95%CI. 
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In total, 36 drug-gene-gene interactions were possible for SBP and DBP. Of these 
interactions, four were associated with a significant difference in blood pressure (see 
figure 2). These were the interaction between diuretic use and ADD1 W-allele+ AGT T-
allele vs. GG+ MM on DBP (3.09 mmHg; 95%CI:0.16-2.93; 169 versus 149 
measurements), β-blocker use and AGTR1 C-allele+ AGT T-allele vs. AA+ MM on
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DBP (2.63 mmHg; 95%CI: 0.30-2.33; 436 versus 223 measurements), ACE-inhibitor 
use and ACE I-allele+ GNB3 TT vs. DD+ C-allele on DBP (6.22 mmHg; 95%CI: 0.93-
5.29; 180 versus 18 measurements), and ACE-inhibitor use and ACE I-allele+ AGT T-
allele vs. DD+ MM on SBP (-10.21 mmHg; 95%CI: -19.47--0.95; 239 versus 29 
measurements).  
 
Figure 2. Adjusted interactions between the five candidate genes resulting in a significant 
difference in systolic and/or diastolic blood pressure among antihypertensive drug users. The 
diamonds with bars depict the mean difference in blood pressure ± 95%CI. 
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Discussion 
 
The data presented here provide evidence that diuretic users with the GNB3 TT 
polymorphism have lower SBP levels. None of the other examined genes had a 
significant influence on blood pressure. Of the 36 possible drug-gene-gene interactions 
on blood pressure, four results were significant, namely diuretic use and ADD1 W-
allele+ AGT T-allele vs. GG+ MM (DBP), β-blocker use and AGTR1 C-allele+ AGT T-
allele vs. AA+ MM (DBP), ACE-inhibitor use and ACE I-allele+ GNB3 TT vs. DD+ C-
allele (DBP), and ACE-inhibitor use and ACE I-allele+ AGT T-allele vs. DD+ MM (SBP).  
Our results concur with that of a non-randomized trial that investigated the role of 
GNB3 in diuretic users.16 In this study a significantly greater decline for both SBP and 
DBP was found in subjects with the TT genotype.16 To confirm these data, additional 
studies (trials and observational studies) are warranted to confirm this potential drug-
gene interaction. Especially, because no interactive effect was found in this study on 
DBP and the effect found on DBP was smaller than for example with the AGT M235T 
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polymorphism. In addition, none of the drug-gene-gene interactions were significant 
with GNB3 in diuretic users.  
There are some explanations why our results might be false-positive. First, we 
have tested multiple genes on multiple outcomes and if we had adjusted for multiple 
testing the interaction between GNB3 and diuretic use would not have been significant. 
A popular correction method for multiple testing is the Bonferroni correction (1-(1-
0.05)^the number of markers), however, this correction would overcorrect the false-
positive rate and thereby might disregard valid information. Second, the medication 
taken during the blood pressure measurement may not have been the first 
antihypertensive drug, but one that through a process of trail and error was found to 
be the most effective. With an overrepresentation of “good responders” the chance to 
find a drug-gene interaction is higher. However, after adjustment for switchers, the 
result remained significant and therefore channeling of diuretics does not seem to be 
the explanation. Third, observational studies compared to trials may be vulnerable for 
confounding. Confounding is also unlikely since we adjusted for potential confounders, 
like dose, duration of therapy, age, gender, and co-morbidities. Race could be an 
additional confounder, but less than 1% of the subjects had a different ethnic 
background. In addition, confounding by indication might have occurred in our study. 
As a physician was free to choose whether a patient receives an antihypertensive drug 
and which, specific patients’ characteristics might have influenced this decision. 
However, the drug-gene interaction between subjects using the same antihypertensive 
class is most likely not influenced by this bias, since users of the same 
antihypertensive drug class have most likely the same characteristics and the 
physician is unaware of a subjects’ genotype. There are other variables e.g. exercise 
and alcohol, which have an impact on blood pressure. Therefore, it is possible that we 
overestimated or underestimated the blood pressure lowering effect of the 
antihypertensive drug classes. However, since this is most likely the same for the 
different genotype groups it would not have influenced our drug-gene interaction 
results. Fourth, an advantage of a trial is the possibility to assess the response to an 
antihypertensive drug, by measuring the blood pressure before and during treatment. 
Owing to the small number of persons with a baseline measurement just preceding the 
start of an antihypertensive drug therapy, the mean difference in blood pressure was 
calculated. If the result is not false-positice, the observed difference of 4.33 mmHg 
systolic could result in a relative risk reduction of about 10% of cardiovascular disease 
in 10 year, according to the Framingham Risk function. 
Regarding the significant drug-gene-gene interactions the chance of a false-
positive result is even higher due to the smaller sample size. However, of the 36 
possible combinations four were found to be significant. The observed interactions 
were only found either with SBP or DBP. Thus further investigations are needed before 
definitive conclusions can be made. It is, however, apparent that the effects of the 
investigated single nucleotide polymorphisms are probably small and that this is the 
same for the drug-gene-gene interactions.  
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Notwithstanding these caveats, the study suggests that some of the drug-gene-
gene interactions had an influence on blood pressure levels in daily practice. In 
addition, the GNB3 polymorphism may influence the mean difference in SBP among 
users of low-ceiling diuretics.  
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Abstract 
 
Introduction: Knowledge of pharmacogenetics might optimise drug therapy in patients 
treated with antihypertensive drugs.  
Aim: To investigate whether the angiotensin converting enzyme (ACE) 
insertion/deletion (I/D), angiotensinogen M235T, or angiotensin II receptor type 1 
573C/T polymorphism modify the risk of atherosclerosis associated with β-blocker or 
ACE-inhibitor therapy.  
Methods: Data were used from the Rotterdam Study, a population based prospective 
cohort study in the Netherlands, which started in 1990 and included 7,983 subjects of 
55 years and older. Three sub-clinical measurements were used for atherosclerosis, 
i.e. peripheral arterial disease, carotid atherosclerosis, and aortic atherosclerosis. This 
study included 2,216 subjects with hypertension. Pharmacy records were available as 
of January 1st, 1991. The interaction between antihypertensive drugs and genetic 
polymorphisms on the risk of atherosclerosis was determined with binary logistic 
regression analysis.  
Results: Of the 2,216 subjects, 1,267 were treated with β-blockers and 727 with ACE-
inhibitors. The risk of peripheral arterial disease associated with short-term (0-4 years) 
use of ACE-inhibitors compared to no use of ACE-inhibitors, was higher among subjects 
with the II genotype than among subjects with the DD genotype of the ACE gene 
(interaction Odds ratio (OR)=2.21; 95%CI: 1.01-4.85). The risk of aortic 
atherosclerosis associated with short-term use of ACE-inhibitors compared to no use of 
ACE-inhibitors, was lower among subjects with the TT genotype than among subjects 
with the MM genotype of the AGT gene (interaction OR=0.39; 95%CI: 0.15-0.99). In 
contrast, the risk of aortic atherosclerosis associated with long-term (≥ 4 years) β-
blockers treatment compared to no use of β-blockers, was higher among subjects with 
the TT genotype compared to subjects with the MM genotype of the AGT gene 
(interaction OR=3.36; 95%CI: 1.14-9.97). The risk of carotid atherosclerosis 
associated with long-term ACE-inhibitors treatment compared to no use of ACE-
inhibitors, was lower among subjects with the TT genotype than among subjects with 
the MM genotype of the AGT gene (interaction OR=0.20; 95%CI: 0.04-0.95). The risk 
of carotid atherosclerosis associated with short-term use of ACE-inhibitors compared to 
no use of ACE-inhibitors, was higher among subjects with the CT genotype than among 
subjects with the CC genotype of the AGTR1 gene (interaction OR=2.63; 95%CI: 1.11-
6.24).   
Conclusion: Overall, we could not consistently demonstrate that the risk of 
atherosclerosis associated with the use of β-blockers or ACE-inhibitors was strongly 
modified by any of the three candidate gene polymorphisms. 
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Introduction 
 
The renin-angiotensin system plays an important role in vascular homeostasis. 
Sequential cleavage occurs of angiotensinogen (AGT) by renin to angiotensin I, and 
subsequently by angiotensin converting enzyme (ACE) to the vasoactive peptide 
angiotensin II. Besides regulating blood pressure, angiotensin II has also various 
actions that can damage blood vessels. For example, angiotensin II stimulates NADH 
and NADPH activity and raises thereby the oxidative potential of vascular tissue.1,2 In 
addition, it plays a role in the vascular-injury response since it stimulates leukocyte 
adhesion to the site of the injury. In addition, it favors superoxide and peroxynitrite 
formation and proliferation and migration of various cell types towards the luminal site 
of injury.3 The cascade of events that follows can result in atherosclerotic plaques. 
Angiotensin II and some of its constituent peptides also stimulate the synthesis of the 
plasminogen activator inhibitor 1 (PAI1). Therefore, it is thought that activation of the 
renin-angiotensin system predisposes to atherosclerosis and thromboembolic events, 
including myocardial infarction (MI) and stroke.4,5  
Of the four mainly prescribed antihypertensive drug classes (i.e. diuretics, β-
blockers, calcium channel blockers, and ACE-inhibitors), only ACE-inhibitors and β-
blockers have a direct effect on the renin-angiotensin system, i.e. ACE-inhibitors inhibit 
the conversion from angiotensin I into angiotensin II and β-blockers inhibit the β-
adrenoceptor mediated release of renin from the kidneys. The objective of this study 
was to determine whether the risk of atherosclerosis varies between ACE-inhibitor or 
β-blocker users with different genotypes of genes that are involved in the renin-
angiotensin system, i.e. ACE, AGT, and angiotensin receptor II type 1 (AGTR1) gene.   
 
 
Methods 
 
Setting and design 
The Rotterdam Study is a prospective, population-based cohort study, which started in 
1990 as a population-based prospective follow-up study. All 10,275 residents of the 
suburb Ommoord in Rotterdam, aged 55 years or older were invited to participate in 
an extensive home interview and two visits to the research center. In total, 7,983 
(78%) subjects gave written informed consent and baseline measurements took place 
until 1993. Information was collected on age, gender, present health status, and 
medical history, including previous MI and stroke. All reported MIs or stroke at 
baseline were verified with medical records. During a physical examination, blood 
pressure, weight, and height were measured and blood was drawn for DNA extraction. 
In total, blood samples were available for genotyping of 86% of the cohort. The design 
of this population-based study has been described elsewhere.6 A second (1993-1995) 
and third (1997-1999) cross-sectional assessment were conducted in a similar way. 
Only atherosclerosis measurements from the third cross-sectional assessment were 
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included, since a limited number of atherosclerosis measurements were performed in 
the second assessment and pharmacy records were only available as of January 1st, 
1991 which is later than most of the baseline atherosclerosis assessments. Of 3,506 
participants’ information on at least one measure of atherosclerosis, assessed during 
the third cross-sectional assessment, was available. Only individuals with hypertension 
were included in this study. Hypertension was defined as systolic blood pressure ≥ 160 
mmHg, and/or diastolic blood pressure ≥ 95 mmHg, and/or the use of a 
antihypertensive drug during follow-up. 
 
Outcome definition 
Atherosclerosis of the lower extremities 
Systolic blood pressure at the ankles (posterior tibial artery) was measured in the 
supine position with a random-zero sphygmomanometer and an 8-MHz continuous 
wave Doppler probe (Huntleigh 500D, Huntleigh Technology). The ratio of the systolic 
blood pressure at the ankle to the systolic blood pressure at the arm was calculated to 
obtain the ankle-arm index (AAI). Peripheral arterial disease was considered present 
when the ankle-brachial blood pressure index was lower than 0.90 in at least one leg.7 
The sensitivity and the specificity of this cut-off are 90% and 98%, respectively, for an 
angiographically defined stenosis of 50% or more in a major leg artery.8 
Aortic atherosclerosis 
Aortic atherosclerosis was diagnosed by radiographic detection of calcified deposits in 
the abdominal aorta on a lateral abdominal film.9 Calcified deposits were graduated on 
a graded scale (with scores of zero to five corresponding to 0, ≤1, 1 to 2.5, 2.5 to 4.9, 
5.0 to 9.9 and ≥10 cm, respectively). Aortic atherosclerosis was considered present if 
the score was one or higher. In addition, aortic atherosclerosis was divided in degrees 
of severity, i.e. score of zero, one to two, and three or higher. 
Carotid atherosclerosis 
Ultrasonography of both carotid arteries was performed with a 7.5-MHz linear-array 
transducer and a duplex scanner (ATL Ultra-Mark IV, Advanced Technology 
Laboratories). The common carotid artery, carotid bifurcation, and internal carotid 
artery were examined on both the left and right sides for the presence of plaques as 
described before.10 A weighted plaque score ranging from zero to six was computed 
by adding the number of sites at which a plaque was detected, divided by the number 
of sites for which an ultrasonographic image was available, and multiplied by six (the 
maximum number of sites). Carotid atherosclerosis was considered present if the 
plaque score was one or higher, respectively. Carotid atherosclerosis was also divided 
in degrees of severity, i.e. plaque score of zero, one to two, three, and four or higher. 
 
Exposure definition 
Pharmacy records were available for approximately 99% of the cohort as of January 
1st, 1991. These records include the name of the drug, the day of dispensing, the 
dosage form, the number of units dispensed, the prescribed daily dose and the 
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Anatomical Therapeutic Chemical (ATC) code of the drug.11 The exposure of interest 
included ACE-inhibitors and β-blockers, because of their direct effect on the renin-
angiotensin system. The use of these antihypertensive drug classes was divided into 
three categories, i.e. no use, short-term (0-4 years), and long-term (≥ 4 years). 
These categories were chosen, because of the expected lag-time between drug 
exposure and the effect on atherosclerosis. 
On the date of the atherosclerosis measurement, the cumulative duration of use 
was calculated for all antihypertensive drug classes for each participant. Hereto, we 
first calculated each prescription length by dividing the number of dispensed tablets or 
capsules by the prescribed daily number. Each refill at the pharmacy which occurred 
within seven days after last intake from the previous prescription was considered as a 
continuous drug episode. For dose-effect associations, we used the defined daily dose 
(DDDs) which consists of the recommended daily dose for the indication hypertension 
in an adult.  
 
Genotyping 
Genomic DNA was extracted from whole blood samples using standard methods, 
described previously.12 The I and D-allele of the ACE gene were identified on the basis 
of polymerase-chain-reaction (PCR) technique according to the method of Lindpainter 
et al.13 with some modifications. Because the D-allele in heterozygous samples is 
preferentially amplified, there is a tendency of misclassification for about 4-5% of the 
ID to DD genotypes. For this reason, a second PCR was performed with a primer pair 
that recognises an insertion specific sequence (5’ TGG GAC CAC AGC GCC CAC TAC 3’ 
and 5’ TCG CCA GCC CTC CCA TGC CCA TAA 3’). The reaction yielded a 335-bp 
amplicon only if the I-allele was present. Two independent investigators read pictures 
from each gel and all ambiguous samples were analysed a second time.  
The AGT M235T and AGTR1 573C/T (exon 5) polymorphism were genotyped with 
TaqMan allelic discrimination Assays-By-Design (Applied Biosystems, Foster City, CA). 
Forward and reverse primer (anti sense strand) sequences were 5’ AGG TTT GCC TTA 
CCT TGG AAG TG 3’ and 5’ GCT GTG ACA GGA TGG AAG ACT 3’ and the minor groove 
binding probes were 5’ CTG GCT CCC ATC AGG 3’ (VIC) and 5’ CTG GCT CCC GTC 
AGG 3’ (FAM) for the AGT M235T polymorphism. Forward and reverse primer 
sequences were 5’ TGT GCT TTC CAT TAT GAG TCC CAA A 3’ and 5’ CAG AAA AGG 
AAA CAG GAA ACC CAG TAT A 3’ and the minor groove binding probes were 5’ CTA 
TCG GGA GGG TTG 3’ (VIC) and 5’ CTA TCG GAA GGG TTG 3’ (FAM) for the AGTR1 
573C/T polymorphism. The assays utilized 5 nanograms of genomic DNA and 2 
microliter reaction volumes. The amplification and extension protocol was as follows: 
an initial activation step of 10 min at 95 deg preceded 40 cycles of denaturation at 95 
deg for 15 s and annealing and extension at 50 deg for 60 s. allele-specific 
fluorescence was then analyzed on an ABI Prism 7900HT Sequence Detection System 
with SDS v 2.1 (Applied Biosystems, Foster City, CA). 
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Potential confounders 
As potential confounders we consider age, gender, diabetes mellitus, systolic blood 
pressure, diastolic blood pressure, body mass index (BMI), use of coumarins, angina 
pectoris, history of stroke, history of coronary heart disease, smoking, cholesterol level 
(total cholesterol/high density cholesterol), use of statins, follow-up time, cumulative 
use of other antihypertensive drugs, and DDDs. We adjusted for the combined use of 
other antihypertensive drugs classes by adding each antihypertensive drug class 
separately in the model for no use, short-term, and long-term treatment. The same 
duration of use categories were used for statin therapy. History of angina pectoris was 
defined as the use of two or more prescriptions of nitrate. History of coronary heart 
disease was defined as a history of MI, history of percutaneous transluminal coronary 
angioplasty, and history of coronary artery bypass grafting.  
 
Statistical analysis 
Binary logistic regression was used for the endpoints: presence of peripheral arterial 
disease, presence of aortic atherosclerosis, and presence of carotid atherosclerosis. 
Cumulative use of antihypertensive drugs was divided into three mutually exclusive 
groups, i.e. no, short-term (0-4 years), and long-term treatment (≥ 4 years). In a 
sensitivity analysis also cut-off point of two and three years were used. Multinomial 
logistic regression was used for the degrees of severity analysis for the outcomes: 
aortic and carotid atherosclerosis. To study the effect modification by the ACE gene 
and the use of ACE-inhibitors (or β-blockers) subjects with the DD genotype and those 
who did not use ACE-inhibitors (or β-blockers) were used as the reference group. For 
the drug-gene interactions four dummy variables were added to the model, e.g. ACE 
genotype (ID or II) x ACE-inhibitor (short-term or long-term treatment).  
 
 
Results 
 
In total, there were 2,305 subjects with hypertension during follow-up. Of 2,216 
subjects (96.1%) data on atherosclerosis and blood samples were available. Of these 
2,216 subjects, 727 were treated with ACE-inhibitors, 1,267 were treated with β-
blockers, and 1,556 were treated with antihypertensive drugs from other classes. A 
subject could contribute to one or more categories of antihypertensive drug classes 
during follow-up. Table 1 shows the characteristics of the subjects included in this 
study at the moment of the third cross-sectional assessment.  
The ACE genotype could be assessed in 2,164 subjects. Of these, 26.3%, 52.2%, 
and 21.4% had the DD, ID, and II genotype, respectively. The AGT genotype could be 
assessed in 2,056 subjects, of whom 37% had the MM, 46.8% the MT, and 16.2% the 
TT genotype. With regard to the AGTR1 genotype, 2,032 could be genotyped, of 
whom 27.5% had the CC, 49% had the CT, and 23.5% had the TT genotype, 
respectively.  
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Table 1. Baseline characteristics of the study population 
 
Characteristics n=2,216 
Age, years  
Gender, male 
SBP, mmHg 
DBP, mmHg 
BMI, kg/m2 
Total cholesterol/HDL, mmol/l 
Cardiovascular disease, yes 
Stroke, yes 
Smoking, current/past/never 
ACE gene, DD/ID/II 
AGT gene, MM/MT/TT 
AGTR1 gene, CC/CT/TT 
Use of ACE-inhibitors, 0/0-4/ ≥ 4 years 
Use of β-blockers, 0/0-4/ ≥ 4 years 
Use of other antihypertensive drugs 
Use of statins 
Use of coumarins 
73.74 ± 23.26  
915 (41.3%) 
153.08 ± 71.13 
82.41 ± 74.13 
73.74 ± 7.02  
10.59 ± 23.26 
437 (19.7%) 
128 (5.8%) 
329/1,110/758  
570/1,130/464 
760/963/333 
559/995/478 
1,489/495/232 
949/773/494 
1,556 (70.2%) 
489 (32.1%) 
162 (7.3%) 
 
ACE I/D polymorphism 
In figure 1 the association between the use of β-blockers or ACE-inhibitors and ACE 
I/D polymorphism and the risk of peripheral arterial disease, aortic atherosclerosis, 
and carotid atherosclerosis is presented. Hypertensive subjects not treated with ACE-
inhibitors with the ACE II genotype had a similar risk of peripheral arterial disease 
compared with untreated hypertensive subjects with the DD genotype (Odds ratio 
(OR)=0.89; 95%CI: 0.58-1.35) (see figure 1a). Individuals treated short-term (0-4 
years) with ACE-inhibitors with the DD genotype the risk of peripheral arterial disease 
was similar compared with untreated subjects with the DD genotype (OR=0.95; 
95%CI: 0.45-1.46). Individuals with the II genotype and treated short-term with 
ACE-inhibitors had an increased risk of peripheral arterial disease (OR=1.87; 95%CI: 
1.01-3.46) compared with untreated subjects with the DD genotype. The risk of 
peripheral arterial disease associated with short-term (0-4 years) use of ACE-
inhibitors compared to no use of ACE-inhibitors, was higher among subjects with the 
II genotype than among subjects with the DD genotype of the ACE gene (interaction 
(OR)=2.21; 95%CI: 1.01-4.85). In individuals with the DD genotype and those 
treated long-term (≥ 4 years) with ACE-inhibitors the risk of peripheral arterial disease 
was increased to 2.75 (95%CI: 1.30-5.81) compared with untreated subjects with the 
DD genotype. However, there was no significant drug-gene interaction with the ACE 
I/D polymorphisms in those treated long-term with ACE-inhibitors. In addition, in 
those treated with β-blockers there was no significant drug-gene interaction with this 
polymorphism. 
Regarding the risk of aortic atherosclerosis, individuals treated short-term with β-
blockers with the DD genotype the risk was reduced compared with untreated 
subjects with the DD genotype (OR=0.51; 95%CI: 0.29-0.91) (see figure 1b). In 
individuals with the II genotype and those treated short-term with ACE-inhibitors the 
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risk of aortic atherosclerosis was increased to 2.13 (95%CI: 1.01-4.50) compared 
with untreated subjects with the DD genotype. In those treated long-term the risk 
was even higher (OR=4.37; 95%CI: 1.11-17.31). No significant interaction was found 
between the use of β-blockers or ACE-inhibitors and the ACE I/D polymorphism on the 
risk of aortic atherosclerosis. 
 
Figure 1. Associations between use of β-blockers or ACE-inhibitors and ACE I/D polymorphisms 
on the risk of peripheral arterial disease (1st histogram), aortic atherosclerosis (2nd histogram), 
and carotid atherosclerosis (3rd histogram) (adjusted for all potential confounders). 
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Subjects with the ID genotype and treated short-term with β-blockers, had a 
lower risk of carotid atherosclerosis was lower compared to subjects with the DD 
genotype who were not treated with β-blockers (OR=0.55; 95%CI: 0.30-1.00) (see 
figure 1c) The risk of carotid atherosclerosis was reducted to 0.40 (95%CI: 0.18-0.89) 
in long-term β-blocker users with the II genotype compared to those untreated with 
the DD genotype. Again no significant drug-gene interaction was found in those 
treated with β-blockers or ACE-inhibitors with the ACE I/D polymorphism. 
 
AGT M235T polymorphism 
With regard to the AGT M235T polymorphism, the risk of peripheral arterial disease 
was increased (OR=1.76; 95%CI: 1.03-3.01) in individuals treated short-term with 
ACE-inhibitors with the MM genotype compared with untreated subjects with the MM 
genotype (see figure 2a). In addition, the risk was increased to 2.19 (95%CI: 1.11-
4.29) for individuals treated long-term with ACE-inhibitors with the MT genotype and 
to 2.55 (95%CI: 1.09-5.98) for those with the TT genotype compared with untreated 
subjects with the MM genotype. However, there was no significant interaction between 
the use of ACE-inhibitors or β-blockers and the AGT M235T polymorphism on the risk 
of peripheral arterial disease. 
Hypertensive subjects with the AGT TT genotype who were not treated with ACE-
inhibitors had a non-significant lower risk of aortic atherosclerosis than untreated 
hypertensive subjects with the MM genotype (OR=0.67; 95%CI: 0.40-1.14). In 
individuals treated long-term with β-blockers with the MM genotype the risk of aortic 
atherosclerosis was non-significantly reduced to 0.57 (95%CI: 0.30-1.06) compared 
with untreated subjects with the MM genotype. In contrast, individuals treated long-
term with β-blockers with the TT genotype the risk of aortic atherosclerosis was 
higher i.e. 1.28 (95%CI: 0.48-3.46) compared with untreated subjects with the MM 
genotype. The drug-gene interaction was significant (interaction OR=3.36; 95%CI: 
1.14-9.97). For those treated short-term with β-blockers there was no significant 
drug-gene interaction with the AGT M235T polymorphism. The opposite effect was 
found in those treated with ACE-inhibitors. The risk on aortic atherosclerosis was i.e. 
reduced, instead of increased, in carriers of the 235T-allele, who were treated short-
term with ACE-inhibitors, compared to no use of ACE-inhibitors (MT versus MM; 
interaction OR=0.42; 95%CI: 0.21-0.86 and TT versus MM; interaction OR=0.39; 
95%CI: 0.15-0.99). Compared with the risk of aortic atherosclerosis in subjects with 
the MM genotype of the AGT polymorphism who were not treated with ACE-inhibitors, 
the risk was increased in subjects with the MT genotype who were untreated 
(OR=1.51; 95%CI: 1.10-2.08) and in subjects with the MM genotype who were 
treated short-term with ACE-inhibitors (OR=2.23; 95%CI: 1.17-4.23). None of the 
drug-gene interactions showed a trend towards an association when we classified 
aortic atherosclerosis in more categories of severity. In addition, none of the drug-
gene interactions were significant when severe aortic atherosclerosis (score ≥ three) 
113 
Chapter 5.1 
was compared with no presence of aortic atherosclerosis (score=zero) (data not 
shown). 
 
Figure 2. Associations between use of β-blockers or ACE-inhibitors and AGT M235T 
polymorphisms on the risk of peripheral arterial disease (1st histogram), aortic atherosclerosis 
(2nd histogram), and carotid atherosclerosis (3rd histogram) (adjusted for all potential 
confounders) 
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    Drug-gene interaction (p < 0.05) 
 
Hypertensive subjects not treated with ACE-inhibitors with the angiotensinogen TT 
genotype had a similar risk of carotid atherosclerosis compared to subjects with the 
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MM genotype (OR=1.29; 95%CI: 0.78-2.09). In individuals treated long-term with 
ACE-inhibitors with the MM genotype, the risk of carotid atherosclerosis was non-
significantly increased to 2.89 (95%CI: 0.84-9.09) compared with the reference group. 
In contrast, individuals treated long-term with the TT genotype had a non-significant 
lower risk (OR=0.75; 95%CI: 0.21-2.72) compared to the reference group. The 
interaction between long-term treatment with ACE-inhibitors and the angiotensinogen 
M235T polymorphism was significant (interaction OR=0.20; 95%CI: 0.04-0.95) (see 
figure 2c). There was, however, no trend towards a drug-gene interaction when carotid 
atherosclerosis was classified in more categories of severity. Also, none of the drug-
gene interactions were significant when severe carotid atherosclerosis (score ≥ four) 
was compared with no presence of carotid atherosclerosis (score=zero) (data not 
shown). 
 
AGTR1 573C/T (exon 5) polymorphism 
With regard to AGTR1, no significant drug-gene interaction was found in those treated 
on the risk of peripheral arterial disease (see figure 3a). Although, there was an 
increased risk for individuals with the CC genotype who were treated long-term with 
ACE-inhibitors compared with untreated subjects with the CC genotype (OR=2.93; 
95%CI: 1.39-6.17). 
Also, no significant drug-gene interaction was found on the risk of aortic 
atherosclerosis (see figure 3b). Individuals with the CC genotype and treated short-
term with β-blockers the risk of aortic atherosclerosis was significantly reduced to 
0.51 (95%CI: 0.28-0.93) compared with untreated subjects with the CC genotype. 
Long-term β-blockers users with the CC genotype had a reduced risk of carotid 
atherosclerosis compared to those untreated with the CC genotype (OR=0.32; 95%CI: 
0.14-0.71), but no drug-gene interaction in β-blockers users was found. Subjects 
treated short-term with ACE-inhibitors had a higher risk of carotid atherosclerosis with 
the CT genotype compared to those treated short-term with the CC genotype 
(interaction OR=2.63; 95%CI: 1.11-6.24). There was no trend towards a interactive 
effect between ACE-inhibitors and the AGTR1 573C/T polymorphism when carotid 
atherosclerosis was classified in more categories of severity. 
 
 
Discussion 
 
Although some of the individual measurements of atherosclerosis showed a significant 
drug-gene interaction, there was no consistency between the different atherosclerosis 
measurements, the different antihypertensive drug classes, or different genotype 
classes. In addition, there was no trend towards a drug-gene interaction when we 
classified aortic and carotid atherosclerosis in more categories of degree of severity. It 
is therefore possible that the drug-gene interactions found were false-positive. In 
conclusion, the data suggested that there was no strong drug-gene interaction 
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between ACE I/D, AGT M235T, or AGTR1 573C/T polymorphism and the use of ACE-
inhibitors or β-blockers on the risk of atherosclerosis found in daily practice.  
Figure 3. Associations between use of β-blockers or ACE-inhibitors and AGTR1 573C/T 
polymorphisms on the risk of peripheral arterial disease (1st histogram), aortic atherosclerosis 
(2nd histogram), and carotid atherosclerosis (3rd histogram) (adjusted for all potential 
confounders). 
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     Drug-gene interaction=p < 0.05 
 
In this study, we have used three different sub-clinical measurements for 
atherosclerosis. All three measurements have been validated before. Carotid 
atherosclerosis as shown on ultrasound, aortic atherosclerosis on abdominal x-ray, 
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and lower-extremity atherosclerosis reflected by the AAI are validated measures of 
atherosclerosis and strongly associated e.g. with the presence of coronary 
calcification,14 coronary heart disease,15,16 and stroke.17 Although, carotid plaques and 
ankle-arm index are predictors of stroke they are less strong predictors than aortic 
calcification.18 
To our knowledge, there are no prior studies which investigated whether there is a 
drug-gene interaction between the three candidate gene polymorphisms and ACE-
inhibitor therapy or β-blocker therapy with these sub-clinical measurements of 
atherosclerosis. Two of the three polymorphisms we have investigated have earlier 
been investigated on other outcomes. For example, the ACE II genotype is associated 
with lower tissue and plasma levels of ACE compared to the DD genotype.19,20 In a 
large trial no drug-gene interaction was found on the risk of cardiovascular disease 
between the I/D polymorphism and ACE-inhibitor therapy.21 With regard to the AGT 
M235T polymorphism, subjects with the TT genotype have in general 10-20% higher 
plasma AGT levels than individuals with the MM genotype.22,23 However, Hopkins et 
al.24 reported no difference in angiotensin II levels between the genotype groups. Bis 
et al.25 reported that subjects carrying one copy of the T-allele who used ACE-
inhibitors might have a reduced risk of (non-fatal) stroke compared to users of other 
antihypertensive drugs, but this interaction was not found on myocardial infarction. 
Only with regard to the AGTR1 573C/T polymorphism no information is available on 
plasma levels or on the risk of myocardial infarction or stroke. Benetos et al.26 found a 
significantly greater reduction in carotid-femoral pulse wave velocity with the AGTR1 
1166A/C (exon 5) polymorphism in 40 patients treated with ACE-inhibitors. The 
distance between the AGTR1 1166 A/C polymorphism and the 573C/T polymorphism 
is about 500 base pairs and is most likely in linkage equilibrium with the 1166A/C 
polymorphism. 
A limitation of this study is that we only had a limited number of pre-treatment 
atherosclerosis measurements. Therefore, we were unable to measure the 
progression/reduction of atherosclerosis. In addition, subjects included in the 
Rotterdam Study were 55 years or older when the study started. Younger subject 
respond better to antihypertensive drug treatment and this might have resulted in 
greater differences in atherosclerosis levels. Therefore, the results can not be 
generalized to the general population. Another limitation is that it is unknown how 
long a patient should be treated with antihypertensive drugs before a change in 
peripheral, carotid, or aortic atherosclerosis can be achieved. In our analysis, we used 
four years as a cut-off value. The data was also analyzed with other cut-off values, 
i.e. two and three years. The results slightly changed, but there was no consistent 
drug-gene interaction with any of the three candidate gene polymorphisms. Due to 
the limited number of subjects treated for five years or more, we could not extend our 
drug treatment window. Another limitation is that only one single nucleotide 
polymorphism per gene was examined, which may not explain the full variation in 
plasma or tissue levels. Therefore, we are only able to exclude a candidate gene
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polymorphism and not a complete gene as candidate for a drug-gene interaction.  
Despite the caveats, the results did not indicate the presence of a strong drug-
gene interaction between the use of ACE-inhibitors or β-blockers and the ACE I/D, AGT 
M235T, or AGTR1 573C/T polymorphism on the overall risk of atherosclerosis. 
However, these results need to be replicated before definitive conclusions can be 
made.  
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Abstract 
 
Introduction: Angiotensinogen is an essential component of the renin-angiotensin 
system. ACE-inhibitors and β-blockers both have a direct influence on this system.  
Aim: To investigate whether the association between use of ACE-inhibitors or β-
blockers and the risk of stroke or myocardial infarction (MI) is modified by the T-allele 
of the angiotensinogen M235T polymorphism. 
Methods: Data were used from the Rotterdam Study, a population-based prospective 
cohort study in the Netherlands, which started in 1990 and included 7,983 subjects of 
55 years or older. In this study, 4,097 subjects with hypertension were included from 
July 1st, 1991 onwards. Follow-up ended at the diagnosis of MI or stroke, death, or the 
end of the study period (January 1st, 2002). The association between the drug-gene 
interaction and the risk of MI or stroke was determined with a Cox proportional hazard 
model with adjustment for each drug class as time-dependent covariates. 
Results: The interaction between current use of ACE-inhibitors and the 
angiotensinogen M235T polymorphism was multiplicative on the risk of MI (interaction 
HR=4.00; 95%CI: 1.32-12.11). Similarly, there was a non-significantly increased risk 
of stroke (interaction HR: 1.83; 95%CI: 0.95-3.54) in subjects with the MT or TT 
genotype compared to the MM genotype. No interaction was found between current 
use of β-blockers and the AGT M235T polymorphism on the risk of MI (interaction HR: 
1.30; 95%CI: 0.60-2.83) or stroke (interaction HR: 1.39; 95%CI: 0.81-2.39). 
Conclusion: Subjects with at least one copy of the 235T-allele of the AGT gene might 
have less benefit from ACE-inhibitor therapy. 
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Introduction 
 
Hypertension is a common disorder affecting approximately 20% of the adult 
populations of most developed countries1, and is a major risk factor for cardiovascular 
disease. In clinical trials, antihypertensive therapy has been associated with a 35% to 
40% risk reduction in stroke incidence and a 20% to 25% reduction in the risk of 
myocardial infarction (MI).2 Although many effective antihypertensive drugs are 
available, it remains difficult to predict the effect of a particular antihypertensive 
agent in an individual patient. Genetic variation in genes may explain differences 
between individuals in their response to antihypertensive drugs. 
One of the genes that might have an influence on the response is the 
angiotensinogen (AGT) gene. AGT is one of the components of the renin-angiotensin 
system, which has a central role in the regulation of blood pressure and fluid 
homeostasis. AGT is cleaved by renin to form angiotensin I, which is converted to the 
vasoactive angiotensin II by angiotensin converting enzyme (ACE). In 1992, 
Jeunemaitre et al.3 reported linkage of the angiotensinogen locus to hypertension in 
hypertensive sibling pairs. Subsequent screening of the angiotensinogen gene for 
molecular variants led to the identification of a missense mutation, resulting in the 
substitution of a threonine (T) for a methionine (M) at codon 235. Further 
investigations showed that the AGT 235T-allele is in linkage equilibrium with a 
guanine (G) to adenosine (A) transition 6 base pairs upstream of the initiation site of 
transcription (-6G/A), which may result in a higher basal transcription rate of this 
gene.4 In general, individuals with the TT genotype have plasma AGT levels, which are 
10-20% higher than individuals with the MM genotype.3,5 Two meta-analyses reported 
a significant association between the M235T polymorphism and hypertension with a 
combined risk of 1.2 for the 235T-allele in Caucasians.6,7 However, such an 
association was not found for MI or stroke.6,8
Of the four mainly prescribed antihypertensive drug classes (diuretics, β-blockers, 
calcium channel blockers, and ACE-inhibitors), only ACE-inhibitors and β-blockers have 
a direct effect on the renin-angiotensin system. ACE-inhibitors inhibit the conversion 
from angiotensin I to angiotensin II and β-blockers inhibit the release of renin. 
Therefore, it is plausible that the response to these antihypertensive drug classes may 
be modified by the M235T polymorphism of the AGT gene. Bis et al.9 reported that the 
235T-allele was associated with a stronger reduction of the risk of non-fatal stroke in 
users of ACE-inhibitors than in users of other antihypertensive drugs, whereas there 
was no difference in the risk of non-fatal MI. 
The objective of our study was to determine whether the risk of MI or stroke in 
hypertensive patients on ACE-inhibitors or β-blockers is modified by the AGT M235T 
polymorphism.
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Methods 
 
Setting 
The Rotterdam Study started in 1990 as a population-based prospective follow-up 
study. All 10,275 residents of the suburb Ommoord in Rotterdam, aged 55 years or 
older were invited to participate. In total, 7,983 (78%) subjects gave written informed 
consent. The baseline measurements took place until 1993. The design of this 
population-based study has been described elsewhere.10 Information was collected on 
age, gender, present health status and medical history, including previous MI and 
stroke. All reported MIs or strokes at baseline were verified with medical records. 
During a physical examination, blood pressure, weight, and height were measured 
and blood was drawn for DNA extraction.  
Hypertension was defined as use of antihypertensive medication, and/or a systolic 
blood pressure ≥ 160 mmHg, and/or diastolic blood pressure ≥ 95 mmHg. Since the 
start of the Rotterdam Study, follow-up examinations have been carried out 
periodically.  
  
Cohort and outcome definition 
Only subjects with hypertension were included in this study. Therefore, follow-up 
started on the day that an elevated blood pressure was measured and/or the day that 
a first antihypertensive drug was prescribed, whichever came first. The beginning of 
the study period was set at July 1st, 1991 because pharmacy records were not 
available before January 1st, 1991 and this resulted in a drug history of at least six 
months. The end of the study was set at January 1st, 2002. Follow-up ended on the 
date of the first MI (or first stroke for the analysis with stroke as primary outcome), or 
a censoring event (end of study period, moving out of the area, or death), whichever 
was earlier. All collected events were verified by review of hospital discharge reports 
and letters from medical specialists, and classified as definitive and possible MI. Two 
research physicians independently coded events according to the International 
Classification of Diseases, 10th Revision (ICD-10).11 MI was defined as ICD codes: I21. 
A medical expert in cardiovascular disease also reviewed all coded events for final 
classification.  
Stroke was defined as ICD codes: K90. A neurologist reviewed all suspected 
cerebrovascular cases and classified them into definite, probable, and possible stroke 
and stroke subtypes.12 For the analyses, definite and probable cases were included. 
Sub-classification into hemorrhagic and ischemic stroke was based on neuroimaging, 
which was available for 64% of all cases. 
 
Exposure definition 
Pharmacy records were available for approximately 99% of the cohort as of January 
1st, 1991. These records include the name of the drug, the day of dispensing, the 
dosage form, the number of units dispensed, the prescribed daily dose, and the 
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Anatomical Therapeutic Chemical code of the drug.13 The exposure of interest included 
ACE-inhibitors and β-blockers, because of their direct effect on the renin-angiotensin 
system.  
When an MI or stroke occurred, the date was defined as the event date and the 
cumulative duration of use for current and past exposure of all antihypertensive drug 
classes on that date was calculated for each participant. Hereto, we first calculated 
each prescription length by dividing the number of dispensed tablets or capsules by 
the prescribed daily number. Each refill at the pharmacy which occurred within 7 days 
after last intake from the previous prescription was considered as a continuous drug 
episode. Current, past, and non-exposure were defined as mutually exclusive 
categories. When the event fell within a usage period, the patient was considered as 
currently exposed, and the cumulative number of days of current use was calculated. 
Similarly for those who were not current user, but had used a representative of the 
drug group in the past the number of days since last intake was calculated. Those who 
had not used the drug during the study period were considered as non-user. For dose-
effect associations, we used the defined daily dosages (DDD) which consist of the 
recommended daily dose for the indication hypertension in an adult.   
 
Genotyping 
Genomic DNA was extracted from whole blood samples using standard methods, 
described previously.14 Samples were genotyped with TaqMan allelic discrimination 
Assays-By-Design (Applied Biosystems, Foster City, CA). Forward and reverse primer 
(anti sense strand) sequences were 5’ AGG TTT GCC TTA CCT TGG AAG TG 3’ and 5’ 
GCT GTG ACA GGA TGG AAG ACT 3’ and the minor groove binding probes were 5’ CTG 
GCT CCC ATC AGG 3’ (VIC) and 5’ CTG GCT CCC GTC AGG 3’ (FAM). The assays 
utilized 5 nanograms of genomic DNA and 2 microliter reaction volumes. The 
amplification and extension protocol was as follows: an initial activation step of 10 min 
at 95 deg preceded 40 cycles of denaturation at 95 deg for 15 s and annealing and 
extension at 50 deg for 60 s. allele-specific fluorescence was then analyzed on an ABI 
Prism 7900HT Sequence Detection System with SDS v 2.1 (Applied Biosystems, Foster 
City, CA). 
 
Potential confounders 
For the analysis with MI as an outcome, we adjusted for age, gender, systolic/diastolic 
blood pressure, body mass index (BMI), current and past smoking, cholesterol level 
(total cholesterol/ high density cholesterol) at baseline). In addition, adjustments 
were made for statin use, coumarin use, ASA use, NSAID use, nitrate use, history of 
stroke, history of MI, history of percutaneous transluminal coronary angioplasty, 
history of coronary artery bypass grafting, use of anti-diabetic medication, history of 
angina, past and current use of other antihypertensive drugs, and the defined daily 
dose as potential confounders (during follow-up). We adjusted for the combined use
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of other antihypertensive drug classes by adding each anti-hypertensive drug class 
separately in the model for past and current users. History of angina was defined as 
the use of two or more prescriptions of nitrate.  
For the analysis with stroke as an endpoint, we considered the same potential 
confounders, but combined history of MI, history of percutaneous transluminal 
coronary angioplasty, and history of coronary artery bypass grafting in one variable 
(coronary heart disease). 
 
Statistical analyses 
The outcomes for MI and stroke were analysed separately because of their different 
aetiology. Both events were evaluated using a Cox proportional hazard model with 
time-varying exposure for each antihypertensive drug class separately. We created 
non-cumulative time-dependent categorical variables (yes/no) for current and past use 
of antihypertensive drugs and follow-up time was the time-axis of the model. Non-use 
of ACE-inhibitors (in the analysis of the association between ACE-inhibitors and risk of 
MI or stroke) and non-use of β-blockers (in the analysis of the association between β-
blockers and risk of MI or stroke) served as a reference. The associations were 
expressed as hazard ratios (HR) with 95% confidence limits (CI). To investigate 
modification by the M235T polymorphism of the effect of ACE-inhibitors (or β-blockers) 
one dummy variable was added to the model: 235T-allele (0/1) x ACE-inhibitors (or β-
blocker) (0/1).  
 
 
Results 
 
There were 4,097 subjects with hypertension during follow-up. Of these 4,097 
persons, 1,642 persons were treated with ACE-inhibitors at any time, 2,387 with β-
blockers, and 2,561 with other antihypertensive drugs. A subject may have 
contributed to one of more categories of antihypertensive drug classes during follow-
up.  
In our cohort, 35.7% of the subjects had the MM genotype and 64.3% the MT or 
TT genotype, respectively. Table 1 shows the baseline characteristics of the 4,097 
subjects stratified by AGT genotypes.  
 
MI 
In total 197 subjects experienced an MI, of whom 30% had an MI before January 1st, 
1990. Forty-two subjects had a MI while they were treated with ACE-inhibitors, of 
whom six had the MM genotype and 36 had the MT or TT genotype. In total, 17 
subjects with the MM genotype and 58 subjects with at least one copy of the T-allele 
had an MI when they were treated with β-blockers (see table 2). 
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Table 1. Baseline characteristics stratified by AGT genotype. 
 
Characteristics MM 
n=1,461 
MT or TT 
n=2,636 
 
Gender, female 901 (61.7%) 1,575 (59.7%)  
Age, years 70.6 ± 8.9 70.6 ± 8.9  
Stroke at baseline, yes 50 (3.4%) 103 (3.9%)  
MI at baseline, yes 226 (15.5%) 406 (15.4%)  
Diabetes mellitus, yes 171 (12.5%) 314 (12.7%)  
SBP, mmHg 142.8 ± 22.0 144.0 ± 22.6  
DBP, mmHg 74.9 ± 11.9 75.3 ± 12.1  
BMI, m/kg2 27.0 ± 3.9 26.8 ± 3.7  
Total cholesterol/high density cholesterol, 
mmol/l 
5.3 ± 1.7 5.3 ± 1.6  
Smoking 
current, yes 
past, yes 
 
280 (19.7%) 
609 (42.8%) 
 
531 (20.7%) 
733 (42.3%) 
 
Use of ACE-inhibitors 126 (8.6%) 231 (8.7%)  
Use of β-blockers 319 (21.8%) 573 (21.7%)  
Use of α-blocker 49 (3.4%) 95 (3.6%)  
Use of low-ceiling diuretic 267 (18.3%) 440 (16.7%)  
Use of high-ceiling diuretic 89 (6.1%) 192 (7.3%)  
Use of calcium channel blocker 144 (9.8 %) 236 (9.0%)  
Use of statins 45 (3.1%) 69 (2.6%)  
Use of coumarins 65 (4.4%) 136 (5.2%)  
Use of NSAID 126 (8.6%) 243 (9.2%)  
Use of ASA/ salicylate 213 (14.6%) 374 (14.2%)  
 
* Significant difference between MM or MT/TT genotype (p < 0.05) 
 
Table 2. Association of ACE-inhibitor and β-blocker use and AGT M235T polymorphism with MI 
risk. 
 
AGT M235T 
genotype 
Type of use MI (N) HR (95% CI)1 HR (95% CI)2
ACE-inhibitors 
MM 
MM 
MT/TT 
MT/TT 
No 
Current 
No  
Current 
44 
6 
74 
36 
1 (reference) 
1.06 (0.39-2.85) 
0.95 (0.66-1.39) 
3.25 (1.70-6.19) 
1 (reference) 
0.71 (0.23-2.21) 
0.99 (0.67-1.45) 
2.73 (1.42-5.23) 
β-blockers 
MM 
MM 
MT/TT 
MT/TT 
No 
Current 
No  
Current 
20 
17 
49 
58 
1 (reference) 
1.69 (0.79-3.61) 
1.36 (0.81-2.30) 
3.16 (1.66-6.01) 
1 (reference) 
1.29 (0.59-2.86) 
1.44 (0.84-2.48) 
2.42 (1.23-4.76) 
 
1 Adjusted for age, gender, other antihypertensive drugs, past exposure to antihypertensive drugs, 
and DDDs 
2 Adjusted for age, gender, other antihypertensive drugs, past exposure to antihypertensive drugs, 
DDDs, BMI, cholesterol level, statin use, and history of PTCA, CABG, and MI 
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Table 3. Gene-drug interaction between ACE-inhibitor and β-blocker use and AGT M235T 
polymorphism on the risk of MI. 
 
AGT M235T genotype Type of use Interaction HR (MT/TT 
versus MM) (95% CI)1
Interaction HR (MT/TT 
versus MM) (95% CI)2
 
ACE-inhibitors 
MT/TT versus MM Current 3.28 (1.28-8.45) 4.00 (1.32-12.11) 
 
β-blockers 
MT/TT versus MM Current 1.37 (0.64-2.91) 1.30 (0.60-2.83) 
 
1 Adjusted for age, gender, other antihypertensive drugs, past exposure to antihypertensive drugs, 
and DDDs 
2 Adjusted for age, gender, other antihypertensive drugs, past exposure to antihypertensive drugs, 
DDDs, BMI, cholesterol level, statin use, and history of PTCA, CABG, and MI 
 
In order to investigate the possible gene-drug interaction between ACE-inhibitors 
or β-blockers users and the AGT M235T polymorphism on the risk of MI, cases were 
grouped by current use and genotype group (see table 2 and 3). Subjects with the MM
genotype who were currently treated with ACE-inhibitors had a non-significantly 
reduced risk of MI compared to subjects with the MM genotype who never used ACE-
inhibitors (HR=0.71; 95%CI: 0.23-2.21). In contrast, subjects with the MT or TT 
genotype who were currently treated with ACE-inhibitors had a significantly increased 
risk of MI compared to subjects with the MM genotype who never used ACE-inhibitors 
(HR=2.73; 95%CI: 1.42-5.23). Among subjects who never used ACE-inhibitors, the 
MT or TT genotype was not associated with the risk of MI (HR=0.99; 95%CI: 0.67-
1.45). The estimate for the risk of MI in subjects with at least one copy of the T-allele 
(HR=2.73) who were currently treated with ACE-inhibitors was higher than expected 
from the joint effect of the MT or TT genotype and ACE-inhibitors on a multiplicative 
scale (0.99x0.71=0.70). This interaction between current use of ACE-inhibitors and 
the AGT M235T polymorphism was statistically significant (HR=4.00; 95%CI: 1.32-
12.11]). There did not seem to be a doses-response effect (MT versus MM genotype 
HR=3.89; 95%CI: 1.27-11.90 and TT versus MM genotype HR=3.75; 95%CI: 1.04-
13.58). 
Beta-blocker users who had the MM genotype had a non-significantly increased 
risk of MI compared to subjects with the MM genotype who never used β-blockers 
(HR=1.29; 95%CI: 0.59-2.86). Compared to subjects with the MM genotype who had 
never used β-blockers, β-blocker users with the MT or TT genotype had a significantly 
increased risk of MI (HR=2.42; 95%CI: 1.23-4.76). The interaction between current 
use of β-blockers and the AGT M235T polymorphism was non-significant significant 
(HR=1.30; 95%CI: 0.60-2.83). Additional analyses in which adjustments were made 
for systolic blood pressure level, diastolic blood pressure level, history of angina, use 
of ASA, use of coumarins, use of NSAID’s, use of anti-diabetic medication, history of 
stroke, and smoking, yielded similar results and were therefore not shown. After 
exclusion of all subjects with a history of MI the (adjusted) interaction 
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between AGT M235T polymorphism and current use of ACE-inhibitors was similar but 
no longer significant (HR=4.62; 95%CI: 1.00-21.36). In addition, no drug-gene
interaction was found between the AGT M235T polymorphism and use of β-blockers 
after this exclusion (HR=1.19; 95%CI: 0.47-3.02).  
When the analysis was repeated with other antihypertensive drug classes (i.e. 
low-ceiling diuretics or calcium channel blockers) there was no significant drug-gene 
interaction with any of these antihypertensive drug classes.  
 
Stroke 
In total, 349 subjects experienced a stroke during follow-up, of whom 14% had a 
stroke before baseline. Of the 365 events, 189 (85%) were classified as ischemic and 
33 (15%) as hemorrhagic. Sixty-three subjects had a stroke when they were treated 
with an ACE-inhibitor, of whom 15 had the MM genotype and 48 had at least one copy 
of the T-allele. During treatment with a β-blocker, 32 subjects with the MM genotype 
and 71 subjects with had at least one copy of the T-allele had a stroke. 
To investigate the possible interaction between ACE-inhibitors or β-blockers users 
and the AGT M235T polymorphism on the risk of stroke, participants were grouped by 
current use and genotype group (see table 4 and 5). The drug-gene interaction 
between current use of ACE-inhibitors and the AGT M235T polymorphism on the risk 
of stroke was increased but this increase was not statistically significant (HR=1.83; 
95%CI: 0.95-3.54). The interaction between current use of β-blockers and the AGT 
M235T polymorphism on the risk of stroke was non-significant (HR=1.39; 95%CI: 
0.81-2.39). Additional analyses in which we adjusted for diastolic blood pressure level, 
serum cholesterol level, BMI, use of coumarins, use of NSAID’s, and smoking, yielded 
similar results and were therefore not shown. 
 
Table 4. Association of ACE-inhibitor and β-blocker use and AGT M235T polymorphism with 
stroke risk.  
 
AGT M235T 
genotype 
Type of use MI (N) HR (95% CI)1 HR (95% CI)2
ACE-inhibitors 
MM 
MM 
MT/TT 
MT/TT 
No 
Current 
No  
Current 
95 
15 
141 
48 
1 (reference) 
0.64 (0.33-1.23) 
0.84 (0.65-1.09) 
1.04 (0.63-1.71) 
1 (reference) 
0.58 (0.29-1.14) 
0.84 (0.64-1.10) 
0.89 (0.53-1.48) 
β-blockers 
MM 
MM 
MT/TT 
MT/TT 
No 
Current 
No  
Current 
66 
32 
104 
71 
1 (reference) 
0.68 (0.40-1.14) 
0.85 (0.63-1.16) 
0.82 (0.51-1.30) 
1 (reference) 
0.73 (0.43-1.23) 
0.85 (0.62-1.21) 
0.86 (0.54-1.39) 
 
1 Adjusted for age, gender, other antihypertensive drugs, past exposure to antihypertensive drugs, 
and DDDs 
2 Adjusted for age, gender, other antihypertensive drugs, past exposure to antihypertensive drugs, 
DDDs, BMI, cholesterol level, statin use, and history of PTCA, CABG, and MI 
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Table 5. Gene-drug interaction between ACE-inhibitor and β-blocker use and AGT M235T 
polymorphism on the risk of stroke. 
 
AGT M235T genotype Type of use Interaction HR (MT/TT 
versus MM) (95% CI)1
Interaction HR (MT/TT 
versus MM) (95% CI)2
 
ACE-inhibitors 
MT/TT versus MM Current 1.93 (1.02-3.65) 1.83 (0.95-3.54) 
 
β-blockers 
MT/TT versus MM Current 1.41 (0.84-2.38) 1.39 (0.81-2.39) 
 
1 Adjusted for age, gender, other antihypertensive drugs, past exposure to antihypertensive 
drugs, and DDDs 
2 Adjusted for age, gender, other antihypertensive drugs, past exposure to antihypertensive 
drugs, DDDs, systolic blood pressure level, diabetes mellitus, use of statins, use of ASA, and 
history of coronary heart disease, stroke, and angina 
 
After exclusion of all subjects with a history of stroke the (adjusted) interaction 
between AGT M235T polymorphism and current use of ACE-inhibitors was significant 
(HR=2.14; 95%CI: 1.06-4.33). No drug-gene interaction was found between β-
blocker use and the AGT M235T polymorphism after this exclusion (HR=1.59; 95%CI: 
0.90-2.78). When we included only ischemic strokes, the interaction was significant 
for ACE-inhibitors (HR=3.52; 95%CI: 1.27-9.80), but not for β-blockers (HR=1.30; 
95%CI: 0.47-3.02). There did not seem to be a doses-response effect in ACE-inhibitor 
users (MM versus MT genotype HR=1.88; 95%CI: 0.96-3.69 and MM versus TT 
genotype HR=1.93; 95%CI: 0.80-4.66). 
When the analysis was repeated with other antihypertensive drug classes (i.e. 
low-ceiling diuretics or calcium channel blockers) or all antihypertensive drug classes 
combined there was no significant drug-gene interaction with current use. 
 
 
Discussion 
 
In this study, a synergistic interaction between the AGT M235T polymorphism and 
current use of ACE-inhibitors on the risk of MI was found. Their joint effect was 
supramultiplicative and approximately four times larger than expected based on the 
product of their individual effects. On the risk of stroke no significant interaction was 
found, although the direction of the synergistic effect was similar to that on the risk of 
MI. No interaction was found between the use of β-blockers and the M235T 
polymorphism. 
Bis et al.9 reported that users of ACE-inhibitors carrying one copy of the T-allele 
might have a reduced risk of non-fatal stroke compared to users of other 
antihypertensive drugs, but there was non-significantly increased risk for non-fatal MI. 
In our study we found the opposite result, i.e. the MT and TT genotype were 
associated with an increased risk of MI in ACE-inhibitor users. In addition, the risk of 
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stroke in β-blockers was higher in subjects carrying a copy of the 235T-allele, albeit 
not significant. In a non-randomized trial, ACE-inhibitor users with the MT or TT 
genotype had a greater BP reduction than those with the MM genotype.15 However, 
this could not be replicated in a smaller study.16 With regard to β-blockers, no drug-
gene interaction on BP was found.16,17 The contribution of these findings on blood 
pressure to cardiovascular risk remains uncertain. For example, no studies have been 
published investigating whether there is an interaction between M235T polymorphism 
and antihypertensive drugs on atherosclerosis, which is an important risk factor for MI 
and stroke besides blood pressure. In addition it is difficult to predict with accuracy, 
which allele would be associated with an increased risk of stroke or MI during 
treatment with an ACE-inhibitor or β-blocker. Plasma AGT levels are 10-20% higher in 
TT homozygotes than in MM homozygotes3,5, but this did not result in higher 
angiotensin II levels due to compensation in renin levels18,19. There are some 
differences between our study and Bis et al.9 which might explain the differences in 
results. For instance, we included fatal and non-fatal cases of MI and stroke, adjusted 
for past use, and compared the use of ACE-inhibitor or β-blockers versus non-users 
instead of users of other antihypertensive drugs.  
The main limitation of our study is the relatively small number of events. 
Although, our analyses consistently showed that current use of ACE-inhibitors among 
subjects with the T-allele was associated with an increased risk of MI and stroke, the 
results should still be interpreted with caution. Therefore, these results need to be 
replicated in other studies before definitive conclusion can be made. In addition, due 
to limited sample size no subgroup analysis could be made and MT and TT genotype 
were combined. Also, the risk of MI or stroke was compared in antihypertensive drug 
users versus non-users and therefore confounding by indication could have biased our 
results. As a physician was free to choose whether a patient received antihypertensive 
drug treatment or not and the type of antihypertensive drug, specific patients 
characteristics my have influenced this decision. However, the interaction between β-
blockers or ACE-inhibitors and the AGT M235T polymorphism is probably not 
influenced by this bias, as the users of the same antihypertensive drug class will have 
most likely the same characteristics and the prescriber is unaware of a subject’s 
genotype. Furthermore, only one SNP in the AGT gene was investigated. Although the 
M235T polymorphism is linked with plasma AGT levels and hypertension, it remains 
controversial in relation to MI and stroke. Since more genes are involved in the renin-
angiotensin system and these might have compensated the increased risk of ACE-
inhibitors in subjects with the T-allele e.g. by lowering the production of renin. One  
explanation of our findings might be that the feedback mechanism that normally 
compensate a rise in the angiotensinogen (e.g. a decrease in renin) are dysfunctional 
in T-allele carriers. This might be of particular importance during treatment with  ACE-
inhibitors, since such a treatment is known to be accompanied by a compensatory rise 
in renin. Future studies, addressing plasma renin levels during ACE-inhibitor treatment 
in T-allele carriers and controls, should evaluate this possibility.   
131 
Chapter 5.2 
In conclusion, our results indicate that the T-allele might be associated with an 
increased risk of MI and stroke in users of ACE-inhibitors.  
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Introduction 
 
Despite advances in drug therapy during the past decades, few drugs are effective in 
all patients, whereas all drugs potentially have adverse effects. Important factors in 
interpreting the variability in outcomes of drug therapy include environmental factors, 
a patient’s health profile, disease severity, compliance, and the genetic profile of a 
patient.1, 2 Clinical observations of genetic differences in drug effects were first 
documented in the 1950s when researchers described the first genetic polymorphisms 
that influenced the disposition of succinylcholine, isoniazid, and antimalaria drugs 
such as primaquine.3-6 These observations gave rise to the field of pharmacogenetics. 
Initially pharmacogenetics focused largely on genetic polymorphisms in drug-
metabolizing enzymes that influenced drug pharmacokinetics. By the mid 1980s, 
about 100 of these polymorphisms were identified.7 Polymorphisms in drug 
metabolizing enzymes can lead to a variety of outcomes, such as therapeutic failure, 
adverse effects, and toxicity in selected sub-populations undergoing treatment. For 
example, CYP2D6 poor metabolizers have a severe impairment of the capacity to 
eliminate > 30 widely used drugs (e.g. β-blockers and anti-depressants). In contrast, 
CYP2D6 ultrarapid metabolizers, may fail to respond to drugs which are inactivated by 
CYP2D6 or may experience exaggerated response and toxicity from exposure to drugs 
activated by CYP2D6.7 In the last decade, the scope of pharmacogenetics expanded to 
transporters and targets that influence the pharmacodynamic response to drugs. For 
example, cell surface receptors (e.g. ion channels and ion channel transporters) are of 
interest because of their role in initiation and transmission of cellular responses to 
hormones, autocoids, neurotransmitters, and environmental chemicals such as drugs.  
Patients who are treated with drugs that show large inter-individual differences in 
response will most likely benefit from pharmacogenetic research. Such an example is 
the pharmacological treatment of hypertension. For instance, only 50% of the patients 
have an adequate blood pressure lowering response when treated with a single 
antihypertensive drug (monotherapy).8-11 Currently, the selection of the most 
appropriate drug treatment for an individual patient with hypertension is considered as 
a "trial and error" approach. Although, there are substantial differences in 
pharmacokinetic properties the magnitude of the blood pressure lowering effect is 
similar for most drugs within a class.10, 11 Therefore, it is unlikely that pharmacokinetic 
effects are responsible for most of the antihypertensive drug-gene interactions. This 
may be explained by the withdrawal of antihypertensive drugs from the market that 
were associated with large interpatient differences in therapeutic or toxic response in 
the past or the diminished use.11, 12  
The goal of pharmacogenetics is to identify subjects who are more likely to have an 
unfavourable response to treatment with a particular drug or drug class prior to drug 
treatment.13 Before this goal can be reached the causal genes need to be identified. 
There are two general approaches to identify these genes i.e. genome wide screens 
and candidate gene studies. A genome wide screen tests for linkage with anonymous
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polymorphic markers, whereas candidate gene studies test for association of specific 
polymorphic markers within or near the functional gene. This gene is selected based on 
a priori hypotheses about their aetiological role in drug response. Genome wide screen 
or candidate gene studies can both be performed as part of a clinical trial and in an 
observational setting. In chapter 3.1, all studies that investigated interacting effects 
between antihypertensive drugs and genetic polymorphisms were reviewed. In this 
thesis, we investigated whether five of these drug-gene interactions modified the effect 
of antihypertensive drugs on blood pressure, atherosclerosis, and the risk of 
myocardial infarction (MI) and stroke in daily practise. The five candidate gene 
polymorphisms were: the angiotensin converting enzyme (ACE) insertion/deletion 
(I/D), angiotensinogen (AGT) M235T, angiotensin II receptor type 1 (AGTR1) 1166A/C 
or 573C/T, α-adducin (ADD1) G460W, and β3-subunit of the G-protein (GNB3) 825C/T 
polymorphism. Since the shortcomings and merits of the individual studies have been 
discussed in the previous chapters, are the main findings in this chapter placed in a 
broader perspective. In addition, the clinical implication of these studies will be 
discussed and recommendations for future research will be given.  
 
 
Main findings 
 
Despite the awareness of the elevated cardiovascular risk associated with hypertension 
and the availability of generally effective and well-tolerated antihypertensive drugs, did 
only a minority of treated hypertensive subjects achieve an adequate blood pressure 
reduction.14 In the Netherlands about 60% of those treated (20-59 years) did not have 
their blood pressure controlled (< 140/90 mmHg) (chapter 2.1). Apart from non-
compliance, one of the factors that could have caused the poor response is of genetic 
origin.  
One of the candidate gene polymorphisms that might play a role in the poor 
response to antihypertensive drugs is the ACE I/D polymorphism. In literature, both 
the I-allele and the D-allele have been associated with a poor response to ACE-
inhibitors (reviewed in chapter 3.1). In the Rotterdam Study and Doetinchem Cohort 
Study, this polymorphism did not seem to influence the response in ACE-inhibitor 
users. For example, there was no significant difference in the adherence to ACE-
inhibitor therapy between subjects with the II, ID, or DD genotype (chapter 4.1). 
Neither was an interaction found between the use of ACE-inhibitors, low-ceiling 
diuretics, β-blockers, or calcium channel blockers and the ACE I/D polymorphism on 
blood pressure (chapter 4.2 + 4.4) or on atherosclerosis (chapter 5.1). These results 
corresponded with the largest trial performed.15 Arnett et al.15 found no significant 
difference between the ACE I/D genotype groups and the response to ACE-inhibitors, 
diuretics, or calcium channel blockers on blood pressure nor on the risk of cardiac 
heart disease or stroke. 
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The second polymorphism which was investigated was the AGT M235T 
polymorphism. Also this polymorphism had no drug-gene interactive effect on blood 
pressure (chapter 4.3 + 4.4) or on atherosclerosis (chapter 5.1). In a case-control 
study, Bis et al.16 found that carriers of the 235M-allele who used ACE-inhibitors had a 
significantly higher risk of non-fatal stroke but not of non-fatal MI than among ACE-
inhibitor users with the TT genotype. Remarkably in our study, we found the opposite. 
ACE-inhibitor users with at least one copy of the 235T-allele had a higher risk of MI 
than ACE-inhibitor users with the MM genotype (interaction HR=4.00; 95%CI: 1.32-
12.11) (chapter 5.2). In addition, a non-significant increased risk of stroke was found 
(interaction HR=1.83; 95%CI: 0.95-3.54). Currently it is still difficult to predict with 
accuracy which allele is the risk allele. It is known that form literature that subjects 
with the TT genotype have 10% to 20% higher plasma AGT levels (circulating renin-
angiotensin system), but the effect on tissue AGT levels is still unknown. The tissue 
renin-angiotensin system operates in two ways. The first pathway is similar to the 
circulating i.e. tissue renin generates angiotensin I, subsequently catalyzed by ACE 
into angiotensin II. The second pathway consists of two alternative enzyme pathways 
i.e. chymase catalyzes the conversion of angiotensin I to angiotensin II and cathepsin 
G and the chymostatin-sensitive angiotensin II pathway directly cleave 
angiotensinogen into angiotensin II.18 The relative importance of alternative pathways 
is still uncertain.19 Since the circulating renin-angiotensin system may be responsible 
for short-term regulation and the tissue levels serves a role in long-term changes17 it is 
impossible to predict with accuracy from plasma levels alone which allele is the risk 
allele. Since we were unable to detect a drug-gene interaction on atherosclerosis and 
blood pressure, our results are somewhat contradictory with regard to the long-term 
outcomes. On the other hand antihypertensive drugs have multiple effects, which may 
explain why we did find an interaction on the risk of MI and not on blood pressure and 
atherosclerosis. Furthermore, our studies on blood pressure and atherosclerosis were 
analyzed cross-sectionally, whereas the risk of MI and stroke were analyzed in a 
follow-up design. 
The third polymorphism which was examined in this thesis was the AGTR1 
1166A/C polymorphism. Literature about a possible drug-gene interactive effect on 
blood pressure is unclear due to small sample sizes and conflicting results.20, 21 In our 
study, no drug-gene interactive effect was found with this polymorphism on blood 
pressure levels (chapter 4.4). In addition, no association was found with the 573C/T 
polymorphism on atherosclerosis (chapter 5.1). The distance between the 1166A/C 
polymorphism and the 573C/T polymorphism is approximately 500 base pairs and is 
probably in linkage equilibrium with the 1166A/C polymorphism.  
The fourth polymorphism which was investigated was the ADD1 G460W 
polymorphism. In our studies, no drug-gene interactive effect was found on blood 
pressure (chapter 4.3 + 4.4). Trials which investigated this drug-gene interaction on 
blood pressure were inconclusive due to conflicting results and small sample sizes.23-26 
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Psaty et al.22 reported that in carriers of at least one copy of the 460W-allele diuretic 
therapy was associated with a lower risk of combined non-fatal MI or non-fatal stroke 
than with other antihypertensive therapies. The authors argued that blood pressure did 
not appear to be affected by the α-adducin gene-diuretic interaction.  
The last polymorphism which was examined was the β3-subunit of the G-protein 
(GNB3) 825C/T polymorphism. Only one trial investigated the role of the 825C/T 
polymorphism.27 In this study, subjects with the TT genotype had a greater systolic 
and diastolic blood pressure reduction when treated with a thiazide diuretic. When the 
same population was investigated in a nested case-control design (non-responder 
versus responder) this polymorphism did not significantly influence the chance to 
become a responder (based on diastolic blood pressure) when treated with 
hydrochlorothiazide.28 In our study a drug-gene interactive effect on blood pressure 
was found (chapter 4.4). Users of low-ceiling diuretics with one copy of the TT 
genotype had a lower systolic blood pressure than subjects with the CC genotype. 
Remarkably in the study of Turner et al.26 and in our study (chapter 4.4), no 
interaction was found between GNB3 825C/T polymorphism and other candidate 
polymorphism in diuretic users (drug-gene-gene-interactions). 
With regard to drug-gene-gene interactions, none of the possible combinations 
with three of the candidate gene polymorphisms (ACE, AGT and ADD1) were significant 
in the Rotterdam Study (chapter 4.2). In the Doetinchem Cohort Study four drug-
gene-gene interactions were significant when five of candidate gene polymorphisms 
(ACE, AGT, AGTR1, GNB3, and ADD1) were combined. There was an interaction 
between diuretic use and ADD1 W-allele+ AGT T-allele vs. GG+ MM on DBP (3.09 
mmHg; 95%CI:0.16-2.93), β-blocker use and AGTR1 C-allele+ AGT T-allele vs. AA+ 
MM on DBP (2.63 mmHg; 95%CI: 0.30-2.33), ACE-inhibitor use and ACE I-allele+ 
GNB3 TT vs. DD+ C-allele on DBP (6.22 mmHg; 95%CI: 0.93-5.29), and ACE-inhibitor 
use and ACE I-allele+ AGT T-allele vs. DD+ MM on SBP (-10.21 mmHg; 95%CI: -
19.47--0.95).  
  
Table 1 overview of the results found in this thesis. 
 
Outcome ACE 
I/D 
AGT M235T AGTR1 
1166A/C or 
573C/T 
ADD1 
G460W 
GNB3 
825C/T 
Blood pressure - - - - ?2 
Atherosclerosis - - -   
MI / stroke  ?1      
 
ACE I/D=angiotensin converting enzyme insertion/deletion polymorphism; ADD1
=α-adducin; AGT=angiotensinogen; AGTR1=angiotensin II receptor type 1;
GNB3=β3-subunit of the G-protein  
1 interaction only found in ACE-inhibitor users on the risk of stroke 
2 interaction only found in diuretic users on systolic blood pressure 
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Pharmacogenetic study designs 
 
As indicated in the introduction, two different settings can be used to evaluate the 
effect of polymorphisms/genes on the response to antihypertensive drugs i.e. trials 
and observational studies. Randomised controlled trials are considered the best 
method for providing evidence on efficacy. However, due to their highly selected 
populations and outcomes and expensive nature they have been criticised.29 
Observational studies can be thought of as natural experiments in which outcomes are 
measured in the “real world” rather than in experimental settings. In these studies it is 
possible to evaluate large groups of diverse individuals, which can be followed for long 
periods and provide evidence on a wide range of outcomes. An important advantage of 
randomised controlled trials is that the random allocation to an intervention enhances 
the internal validity of a study by minimising confounding.30 This allocation should 
results in groups that are comparable in baseline prognosis.31 In an observational 
study factors that determined whether a person received a specific drug or not could 
result in difference between groups in prognostic factors related to the outcome. For 
example, a physician might think that antihypertensive drugs from one class have 
fewer side effects than antihypertensive drug from another class, and might therefore 
prescribe this class to frailer patients. This form of selection bias is referred to as 
channelling bias or confounding by severity.32 In observational studies on drug-gene 
interactive effects, confounding by severity is less likely unless the doctor is aware of 
the genetic status. Especially in starters of new drugs, however, the doctor is mostly 
unaware of that which leads to some sort of 'randomization'. For instance, in the 
Netherlands persons with hypertension are first started on thiazide diuretics. This 
choice is made without knowledge of the genetic profile and unbiased. Consequently, 
this makes such observational studies on drug-gene interactions relative resistant to 
confounding by severity. 
 
 
Limitations and strengths  
 
All the data that were used for the pharmacogenetic studies described in this thesis 
were collected in two observational cohorts (Rotterdam Study and Doetinchem 
Cohort). Most of the pharmacogenetic studies on blood pressure (short-term outcome) 
were performed in a clinical trial settings and on long-term outcomes in observational 
studies. To be precise only one study, i.e. GENHAT,33 used trial data for long-term 
outcomes.  
The use of observational data is a potential limitation for the short-term outcomes 
presented in this thesis, since well designed trials remain the gold standard. For 
example, in all clinical trials pre-treatment blood pressure measurements were 
available, which made it possible to calculate the response after the start of the 
treatment. In the Rotterdam Study and Doetinchem Study, it was impossible to 
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perform this analysis. Therefore, we might have missed early responses, which might 
have diminished over time. Nevertheless, our results corroborated with the results 
found in most (larger) trials. Another limitation of the use of observational cohort 
studies is that confounding e.g. residual confounding could have biased our results due 
to unmeasured or inaccurately measured confounders. This possibility remains even 
after the adjustment for several potential confounders which were available in the 
Rotterdam Study and Doetinchem cohort. For example, no adjustments were made for 
physical activity and therefore we may have over- or underestimated the blood 
pressure lowering effect. However, even than the drug-gene interaction will remain 
valid as long as the bias due to the unadjusted variable is similar for the different 
genotype groups. An additional, difference between observational studies and 
randomized clinical trials is that all observational studies combined all antihypertensive 
drugs in classes. Antihypertensive drugs within the same class might have different 
pharmacokinetic or -dynamic properties, which could have led to differences in 
responses to antihypertensive drugs of the same antihypertensive drug class. For 
example, calcium channel blockers such as nifedipine and amlodipine have little effect 
on the atrioventricular node, but are potent vasodilators and have mild diuretic effects. 
In contrast, the calcium channel blocker verapamil is an antiarrythmic drug with some 
vasodilatory action and the related compound diltiazem has some effect on both 
cardiac conduction and vascular smooth muscle cells. Another example is carvedilol, 
which is a β1-, β2-, and α-adrenergic blocker which account for its vasodilatory effects 
in contrast to β1-selective agents.34 An additional advantage of a trial is that drug 
treatment can be standardized. This will minimise the number of subjects switching to 
another drug class or adding another antihypertensive drug class. 
A limitation which applies to all pharmacogenetic studies, including ours, is that 
most studies genotyped only one SNP per gene. Some studies genotyped different 
polymorphisms in the same gene, but they all failed to fully represent the large 
variation in genes. Therefore, our results did not rule out involvement of a specific 
gene but only of a candidate gene polymorphism. A disadvantage of taking only one 
SNP per gene is that the folding kinetics, stability, or many other physical properties of 
a protein may depend on the interaction between pairs or combinations of several 
amino acid sites. APOE is one of the examples of a protein which function is influenced 
by a pair of polymorphic amino acids. The major alleles ε2, ε3, ε4 differ at two amino 
acid residues. 
 One of the main limitations of almost all pharmacogenetic studies is the sample 
size. This is one of the strengths of our studies with blood pressure as outcome. Most 
pharmacogenetic trials on short-term outcomes consisted of approximately 100 
subjects. This lack of sample size might have increased the chance of missing genuine 
associations or of reporting spurious results. However, with regard to our study on 
stroke and MI the number of treated cases was in general small, although, similar as 
other observational studies. The small number of cases might have lead to biased 
results, for example, we had to reduce our drug exposure data into a dichotomous 
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variable (exposed versus non-exposed) and this may have increased the rate of 
exposure misclassification.35 An example which shows the merits of large sample size 
concerns the studies on the role of polymorphisms in the ACE gene and its contribution 
to the risk of cardiovascular disease. Early publications on this disease association in 
the ECTIM (Etude Cas-Temoin d’Infarctus du Myocarde) study which involved 610 men 
who survived an MI and 733 controls, suggested that the ACE gene had a role in the 
risk of particular subgroups to cardiovascular disease.36 Confidence intervals for this 
initial study were large. Subsequent studies often involved fewer patients, and those 
published produced variable results. When the hypothesis was tested in a very large 
case-control study (4,629 cases and 5,943 controls), the evidence of an association 
between ACE and an increased risk of cardiovascular risk was much diminished (RR 
1.1, 95%CI 1.00-1.21).37 This example suggests that for genetic effects of modest 
magnitude and subgroup analysis, 1,000 to 10,000 of individuals might be required to 
generate precise estimates. In comparison, to these numbers, many pharmacogenetic 
studies are too small. Besides false-negative results, also false-positive results could 
have been reported as most of the pharmacogenetic studies performed multiple tests 
on the same population. The expected frequency of false-positive results is given by 1-
(1-k)m (where m is the number of independent markers and k is the significance level 
for a single marker).38 Adjustments for multiple testing can be made, but a 
disadvantage of these approaches is that genuine associations might be missed. 
Therefore, some investigators argue that the likelihood of a chance association may be 
considered in the light of biological plausibility of any observed observation.39 
Therefore, we did not adjust for multiple testing in our analysis. 
A strength of our study compared to other pharmacogenetic studies with the 
outcome blood pressure, is that we evaluated the effect of the five polymorphisms in 
two study settings in the Netherlands. Replication of the same findings in the same 
population will give a better prediction of the (non) existence of a drug-gene 
interaction. The probability that a second association study is also positive in the same 
population may also vary with sample size, the measurement value, and 
environmental factors.40 It may be questioned whether the two cohorts were not too 
different. Although both cohorts consisted mainly of Caucasians, the mean age 
difference was approximately 20 years between the hypertensive subjects in both 
cohorts. The difference resulted in an overrepresentation of subjects with isolated-
systolic hypertension in the Rotterdam Study compared to Doetinchem Cohort Study. 
Furthermore, younger subjects are also more likely to respond to antihypertensive 
drug therapy then older subjects. In addition, there is also a difference in the 
standardisation of the blood pressure measurements between both cohorts. 
An additional strength of our study is that we were able to evaluate the effect of 
drug-gene-gene interactions. Namely, the behaviour of antihypertensive drugs are 
influenced by a range of gene products. Therefore, it might be important to consider 
groups of potentially interacting genes as a set, such as those that act in common 
pathways (e.g. renin-angiotensin system), to identify interactions between 
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polymorphisms in different genes (chapter 4.3 and 4.4). A small number of studies 
tested for interactions between polymorphisms in different genes. The results for the 
drug-gene-gene interactions between the Rotterdam Study and Doetinchem Cohort 
Study were not similar and this could have been the result of differences in study 
population as mentioned in the previous paragraph. Another possible explanation for 
the difference in results is the higher chance of reporting false-positive and false-
negative results in drug-gene-gene studies. Namely, when more then one variable is 
studied simultaneously larger patient groups are required to ensure that individual 
subgroups retain adequate power to detect significant associations with narrow 
confidence intervals. 
 
 
Non-replication 
 
Most of the drug-gene interactions in the literature were not replicated by other studies 
(observational studies and trials). Non-replication can be the result of differences in 
phenotype definition, lack of statistical power, population stratification, different 
environmental factors within a population, the effects of other genes, and the varying 
effects of several causal polymorphisms within the candidate gene.41, 42 Consistency of 
association across studies is a useful indicator of a causal association, when present. 
However, genuine biological differences between study populations could have resulted 
in non-replication. One of these biological factors is the differences in linkage 
disequilibrium (LD) between the studied polymorphism and the causal mutation. 
Difference in LD between populations is the result of a number of contributing factors, 
including regional variability in recombination patterns, genetic drift, mutation age, 
ethnic diversity, recent population admixture, local chromosomal composition, and the 
patterns of mating within a population.43-47 Due to the variation within populations, 
markers close to a functional DNA variant might show less or more LD than markers 
further away. As a result, associations with some markers might not be identified in a 
region containing a disease-mediating polymorphism, whereas associations at adjacent 
markers are convincingly detected. Since all of the polymorphisms studied are most 
likely not the causal mutation this may lead to differences in results. Another factor 
which could explain the real biological difference between populations is the difference 
in allele frequencies. For example, the 235T-allele of the AGT gene varies widely in 
frequency, occurring in 35-45% of whites, 75-80% of Asians, 75-80% of African 
Americans, and ≥ 90% of Africans.48, 49 This pattern led to the hypothesis that the 
235T-allele, which is associated with a higher angiotensinogen expression (-6G/A) and 
greater sodium reabsorption, was adaptive in the tropical and sodium-poor 
environment of Africa. When humans migrated out of Africa into other environments 
the 235T-allele became neutral or selected against.50  
Although genuine biological differences are a possible explanation for the 
discrepancies in results, it most likely explains only a small percentage of the 
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inconsistencies in results. A more likely explanation for the non-replication is the 
limited sample sizes as most of the drug-gene interactions were found in studies with 
small sample sizes. To reduce the number of (potentially) false-positive and false-
negative results pharmacogenetic study designs should be standardized, for example, 
with regard to criteria used for hypertension, the wash-out period, and the minimum 
duration of treatment. A meta-analysis might provide a quantitative approach for 
combining the results of various studies on the same topic51, 52 but due to the 
variability in inclusion criteria, duration of treatment, and the limited number of studies 
it is currently not yet possible to perform a meta-analysis. Another solution is to 
perform multi-centre studies to increase sample size (e.g. GENHAT33) or by replication 
of an interaction in the same population as we did by studying a research hypothesis in 
two different observational settings, i.e. the Doetinchem Cohort Study and Rotterdam 
Study.  
 
 
Clinical implications  
 
Knowledge of polymorphisms or genes that influence the pharmacodynamic response 
of blood pressure to antihypertensive medication has the potential to provide new 
insights into the molecular mechanisms that influence drug response. On the basis of 
previous results, clinical implications are unclear since most of the pharmacogenetic 
studies so far have fallen short of the ideal approach to study the genetics of drug 
responses and data most likely have been over interpreted. Also the studies in this 
thesis do not give conclusive results. However on the basis of our results, it does not 
seem likely that these five polymorphisms have a big influence on the blood pressure 
response or on long-term cardiovascular outcomes associated with antihypertensive 
drug use in daily clinical practise. Although, conclusive answers can not be drawn from 
the available data this does not mean that pharmacogenetics will never provide the 
answers to our questions. For example, for genes involved in drug metabolizing 
enzymes (e.g. CYP2D6 and CYP2C19) diagnostic tools have already been developed.53 
However, in complex causal pathways with multiple interacting risk-enhancing alleles 
associations tend to be of modest strength. For example, blood pressure levels 
arecontrolled by a complex combination of processes that influence cardiac output and 
peripheral resistance.54, 55 Thus there are many more candidate genes and 
polymorphisms that could be involved in the response to antihypertensive drugs than 
the five presented in this thesis for the short and long-term outcomes.  
Even after the discovery of the causal polymorphisms (or those in linkage with the 
causal mutation) there might still be some problems with the implication of genetic 
tests. For example, the choice which antihypertensive drug to prescribe can be difficult 
when a subject has risk-enhancing alleles for each class of antihypertensive drug.  
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Future research 
 
There are still a number of questions that are raised with this thesis that need to be 
answered. For example, the association between the M235T polymorphism and the risk 
of stroke and MI warrants further investigation. In addition, the interaction between 
the 825C/T polymorphism of the GNB3 gene and low-ceiling diuretics is still uncertain. 
For definitive conclusions larger sample sizes and/or meta-analysis are needed.  
In addition, which SNPs and how many to genotype is important to consider. There 
are approximately 10 million SNP’s (minor allele frequencies > 1%) in the human 
genome.56 It is not practical, at present, to genotype and test all SNPs in the genome 
for association with phenotypes. Therefore, it is important to select a limited number. 
In theory this would be those polymorphisms that affect the function of the protein or 
its expression, however, in most situations this information is not available. In 
addition, polymorphisms in non coding regions are still able to affect gene function by 
altering the stability and splicing of mRNA.57  Selecting a limited number of markers 
will result in a loss of power compared to genotyping all SNP’s. The loss of power 
depends on four factors: 1) the strength of the association between a true disease-
causing SNP and the disease, 2) linkage disequilibrium (LD) between markers and the 
causal SNP, 3) the marker allele frequency, 4) the disease allele frequency. In order to 
create considerable marker redundancy and still capture almost all information the 
map based strategy was developed. This strategy is greatly influenced by data showing 
that LD is composed in block like regions of low diversity of haplotypes, and stretches 
of more rapid breakdown of LD, which correspond to hotspots of meotic 
recombination.58, 59 This inspired the idea of haplotype tagging, in which a set of SNPs 
is identified that tag each of the common haplotypes with in a block of LD (so called 
tagging SNPs). By some estimates, an average of five to seven SNPs per gene would 
be required to represent all the common polymorphisms in candidate genes. Tagging 
SNP’s need to be carefully selected and validated, because not all five to seven SNP’s 
will do. A disadvantage of this approach is that it remains unclear whether tagging 
SNPs will be able to represent variants with lower minor allele frequencies. Although, 
this frequency bias is likely to be a minor problem, if the response to a drug is caused 
by common polymorphisms, it will limit the usefulness if it is caused by rare variants.60, 
61  
In the future, it might be possible to perform genome association screens to 
determine which genes influence the response to antihypertensive drugs. This is not 
yet feasible, since estimates of the number of SNPs required for a complete genome-
wide haplotype map suggest that this is likely to be in the region of 500,000 separate 
SNPs or fewer if only the genes are genotyped (100,000-200,000). At the moment, 
studies are using this approach on single chromosome, although, the statistical 
analysis remains a problem.  
To assess whether the intended effects on antihypertensive drug treatment are 
modified by genetic polymorphisms, randomized controlled trials are preferred. For 
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short-term outcomes of antihypertensive drug treatment such as blood pressure, it is 
feasible to design such a trial. However, for long-term outcomes such as MI and 
stroke, randomized controlled trials may not be feasible due to practical, financial, or 
ethical reasons. In situations where randomized controlled trials are not feasible, 
observational studies are an alternative to obtain information on drug-gene 
interactions in daily clinical practice.  
 
In conclusion, the results of this thesis suggests the presences of two drug-gene 
interactions i.e. the interaction between the use of ACE-inhibitors and AGT M235T 
polymorphism on the risk of MI and the interaction between the use of diuretics and 
the GNB3 825C/T polymorphism on systolic blood pressure.  
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Summary 
 
Hypertension is a major public health hazard, because of its high prevalence and 
strong positive association with cardiovascular diseases. Suboptimal blood pressure 
control is the number one attributable risk for death in the Western world, despite the 
possibilities to treat hypertension. Higher pre-treatment blood pressure levels are 
associated with a greater antihypertensive drug response, but this relation is not 
specific to a particular antihypertensive drug or drug class nor can it be predicted from 
patient’s characteristics. Therefore, the selection of the most appropriate 
pharmacological treatment for an individual patient is a matter of ‘trial and error’. 
Pharmacogenetics aims to understand how genetic variations contribute to the 
variation in response to medication. This thesis contains a number of epidemiological 
studies that are aimed at gaining more insight into the effect of five candidate gene 
polymorphisms on the response to antihypertensive medication.  
 After a general introduction in chapter 1, chapter 2 focuses on the current status 
of hypertension treatment in the Netherlands. In chapter 2.1, estimates are provided 
on the prevalence, treatment, and control of hypertension and determinants of 
undertreatment in the Netherlands. Data were obtained from a population-based 
survey on cardiovascular risk factors in the Netherlands from 1996 through 2002 
(MORGEN project). A total of 10,820 men and women were included in this study. The 
prevalence of hypertension in men was 21.4% and in women 14.9%. Of the 
hypertensive men 17.9% was treated, of whom 67.6% had a blood pressure level 
during treatment which was too high according to the guidelines. Of the hypertensive 
women, 38.5% were receiving antihypertensive medication, of whom 51.9% had a 
blood pressure level which was too high. One of the factors associated with a better 
control of blood pressure was the use of cholesterol-lowering medication. Of the 
untreated patients, 21.9% of the men and 13.6% of the women were eligible for 
treatment according to the Dutch guidelines for antihypertensive treatment. Subjects 
who were physically active, on a low salt diet, and current smokers had an increased 
chance of being untreated.  
 In chapter 3, a general introduction is given on the interaction between 
antihypertensive drugs and genes. Chapter 3.1 contains all studies until October 2003 
that reported data on genetic polymorphisms and response to antihypertensive drugs. 
In some candidate gene studies, drug-gene interactions were found. Unfortunately, the 
quality of these studies is quite variable and initial associations were often difficult to 
replicate. Therefore, further research is needed to be able to make definitive 
conclusions.  
 Chapter 4 consists of four studies that investigated the drug-gene interaction 
between five candidate gene polymorphisms and four antihypertensive drug classes on 
short-term outcomes. The first three studies were performed in the Rotterdam Study, 
a population-based prospective cohort study among 7,983 individuals aged 55 years or 
over. In chapter 4.1 we investigated whether the angiotensin converting enzyme 
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(ACE) insertion/deletion (I/D) polymorphism modified the adherence to ACE-inhibitors 
as measured by the discontinuation of an ACE-inhibitor or addition of another 
antihypertensive drug. There was no significant difference between subjects with the 
DD, ID, or II genotype in adherence (DD versus II; relative risk (RR)=1.17; 95%CI: 
0.78-1.77 and ID versus II; RR=1.06; 95%CI: 0.73-1.55). Also, no difference in blood 
pressure levels was found in ACE-inhibitor users, as demonstrated in chapter 4.2 
(systolic blood pressure II versus DD; -2.01 mmHg; 95%CI: -9.82-5.79 and diastolic 
blood pressure II versus DD; -1.04 mmHg; 95%CI: -5.45-3.37). nor did it modify 
blood pressure levels in users of low-ceiling diuretics, β-blockers, or calcium channel 
blockers. Also, the angiotensinogen (AGT) M235T and α-adducin (ADD1) G460W 
polymorphisms did not modify blood pressure levels in antihypertensive drug users as 
described in chapter 4.3. Chapter 4.4 contains data from the Doetinchem Cohort 
Study. This cohort is part of a population-based prospective study on cardiovascular 
risk factors conducted in the Netherlands (MORGEN project). In total, 625 hypertensive 
subjects had complete information on blood pressure, medication use and genotypes. 
No drug-gene interaction was found with the ACE I/D, AGT M235T, angiotensin 
receptor II type 1 (AGTR1) 1166A/C, or ADD1 G460W polymorphism. Only the β3-
subunit of G-protein (GNB3) 825C/T polymorphism modified the systolic blood 
pressure levels in diuretic users (C-allele versus TT 4.33 mmHg; 95%CI: 0.14-8.54). 
Thus subjects with one or two copies of the 825C-allele might have less benefit from 
the use of low-ceiling diuretics. In addition, four significant drug-gene-gene 
interactions were found which were associated with an increased systolic or diastolic 
blood pressure.  
 Chapter 5 provides the data of two studies investigating drug-gene interactions on 
long-term outcomes. These studies were performed in the Rotterdam Study. In 
chapter 5.1, we investigated whether the ACE I/D, AGT M235T, or AGTR1 573C/T 
polymorphism modifies atherosclerosis levels in patients treated with ACE-inhibitors or 
β-blockers. We used three different sub-clinical measurements of atherosclerosis, i.e. 
peripheral arterial disease, carotid atherosclerosis, and aortic atherosclerosis. No 
consistent drug-gene interaction was found in association with these three 
measurements. Chapter 5.2, presents the data on the risk of myocardial infarction 
(MI) and stroke and the interaction between the AGT M235T polymorphisms and the 
use of ACE-inhibitors and β-blockers. The interaction between current use of ACE-
inhibitor users was multiplicative on the risk of MI (hazard ratio (HR)=4.00; 95%CI: 
1.32-12.11) in subjects with the MT or TT genotype compared to subjects with the MM 
genotype. Similarly, there was a non-significantly increased risk of stroke (HR=1.83; 
95%CI: 0.95-3.54). No significant interaction was found between the current use of β-
blockers and the AGT M235T polymorphism on the risk of MI or stroke. Subjects with 
at least one copy of the 235T-allele of the AGT gene might have less benefit from ACE-
inhibitor therapy. 
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Chapter 6 contains the main findings of the studies in this thesis and the main 
limitations/strengths of these studies. In addition, the clinical relevance of the findings 
and recommendations for further research are given. 
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Samenvatting 
 
Hypertensie is een belangrijk probleem voor de volksgezondheid, vanwege de hoge 
prevalentie en sterke associatie met cardiovasculaire ziektes. Suboptimale bloeddruk 
controle is de belangrijkste doodsoorzaak in de Westerse wereld, ondanks de 
ontwikkelingen in de behandeling van hypertensie. Ofschoon een hogere bloeddruk 
voor behandeling geassocieerd is met een betere respons op antihypertensiva is de 
relatie niet specifiek voor een bepaald antihypertensivum of gerelateerd aan speciale 
patiëntkarakteristieken. De selectie van de beste farmacologische behandeling voor 
een individu is daarom moeilijk. Farmacogenetica heeft als doel om meer inzicht te 
geven in de bijdrage van genetische variatie in de response op geneesmiddelen. Dit 
proefschrift bevat een aantal epidemiologische studies, die als doel hadden de effecten 
van vijf polymorfimen in kandidaat-genen op de response van antihypertensiva te 
onderzoeken. 
 Na een algemene introductie in hoofdstuk 1 wordt in hoofdstuk 2 de actuele 
status van de behandeling van hypertensie in Nederland besproken. In hoofdstuk 2.1 
worden schattingen gegeven over de prevalentie, behandeling en controle van 
hypertensie. Daarbij worden de determinanten van onderbehandeling van hypertensie 
in Nederland onderzocht. Gegevens waren afkomstig van het bevolkingsonderzoek 
naar risicofactoren voor hart- en vaatziekten in Nederland van 1996 tot en met 2002 
(MORGEN project). In totaal werden 10.820 mannen en vrouwen in deze studie 
opgenomen. De prevalentie van hypertensie was 21,4% voor mannen en 14,9% voor 
vrouwen. Ongeveer 18% van de mannen met hypertensie werd behandeld. Hiervan 
had 67,6% een te hoge bloeddruk tijdens de behandeling volgens de richtlijnen. Van 
de vrouwen met hypertensie kreeg 38,5% antihypertensiva. Hiervan had 51,9% een te 
hoge bloeddruk tijdens behandeling. Een van de factoren die geassocieerd was met 
een betere controle van de bloeddruk is het gebruik van cholesterolverlagende 
geneesmiddelen. Van de onbehandelde patiënten zou 21,9% van de mannen en 13,6% 
van de vrouwen volgens de richtlijnen in aanmerking komen voor behandeling. Mensen 
die lichamelijk actief waren, een zoutarm dieet hadden of rookten hadden een 
verhoogde kans om niet behandeld te worden. 
 In hoofdstuk 3 wordt een algemene introductie gegeven over interacties tussen 
antihypertensiva en genen. Hoofdstuk 3.1 geeft een overzicht van alle studies (tot 
oktober 2003), die gegevens bevatten over genetische polymorfismen en de respons 
op antihypertensiva. In sommige studies met kandidaatgenen werden geneesmiddel-
gen interacties gevonden. Helaas was de kwaliteit van deze studies variabel and was 
het over het algemeen lastig om eerder beschreven associaties te reproduceren. 
Daarom is extra onderzoek nodig om definitieve conclusies te trekken. 
 Hoofdstuk 4 bestaat uit vier studies, waarin wij onderzochten of er een 
geneesmiddel-gen interactie aantoonbaar was tussen vijf polymorfismen in kandidaat-
genen en vier verschillende groepen antihypertensiva op korte termijn uitkomsten. De 
eerste drie studies werden uitgevoerd met gegevens van het Erasmus Rotterdam 
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Gezondheid en Ouderen (ERGO) onderzoek, een bevolkingsonderzoek van 7.983 
personen van 55 jaar en ouder. In hoofdstuk 4.1 hebben we onderzocht of het ACE 
I/D polymorfisme het gebruik van ACE-remmers verandert. Een verandering werd 
gedefinieerd als het stoppen van het gebruik van een ACE-remmer of de additie van 
een ander antihypertensivum. Er was geen significant verschil tussen mensen met het 
DD, ID en II genotype in het gebruik van ACE-remmers (DD versus II; relatieve risico 
(RR)=1.17; 95%BI: 0.78-1.77 en ID versus DD; RR=1.06; 95%BI: 0.73-1.55). 
Daarnaast werd er bij gebruikers van ACE-remmers geen verschil gevonden in de 
hoogte van de bloeddruk, zoals aangetoond in hoofdstuk 4.2 (systolische bloeddruk 
II versus DD; -2,01 mmHg; 95%BI: -9,82-5,79 en diastolische bloeddruk II versus DD 
-1,04 mmHg; 95%BI: -5,45-3,37). Ook veranderde het ACE I/D polymorfisme de 
bloeddruk niveau’s niet in mensen die diuretica (exclusief lisdiuretica), β-blokkers of 
calciumantagonisten gebruikten. Ook de AGT M235T en ADD1 G460W polymorfismen 
veranderde bloeddruk niveau’s niet, zoals beschreven in hoofdstuk 4.3. Hoofdstuk 
4.4 bevat gegevens uit de Doetinchem Cohort Studie. Dit cohort is een gedeelte van 
het bevolkingsonderzoek naar risicofactoren van hart- en vaatziekten in Nederland 
(MORGEN project). In totaal hadden 625 personen met hypertensie complete 
informatie over bloeddruk, geneesmiddelgebruik en genotypes. Er werd geen 
geneesmiddel-gen interactie gevonden met het ACE I/D, AGT M235T, AGTR1 1166A/C, 
of ADD1 G460W polymorfisme. Alleen het GNB3 825C/T polymorfisme veranderde de 
systolische bloeddruk niveau’s in diuretica gebruikers (C-allele versus TT; 4,33 mmHg; 
95%BI: 0,14-8,54). Mensen met één of twee kopieën van het 825C allel zouden 
misschien minder baat hebben bij het gebruik van diuretica. Bovendien werden er vier 
significante geneesmiddel-gen-gen interacties gevonden met consequenties voor de 
systolische of diastolische bloeddruk. 
 Hoofdstuk 5 bevat gegevens van twee studies naar de associatie tussen 
geneesmiddel-gen interacties en uitkomsten op de lange termijn. Deze studies zijn 
uitgevoerd met data uit het ERGO onderzoek. In hoofdstuk 5.1, werd onderzocht of 
het ACE I/D, AGT M235T of AGTR1 573C/T polymorfisme geassocieerd was met de 
mate van atherosclerose in patiënten, die behandeld werden met ACE-remmers of β-
blokkers. We gebruikten drie subklinische parameters voor atherosclerose, namelijk 
perifeer vaatlijden, atherosclerose van de arteria carotis en atherosclerose van de 
aorta. Er werd geen consistente geneesmiddel-gen interactie gevonden met deze drie 
uitkomstmaten. Hoofdstuk 5.2 geeft het risico op een hart- en herseninfarct en de 
interactie tussen het AGT M235T polymorfisme en het gebruik van ACE-remmers of β-
blokkers. De interactie tussen het AGT M235T polymorfisme en het gebruik van ACE-
remmers was multiplicatief op het risico van een hartinfarct (HR=4,00; 95%BI: 1,32-
12,11) in personen met het MT of TT genotype ten opzichte van mensen met het MM 
genotype. Ook was er een (niet significant) hoger risico op een herseninfarct 
(HR=1,83; 95%BI: 0,95-3,54). Er werd geen interactie gevonden tussen gebruik van 
β-blokkers en het AGT M235T polymorfisme op het risico van een hart- of 
herseninfarct. Mensen met tenminste één kopie van het 235T allel op het AGT gen
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lijken minder baat te hebben bij behandeling met ACE-remmers.  
 Hoofdstuk 6 bevat de belangrijkste resultaten van dit proefschrift en bespreekt de 
sterke punten, de klinische relevantie en beperkingen van studies uit dit proefschrift. 
Daarnaast worden aanbevelingen gegeven voor toekomstig onderzoek. 
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Dit proefschrift had ik niet alleen kunnen maken en daarom zou ik de volgende 
mensen willen bedanken voor hun steun. 
  
Dr. O.H. Klungel, beste Olaf, bedankt voor al je commentaar op mijn artikelen.en dat 
ik altijd even bij je binnen lopen voor advies als ik problemen had met een 
onderzoeksopzet.  
Prof dr. B.H.Ch. Stricker, beste Bruno, ik heb altijd ons overleg uurtje op de vrijdag 
erg op prijs gesteld (ook al was ik niet elke vrijdag in Rotterdam). Meestal wist je 
binnen dat uurtje de zwakke plekken in mijn analyses en artikelen te vinden en had ik 
weer genoeg werk tot de volgende vrijdag. 
Prof. dr. A. de Boer, beste Ton, ondanks jouw ‘overvolle’ agenda nam je altijd de tijd 
om nog even een artikel te bespreken of weer eens naar mijn stellingen te kijken.  
 
Prof. dr. P.W. de Leeuw, Prof. dr.T. Stijnen en Prof. dr. C.M. van Duijn wil ik bedanken 
voor hun bereidheid plaats te nemen in de kleine commissie en dit proefschrift te 
beoordelen.  
 
Graag wil ik nog iedereen bedanken die het mogelijk maakten dat ik data had om te 
analyseren. Allereerst de deelnemers, de huisartsen en apothekers voor hun 
medewerking (ERGO + Doetinchem cohort) en natuurlijk ook Monique Verschuren van 
het RIVM en Bram  Kroon van de Universiteit van Maastricht voor hun hulp bij het 
verrichten van mijn promotie-onderzoek. Ten tweede de mensen die het mogelijk 
maakte dat ik zelf niet in het lab hoefde te staan. Mojgan and Aaron, thank you for 
the work you have done (ERGO). Verder wil ik Ellen den Hoedt, Petra van Impelen en 
Barbara Hoebee bedanken voor hun hulp in het verzamelen en opwerken van het DNA 
van het Doetinchem cohort. Verder zou ik het laboratorium van Maastricht willen 
bedanken voor het genotyperen van het Doetinchem cohort en met name Paul 
Schiffers.  
 
Pages eight and nine show that quite a number of co-authors contributed to the work 
in this thesis. I would like to thank them all for their contribution and comments, 
which helped me to improve my articles. In particular, not previously mentioned, 
Jacqueline Witteman, Monique Breteler, Bert Hofman, Bruce Psaty, Daan Kromhout, 
and Jan Danser.   
 
Mijn collega’s uit Utrecht. In het begin was het toch wel even wennen om niet naar 
het UMCU, maar naar het Went te fietsen. Ik wil iedereen erg bedanken voor de 
gezellige tijd die ik bij F&F heb gehad (sporten, borrelen, eten, congressen en 
natuurlijk tijdens het werk). Pearl erg bedankt voor alle kopjes thee, sporten en 
gesprekken die we gehad hebben in N803. Ook mijn andere (ex-) kamergenoten Anke 
Hilse, Aukje, Edwin, Emmeke, Ewoudt en Ingeborg erg bedankt voor alle gezelligheid
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en het vergroten van kennis m.b.t kinderen krijgen, farmacie, statistiek en nog veel 
meer. Tanja en Mira erg bedankt dat ik altijd even bij jullie kon aankloppen als het 
even niet ging zoals ik wilde. Ineke, Addy en Suzanne bedankt voor al jullie steun en 
toeverlaat.  
 
Verder wil ik mijn collega’s uit Rotterdam bedanken. Dika, bedankt dat je me ook een 
ander stukje van Rotterdam hebt laten zien. Mijn andere collega’s wil ik bedanken 
voor de gezelligheid op de vrijdag en tijdens de ISPE en promoties: Albert-Jan, Bert, 
Bettie, Claire, Cornelis, Georgio, Gysèle, Jeanne, Loes, Mariëtte, Martina, Mendel, 
Miriam, Katia, Sabine. De dames van het secretariaat wil ik bedanken voor hun hulp, 
vooral toen ik op het laatste moment nog een paar handtekeningen van de kleine 
commissie nodig had.  
 
Mijn vrienden en familie wil ik bedanken voor hun belangstelling en steun bij het 
maken van dit proefschrift. Paranimfen Brigitte van Doorn en Denise van Suijlekom, ik 
ben erg blij dat jullie me willen bij staan bij de verdediging. Brigitte, we kennen elkaar 
nu al een lange tijd en ik hoop dat we elkaar in de toekomst zullen blijven steunen. 
Denise, samen dezelfde studie en daarna beiden AIO (en beiden niet in het UMCU). 
Bedankt voor alle lunchen, diners, etc. waar we o.a. konden "klagen" over het bestaan 
van een AIO.  
Dear Jorgen and Mick, even though you can not be here today, I know you support 
me and I wish you all the best in the future with your baby boy (?). Mick, good luck 
with your PhD.  
Beste mam en pap, bedankt voor al jullie steun om dit proefschrift tot een goed einde 
te brengen. Ik zal jullie missen in Philadelphia. 
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